

**DRAFT
TOXICOLOGICAL PROFILE FOR
1,3-BUTADIENE**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

September 2009

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

UPDATE STATEMENT

A Toxicological Profile for 1,3-butadiene was released in 1992. This present edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine/Applied Toxicology Branch
1600 Clifton Road NE
Mailstop F-62
Atlanta, Georgia 30333

This page is intentionally blank.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information. Each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. We plan to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Comments should be sent to:


Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine
1600 Clifton Road, N.E.
Mail Stop F-62
Atlanta, Georgia 30333

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the National Priorities List, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Howard Frumkin, M.D., Dr. P.H.
Director, National Center for Environmental
Health/Agency for Toxic Substances and Disease
Registry



Thomas R. Frieden, M.D., M.P.H.
Administrator, Agency for Toxic Substances and
Disease Registry

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

- Section 1.6** **How Can (Chemical X) Affect Children?**
- Section 1.7** **How Can Families Reduce the Risk of Exposure to (Chemical X)?**
- Section 3.7** **Children's Susceptibility**
- Section 6.6** **Exposures of Children**

Other Sections of Interest:

- Section 3.8** **Biomarkers of Exposure and Effect**
 - Section 3.11** **Methods for Reducing Toxic Effects**
-

ATSDR Information Center

Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) **Fax:** (770) 488-4178
E-mail: cdcinfo@cdc.gov **Internet:** <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Annette Ashizawa, Ph.D.
Nickolette Roney, M.P.H.
Pamela G. Tucker, M.D.
Carolyn Harper, Ph.D.
Diana Cronin
ATSDR, Division of Toxicology and Environmental Medicine, Atlanta, GA

Mike Lumpkin, Ph.D.
Daniel J. Plewak, B.S.
SRC, Inc., North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Applied Toxicology Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.

This page is intentionally blank.

PEER REVIEW

A peer review panel was assembled for 1,3-butadiene. The panel consisted of the following members:

1. Sherif Abdel-Rahman, Ph.D., Department of Preventative Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas
2. Genevieve Matanoski, M.D., Dr.PH, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, Maryland
3. Amir Sapkota, Ph.D., Maryland Institute for Applied Environmental Health, University of Maryland, School of Public Health, College Park, Maryland

These experts collectively have knowledge of 1,3-butadiene's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

This page is intentionally blank.

CONTENTS

DISCLAIMER	ii
UPDATE STATEMENT	iii
FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
CONTENTS	xiii
LIST OF FIGURES	xvii
LIST OF TABLES	xix
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS 1,3-BUTADIENE?	1
1.2 WHAT HAPPENS TO 1,3-BUTADIENE WHEN IT ENTERS THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO 1,3-BUTADIENE?	2
1.4 HOW CAN 1,3-BUTADIENE ENTER AND LEAVE MY BODY?	3
1.5 HOW CAN 1,3-BUTADIENE AFFECT MY HEALTH?	3
1.6 HOW CAN 1,3-BUTADIENE AFFECT CHILDREN?	4
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO 1,3-BUTADIENE?	4
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 1,3-BUTADIENE?	5
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	5
1.10 WHERE CAN I GET MORE INFORMATION?	6
2. RELEVANCE TO PUBLIC HEALTH	7
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO 1,3-BUTADIENE IN THE UNITED STATES	7
2.2 SUMMARY OF HEALTH EFFECTS	7
2.3 MINIMAL RISK LEVELS (MRLs)	9
3. HEALTH EFFECTS	13
3.1 INTRODUCTION	13
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	13
3.2.1 Inhalation Exposure	14
3.2.1.1 Death	14
3.2.1.2 Systemic Effects	15
3.2.1.3 Immunological and Lymphoreticular Effects	32
3.2.1.4 Neurological Effects	33
3.2.1.5 Reproductive Effects	34
3.2.1.6 Developmental Effects	35
3.2.1.7 Cancer	35
3.2.2 Oral Exposure	38
3.2.3 Dermal Exposure	38
3.3 GENOTOXICITY	39
3.4 TOXICOKINETICS	44
3.4.1 Absorption	44
3.4.1.1 Inhalation Exposure	44
3.4.1.2 Oral Exposure	45
3.4.1.3 Dermal Exposure	45

3.4.2	Distribution	45
3.4.2.1	Inhalation Exposure	45
3.4.2.2	Oral Exposure	46
3.4.2.3	Dermal Exposure.....	46
3.4.3	Metabolism	46
3.4.4	Elimination and Excretion	49
3.4.4.1	Inhalation Exposure	49
3.4.4.2	Oral Exposure	50
3.4.4.3	Dermal Exposure.....	50
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	50
3.5	MECHANISMS OF ACTION.....	57
3.5.1	Pharmacokinetic Mechanisms.....	57
3.5.2	Mechanisms of Toxicity.....	57
3.5.3	Animal-to-Human Extrapolations.....	58
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	59
3.7	CHILDREN'S SUSCEPTIBILITY	60
3.8	BIOMARKERS OF EXPOSURE AND EFFECT.....	62
3.8.1	Biomarkers Used to Identify or Quantify Exposure to 1,3-Butadiene.....	63
3.8.2	Biomarkers Used to Characterize Effects Caused by 1,3-Butadiene	64
3.9	INTERACTIONS WITH OTHER CHEMICALS.....	65
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	65
3.11	METHODS FOR REDUCING TOXIC EFFECTS.....	66
3.11.1	Reducing Peak Absorption Following Exposure	66
3.11.2	Reducing Body Burden.....	67
3.11.3	Interfering with the Mechanism of Action for Toxic Effects.....	67
3.12	ADEQUACY OF THE DATABASE.....	67
3.12.1	Existing Information on Health Effects of 1,3-Butadiene.....	68
3.12.2	Identification of Data Needs	68
3.12.3	Ongoing Studies.....	76
4.	CHEMICAL AND PHYSICAL INFORMATION.....	79
4.1	CHEMICAL IDENTITY	79
4.2	PHYSICAL AND CHEMICAL PROPERTIES	79
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	83
5.1	PRODUCTION.....	83
5.2	IMPORT/EXPORT.....	87
5.3	USE.....	88
5.4	DISPOSAL	88
6.	POTENTIAL FOR HUMAN EXPOSURE.....	89
6.1	OVERVIEW	89
6.2	RELEASES TO THE ENVIRONMENT	91
6.2.1	Air.....	92
6.2.2	Water.....	97
6.2.3	Soil.....	97
6.3	ENVIRONMENTAL FATE.....	98
6.3.1	Transport and Partitioning	98
6.3.2	Transformation and Degradation	99
6.3.2.1	Air.....	99
6.3.2.2	Water.....	100

6.3.2.3	Sediment and Soil	101
6.3.2.4	Other Media	101
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	101
6.4.1	Air	101
6.4.2	Water.....	102
6.4.3	Sediment and Soil	102
6.4.4	Other Environmental Media.....	105
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE.....	105
6.6	EXPOSURES OF CHILDREN	109
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	110
6.8	ADEQUACY OF THE DATABASE	110
6.8.1	Identification of Data Needs	111
6.8.2	Ongoing Studies.....	113
7.	ANALYTICAL METHODS.....	115
7.1	BIOLOGICAL MATERIALS	115
7.2	ENVIRONMENTAL SAMPLES	116
7.3	ADEQUACY OF THE DATABASE	118
7.3.1	Identification of Data Needs	119
7.3.2	Ongoing Studies.....	120
8.	REGULATIONS, ADVISORIES, AND GUIDELINES.....	121
9.	REFERENCES	125
10.	GLOSSARY	159
 APPENDICES		
A.	ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B.	USER’S GUIDE.....	B-1
C.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	C-1
D.	INDEX	D-1

This page is intentionally blank.

LIST OF FIGURES

3-1. Levels of Significant Exposure to 1,3-Butadiene - Inhalation.....	25
3-2. Metabolism of 1,3-Butadiene	47
3-3. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance.....	52
3-4. Existing Information on Health Effects of 1,3-Butadiene	69
6-1. Frequency of NPL Sites with 1,3-Butadiene Contamination	90

This page is intentionally blank.

LIST OF TABLES

3-1. Levels of Significant Exposure to 1,3-Butadiene - Inhalation	16
3-2. Genotoxicity of 1,3-Butadiene In Vitro.....	40
3-3. Genotoxicity of 1,3 Butadiene In Vivo	41
4-1. Chemical Identity of 1,3-Butadiene.....	80
4-2. Physical and Chemical Properties of 1,3-Butadiene.....	81
5-1. Companies that Produce 1,3-Butadiene in the United States and Annual Capacities During 2008.....	84
5-2. Facilities that Produce, Process, or Use 1,3-Butadiene	85
6-1. Releases to the Environment from Facilities that Produce, Process, or Use 1,3-Butadiene.....	93
6-2. 1,3-Butadiene Emission Data for 2005.....	95
6-3. 1,3-Butadiene Concentrations in Outdoor Air.....	103
6-4. 1,3-Butadiene Concentrations in Indoor Air	104
6-5. Air Concentrations of 1,3-Butadiene Corresponding to Typical Operations Within a Styrene- Butadiene Rubber (SBR) Plant.....	108
7-1. Analytical Methods For Determining 1,3-Butadiene in Environmental Samples.....	117
8-1. Regulations, Advisories, and Guidelines Applicable to 1,3-Butadiene.....	122

This page is intentionally blank.

1. PUBLIC HEALTH STATEMENT

This public health statement tells you about 1,3-butadiene and the effects of exposure to it.

The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the nation. These sites are then placed on the National Priorities List (NPL) and are targeted for long-term federal clean-up activities. 1,3-Butadiene has been found in at least 13 of the 1,699 current or former NPL sites. Although the total number of NPL sites evaluated for this substance is not known, the possibility exists that the number of sites at which 1,3-butadiene is found may increase in the future as more sites are evaluated. This information is important because these sites may be sources of exposure and exposure to this substance may be harmful.

When a substance is released either from a large area, such as an industrial plant, or from a container, such as a drum or bottle, it enters the environment. Such a release does not always lead to exposure. You can be exposed to a substance only when you come in contact with it. You may be exposed by breathing, eating, or drinking the substance, or by skin contact.

If you are exposed to 1,3-butadiene, many factors will determine whether you will be harmed. These factors include the dose (how much), the duration (how long), and how you come in contact with it. You must also consider any other chemicals you are exposed to and your age, sex, diet, family traits, lifestyle, and state of health.

1.1 WHAT IS 1,3-BUTADIENE?

Description	1,3-Butadiene is a colorless gas with a mild gasoline-like odor.
Uses	About 60% of 1,3-butadiene is used to make man-made rubber, which is then used mostly for car and truck tires. 1,3-Butadiene is also used to make certain types of plastics such as acrylics.

See Chapters 4 and 5 for more information on the sources, properties, and uses of 1,3-butadiene.

1. PUBLIC HEALTH STATEMENT

1.2 WHAT HAPPENS TO 1,3-BUTADIENE WHEN IT ENTERS THE ENVIRONMENT?

Sources	<p>Large amounts of 1,3-butadiene are released into the air by industrial sources. Industrial releases to water and soil are relatively low. Smaller amounts of 1,3-butadiene are constantly released into the air from vehicle exhaust. Other sources of 1,3-butadiene include cigarette smoke and the smoke of wood fires.</p> <p>Forest fires are considered to be a natural source of 1,3-butadiene in the air.</p>
Break-down <ul style="list-style-type: none"> • Air • Water and soil 	<p>Half of the 1,3-butadiene that enters into air is expected to be broken down in about 6 hours.</p> <p>1,3-Butadiene that is spilled onto water or soil is expected to evaporate quickly into the air based on its physical and chemical properties.</p>

See Chapters 5 and 6 for more information on 1,3-butadiene in the environment.

1.3 HOW MIGHT I BE EXPOSED TO 1,3-BUTADIENE?

Air	<p>The primary way you can be exposed to 1,3-butadiene is by breathing air containing it. Releases of 1,3-butadiene into the air occur from:</p> <ul style="list-style-type: none"> • vehicle exhaust • tobacco smoke • wood burning • burning of rubber and plastic • forest fires • accidental or intentional release at manufacturing plants <p>The average amount of 1,3-butadiene in the air is between 0.4 and 1 parts of 1,3-butadiene per billion parts of air (ppb) in cities and suburban areas.</p>
Workplace air	<p>Workers in the production of rubber, plastics, and resins are likely exposed to higher levels of 1,3-butadiene.</p>

1. PUBLIC HEALTH STATEMENT

Food and drinking water	<p>1,3-Butadiene has been measured at very low levels in plastic or rubber of food containers, but it has not been found often in food samples.</p> <p>Exposure to 1,3-butadiene through ingestion of food and drinking water is expected to be very low compared to exposure through breathing contaminated air.</p>
Gasoline	<p>People may be exposed to small amounts of 1,3-butadiene by touching gasoline or by breathing air that contains gasoline fumes.</p>

1.4 HOW CAN 1,3-BUTADIENE ENTER AND LEAVE MY BODY?

Enter your body	<p>Breathing in air containing 1,3-butadiene may cause the chemical to be absorbed from the lungs to the blood stream.</p> <p>Eating or drinking foods and water containing 1,3-butadiene may result in the chemical being taken up into the gut and bloodstream, although we do not know how much would be absorbed.</p>
Leave your body	<p>1,3-Butadiene is broken down to other chemicals in the liver.</p> <p>About half of inhaled 1,3-butadiene is broken down and exhaled, while most of the remaining chemical is broken down and excreted in the urine. 1,3-Butadiene typically leaves the body by 10 hours.</p>

For more information on how 1,3-butadiene enters and leaves the body, see Chapter 3.

1.5 HOW CAN 1,3-BUTADIENE AFFECT MY HEALTH?

This section looks at studies concerning potential health effects in animal and human studies.

Noncancer	<p>In the short term, 1,3-butadiene exposure in humans may cause nausea, dry mouth and nose, headache, and decreased blood pressure and pulse rate.</p> <p>In laboratory animals, 1,3-butadiene causes inflammation of nasal tissues, changes to lung, heart, and reproductive tissues, neurological effects, blood changes, reduced fetal body weight, and birth defects.</p>
------------------	--

1. PUBLIC HEALTH STATEMENT

Cancer	<p>Studies of workers exposed to 1,3-butadiene suggest that workers may have an increased risk for cancers of the stomach, blood, and lymphatic system.</p> <p>Laboratory animals have developed cancer in multiple body tissues after exposure to 1,3-butadiene for 13 weeks or longer. Animals appear to be most sensitive to blood and lymphatic system cancers.</p> <p>The International Agency for Research on Cancer (IARC), National Toxicology Program (NTP), and EPA all classify 1,3-butadiene as a human carcinogen.</p>
---------------	---

1.6 HOW CAN 1,3-BUTADIENE AFFECT CHILDREN?

This section discusses potential health effects in humans from exposures during the period from conception to maturity at 18 years of age.

Effects in children	It is likely that children would show the same health effects as adults. We do not know whether children are more sensitive to the effects of 1,3-butadiene.
Birth defects	We do not know whether 1,3-butadiene causes birth defects in people. In laboratory animals, 1,3-butadiene caused birth defects, such as skull defects, and brain growth outside of the skull.

1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO 1,3-BUTADIENE?

Wood burning	Take precautions to minimize the amount of smoke released into the home during wood burning.
Vehicle engines	Make sure vehicle engines are turned off when in an enclosed space such as a garage.
Vehicle traffic	Minimize time spent near areas of heavy vehicle traffic and avoid living very close to busy roads.
Tobacco smoke	Families can reduce exposure to 1,3-butadiene by avoiding tobacco smoke, particularly indoors.

1. PUBLIC HEALTH STATEMENT

1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 1,3-BUTADIENE?

Development of blood tests	We currently have no reliable medical test to determine if someone has been exposed to 1,3-butadiene. However, scientists are working on tests to show if 1,3-butadiene attaches to compounds in the blood, such as proteins or deoxyribonucleic acid (DNA).
-----------------------------------	--

1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?

The federal government develops regulations and recommendations to protect public health. Regulations can be enforced by law. The EPA, the Occupational Safety and Health Administration (OSHA), and the Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic substances. Recommendations provide valuable guidelines to protect public health, but cannot be enforced by law. The Agency for Toxic Substances and Disease Registry (ATSDR) and the National Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop recommendations for toxic substances.

Regulations and recommendations can be expressed as “not-to-exceed” levels. These are levels of a toxic substance in air, water, soil, or food that do not exceed a critical value. This critical value is usually based on levels that affect animals; they are then adjusted to levels that will help protect humans. Sometimes these not-to-exceed levels differ among federal organizations because they used different exposure times (an 8-hour workday or a 24-hour day), different animal studies, or other factors.

Recommendations and regulations are also updated periodically as more information becomes available. For the most current information, check with the federal agency or organization that provides it.

Some regulations and recommendations for 1,3-butadiene include the following:

Levels in breathing air set by EPA	EPA has set a reference concentration in breathing air of 0.9 ppb for 1,3-butadiene.
Levels in drinking water set by EPA	EPA has not set levels in drinking water for 1,3-butadiene.
Levels in workplace air set by OSHA	OSHA set a legal limit of 1 ppm for 1,3-butadiene in air averaged over an 8-hour work day.

1. PUBLIC HEALTH STATEMENT

1.10 WHERE CAN I GET MORE INFORMATION?

If you have any more questions or concerns, please contact your community or state health or environmental quality department, or contact ATSDR at the address and phone number below.

ATSDR can also tell you the location of occupational and environmental health clinics. These clinics specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous substances.

Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You may request a copy of the ATSDR ToxProfiles™ CD-ROM by calling the toll-free information and technical assistance number at 1-800-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by writing to:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine
1600 Clifton Road NE
Mailstop F-62
Atlanta, GA 30333
Fax: 1-770-488-4178

Organizations for-profit may request copies of final Toxicological Profiles from the following:

National Technical Information Service (NTIS)
5285 Port Royal Road
Springfield, VA 22161
Phone: 1-800-553-6847 or 1-703-605-6000
Web site: <http://www.ntis.gov/>

2. RELEVANCE TO PUBLIC HEALTH

2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO 1,3-BUTADIENE IN THE UNITED STATES

1,3-Butadiene is a gas used to make synthetic rubber, which is then used mostly for car and truck tires. Some plastics, such as acrylics, use 1,3-butadiene in their formulations. Large amounts of 1,3-butadiene are released into the air by industrial sources, while releases to water and soil are relatively low. Smaller amounts of 1,3-butadiene are constantly released into the air from vehicle exhaust, cigarette smoke, wood burning, and the burning of rubber and plastics. Naturally-occurring 1,3-butadiene in the air comes from forest fires. Half of the 1,3-butadiene that enters into air is expected to be broken down in about 6 hours. Evaporation is expected to remove most 1,3-butadiene spilled into water or soil.

The general public can be exposed to 1,3-butadiene by breathing urban and suburban air. The average amount of 1,3-butadiene in the air is between 0.4 and 1 ppb in cities and suburban areas. Workers involved in the production of rubber, plastics, and resins are most likely to receive the largest exposures. People may be exposed to 1,3-butadiene by breathing air mixed with vehicle engine exhaust, smoke from fires, and cigarettes or cigarette smoke (including second-hand smoke). They may also be exposed to small amounts of 1,3-butadiene by touching gasoline or by breathing air that contains gasoline fumes. Higher amounts of 1,3-butadiene may be in the air near polluted cities or oil refineries, chemical manufacturing plants, and plastic and rubber factories where this chemical is made or used. Leaks or intentional releases from manufacturing plants account for large amounts of 1,3-butadiene in the air. 1,3-Butadiene has been measured at very low levels in the plastic or rubber of food containers, but it has not been found often in food samples. 1,3-Butadiene has been found in drinking water, but no concentrations or sources were identified. Contact with 1,3-butadiene through food and drinking water is expected to be very low compared to breathing contaminated air.

2.2 SUMMARY OF HEALTH EFFECTS

Numerous target organs for 1,3-butadiene toxicity have been suggested in humans, as reported in case reports and epidemiological studies, and in animals, as shown in well-conducted laboratory studies ranging from single episode to lifetime exposures. Observed effects include death, neurological dysfunction, reproductive and developmental effects, hematological and lymphoreticular effects, and cancer. The available data for 1,3-butadiene exposure and toxicity in humans and animals are limited to

2. RELEVANCE TO PUBLIC HEALTH

inhalation exposures; the effects from significant oral or dermal exposures are not known. In animals, mice are more sensitive than rats to almost all toxic effects observed for 1,3-butadiene.

Very high exposures to 1,3-butadiene vapors in humans ($>10,000$ ppm) may result in narcosis and death from respiratory paralysis, although the required concentrations for these frank neurological effects are not known. Nausea, dryness of the mouth and nose, headache, and decreased blood pressure and pulse rate are the first signs observed in humans (Sandmeyer 1981). In rodents, anesthesia and acute death occurred following half-hour to 4-hour exposures to $\geq 120,000$ ppm 1,3-butadiene.

Lesions of the respiratory tract (olfactory tissues and lungs), liver, kidney, stomach, and eyes have been seen in rodents exposed to ≥ 200 ppm for intermediate durations, but these lesions are typically epithelial or endothelial hyperplasias and are precancerous in nature. Non-neoplastic lesions of the liver (necrosis) in rats and kidney (renal nephrosis) in mice occurred following intermediate-duration exposure to 625 or 8,000 ppm, respectively.

Changes in the blood and lymphoid tissues are common observations in rodents exposed for intermediate and chronic durations. Decreases in red blood cell counts and hemoglobin concentration occurred at 65 ppm in mice, progressing to macrocytic megaloblastic anemia from exposures of 200 ppm. These effects are likely associated with observed changes in normal bone marrow function, as indicated by reduced circulation of erythrocytes and leukocytes, and increased proliferative activity with no associated change in bone marrow cellularity. This is similar to humans, in which slightly lower levels of red blood cells, hemoglobin, platelets, and neutrophils were seen in tank car fillers, compared to other styrene-butadiene rubber workers, ostensibly because these workers experienced exposure to 1,3-butadiene that was at least one order of magnitude higher than workers in other areas of the plant. Lymphoreticular toxicity in mice was indicated by significant changes in thymus weight and lesions in lymphoid organs following intermediate-duration exposures to 625–1,250 ppm in mice. A reversible suppression of cytotoxic T-lymphocyte generation to mastocytoma cells and a depression of spleen cellularity were observed at these exposures. The changes in spleen and thymus weights, lymphocytic differentiation, and appearance of lymphoid lesions comport with the onset of lymphoma in mice after chronic exposure to 1,3-butadiene.

Reproductive and developmental effects are the most sensitive non-cancer effects observed in rodents. Wavy ribs and skeletal abnormalities occurred in offspring of rats exposed to 1,000–8,000 ppm during gestation days (GDs) 6–15. In mice, exposure of pregnant dams to 40 ppm on GDs 6–15 resulted in a 5%

2. RELEVANCE TO PUBLIC HEALTH

decrease in fetal body weight among male mice. This was the lowest LOAEL identified in any of the acute-duration animal studies. Exposure of mice to ≥ 200 ppm resulted in $\geq 19\%$ reductions in fetal weight. A possible dominant lethal effect was observed in mice in which increased fetal deaths occurred from exposure to 200 ppm. The lowest LOAEL identified for intermediate-duration exposures was 12.5 ppm in male mice mated with unexposed females, resulting in increased late fetal death, exencephaly, and skull abnormalities of fetuses. Serious lesions of reproductive tissues in male and female mice have arisen from intermediate- and chronic-duration exposures. Ovarian atrophy, including complete loss of oocytes, follicles, and corpora lutea, occurred in mice exposed to 200 ppm for 9 months and as low as 6.25 ppm for 2 years. Male mice were somewhat less sensitive, with testicular atrophy observed after 15-month exposures to 625 ppm 1,3-butadiene.

Numerous epidemiological studies of multiple occupational cohorts, including one encompassing 15,000 workers, have associated a higher incidence of hemato-lymphopoietic, stomach, and respiratory cancer mortality among exposed workers. Although most of these workers were co-exposed to other organic compounds, including styrene, benzene, and dithiocarbamates, multivariate analysis suggested that the estimates of 1,3-butadiene exposure provided the best correlation with the rates of lympho-hematopoietic cancers. The consistent carcinogenic responses in rodents bioassays support the associations derived in epidemiological studies between hemato-lymphopoietic cancer and 1,3-butadiene exposure. In rats, 2-year exposure to 1,000 or 8,000 ppm resulted in increased tumor incidences of the testes, pancreas, uterus, mammary gland, Zymbal gland, and thyroid. In mice, exposure to 200 ppm for 40 weeks resulted in increased tumor incidences of lymphopoietic system, heart, lung, stomach, liver, and eye. These same tumors developed in mice in as little as 13 weeks after exposure to 625 ppm. Chronic exposure of mice to concentrations of 20 ppm (males) and 6.25 ppm (females) of 1,3-butadiene resulted in increased tumor development in the lymphopoietic system, heart, lung, stomach, liver, eye, mammary glands, and ovaries.

2.3 MINIMAL RISK LEVELS (MRLs)

Inhalation MRLs

- An MRL of 0.1 ppm has been derived for acute-duration inhalation exposure (14 days or less) to 1,3-butadiene.

Death and neurological effects have been observed in rats, mice, and rabbits exposed to 8,000–250,000 ppm from <1 to 4 hours (Carpenter et al. 1944; Shugaev 1969). In rats, wavy ribs were seen in

2. RELEVANCE TO PUBLIC HEALTH

offspring from females inhaling 1,000 ppm 6 hours/day for 10 days, while skeletal abnormalities occurred at 8,000 ppm for the same duration (Irvine 1981). In mice, increased fetal death (a dominant lethal effect) occurred in offspring of males exposed to 200 ppm 6 hours/day for 5 days (DOE/NTP 1988b). However, the most sensitive effect observed during acute-duration exposures was a 5% reduction in male fetal weight following exposure of pregnant dams to 40 ppm (DOE/NTP 1987b). In this study, groups of 18–20 pregnant CD-1 mice were subjected to inhalation exposures of 0, 40, 200, or 1,000 ppm 1,3-butadiene for 6 hours/day on GDs 6–15. On GD 16, decreased maternal weights of 5, 14, and 24% were observed in the 40, 200, and 1,000 ppm groups, respectively. No significant differences in body weights were seen at GDs 6–18. In the 200 and 1,000 ppm groups, GD 18 body weight and gravid uterine weights were 4–7% and 7–13% less than controls, respectively. Male fetal body weights at 40 ppm were significantly less than controls (5%), while female fetal body weights were reduced (4% lower than controls), but not significantly. Mean whole-litter fetal body weights at 40 ppm were reduced (4% lower than controls), but also not statistically significantly. Mean whole-litter fetal weights at ≥ 200 ppm were reduced $>15\%$ lower than controls. There was no observed treatment-related effect on number of implants, total resorptions, or live/dead fetuses/litter. At ≥ 200 ppm, significantly increased incidences of extra rudimentary ribs and reduced sternebral ossification were observed. Male fetal weights on GD 18 were 5, 18, and 23% lower than controls (all significant to $p \leq 0.05$) in the 40, 200, and 1,000 ppm groups, respectively, while female fetal weights were 4, 15, and 22% lower than controls (significant to $p \leq 0.05$ for ≥ 200 ppm). Since the reduced fetal weight in the low-dose males was 5% and was not associated with other fetal effects, it is considered a minimally adverse LOAEL.

An acute-duration inhalation MRL of 0.1 ppm was derived using the LOAEL of 40 ppm for reduced male fetal body weight gain from exposed pregnant mice. The LOAEL of 40 ppm was adjusted for intermittent exposure (6 hours/day) resulting in a duration-adjusted LOAEL of 10 ppm. A LOAEL_{HEC} (human equivalent concentration) of 10 ppm was derived (see Appendix A), which was divided by an uncertainty factor of 90 (3 for use of a minimally adverse effect, 3 for extrapolation from animals to humans, and 10 for human variability).

Intermediate-duration exposures resulted in death in mice exposed to 5,000 ppm, 6 hours/day for 5 weeks (NTP 1984) and 200 ppm, 6 hours/day for 40 weeks (NTP 1993). No systemic effects were seen in rats or mice exposed to 8,000 ppm, 6 hours/day for 13–14 weeks, with the exception of a 13% body weight reduction in mice exposed to 2,500 ppm (NTP 1984). Exposure of mice to 625 ppm, 6 hours/day for 40 weeks resulted in pre-cancerous hyperplasia of the respiratory and gastrointestinal systems (epithelial hyperplasia), as well as a 19% reduction in thymus weight. Multi-site cancer was observed in mice after

2. RELEVANCE TO PUBLIC HEALTH

13–52 weeks of exposure to 200 ppm for 6 hours/day (NTP 1993). Hematological effects included decreased erythrocyte counts, hemoglobin concentration, and red blood cell volume in mice at 62.5 ppm and macrocytic megaloblastic anemia at 200 ppm, administered 6 hours/day for 40 weeks (NTP 1993). Reproductive effects in mice were the most sensitive effects observed, with ovarian atrophy occurring at exposures of 200 ppm, 6 hours/day for 40 weeks (NTP 1993). The most sensitive developmental effects observed were exencephalies, skull abnormalities, and late fetal death in mice exposed to 12.5 ppm for 10 weeks (Anderson et al. 1996). Because the lowest LOAEL identified for intermediate-duration inhalation exposure (12.5 ppm) is a serious effect, no MRL was derived for this duration.

Chronic-duration exposures resulted in increased mortality in rats and mice exposed to 8,000 or 20 ppm, 6 hours/day for 2 years. Rats exposed to 8,000 ppm, 6 hours/day for 2 years exhibited increased lung weight and metaplasia and kidney nephrosis (Owen and Glaister 1990; Owen et al. 1987). Exposures of 1,250 ppm, 6 hours/day for 65 weeks resulted in nasal olfactory epithelial atrophy in mice (NTP 1984). Hepatic necrosis and hyperplasia of gastrointestinal and cardiovascular tissue hyperplasia, as well as megaloblastic anemia, were seen in mice exposed to 625 ppm, 6 hours/day for 65 weeks to 2 years (NTP 1993). Mammary gland tumors developed in rats exposed to 1,000 ppm, 6 hours/day for 2 years (Owen and Glaister 1990; Owen et al. 1987), while multi-site cancer was observed in mice exposed to 625 ppm, 6 hours/day for 61 weeks (NTP 1984). Lung cancer in mice occurred following exposure to 6.25 ppm, 6 hours/day for 2 years (NTP 1993). The most sensitive chronic-duration effect observed was ovarian atrophy occurring in mice exposed to 6.25 ppm, 6 hours/day for 2 years (NTP 1993), which included complete destruction of oocytes, follicles, and corpora lutea. No chronic-duration inhalation MRL was derived because the lowest LOAEL (6.25 ppm) identified for this duration was a serious reproductive effect.

Oral MRLs

There are no data available for effects in humans or animals exposed orally to 1,3-butadiene. For this reason, no acute-, intermediate-, or oral-duration MRLs could be derived.

2. RELEVANCE TO PUBLIC HEALTH

This page is intentionally blank.

3. HEALTH EFFECTS

3.1 INTRODUCTION

The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and other interested individuals and groups with an overall perspective on the toxicology of 1,3-butadiene. It contains descriptions and evaluations of toxicological studies and epidemiological investigations and provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.

A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.

3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE

To help public health professionals and others address the needs of persons living or working near hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).

Levels of significant exposure for each route and duration are presented in tables and illustrated in figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, or those whose significance to the organism is not entirely clear. ATSDR acknowledges that a considerable amount of judgment may be required in establishing whether an end point should be classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be insufficient data to decide whether the effect is indicative of significant dysfunction. However, the Agency has established guidelines and policies that are used to classify these end points. ATSDR believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between "less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is considered to be important because it helps the users of the profiles to identify levels of exposure at which major health effects start to appear. LOAELs or NOAELs should also help in determining whether or not

3. HEALTH EFFECTS

the effects vary with dose and/or duration, and place into perspective the possible significance of these effects to human health.

The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and figures may differ depending on the user's perspective. Public health officials and others concerned with appropriate actions to take at hazardous waste sites may want information on levels of exposure associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no adverse effects (NOAELs) have been observed. Estimates of levels posing minimal risk to humans (Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.

Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of 1,3-butadiene are indicated in Tables 3-1 and Figure 3-1. Because cancer effects could occur at lower exposure levels, Figure 3-1 also shows a range for the upper bound of estimated excess risks, ranging from a risk of 1 in 10,000 to 1 in 1,000,000 (10^{-4} to 10^{-6}), as developed by EPA.

A User's Guide has been provided at the end of this profile (see Appendix B). This guide should aid in the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.

3.2.1 Inhalation Exposure

3.2.1.1 Death

Information on the lethality of 1,3-butadiene in humans is limited. A number of epidemiological studies of cohorts of styrene-butadiene rubber (SBR) and 1,3-butadiene monomer workers have been performed to investigate whether occupational exposure to 1,3-butadiene is associated with increased mortality. Several studies suggest that higher than-normal mortality rates from cancer (specifically of lympho-hematopoietic etiology, see Sections 3.2.1.7) and certain cardiovascular diseases (see Section 3.2.1.2) occurred among SBR workers and 1,3-butadiene monomer workers (Delzell et al. 1996; Divine and Hartman 1996, 2001; Divine et al. 1993; Downs et al. 1987; Fox et al. 1974; HEI 2006; Matanoski et al. 1982, 1988, 1989a; McMichael et al. 1974, 1975, 1976; Santos-Burgoa et al. 1992; Ward et al. 1995). Although no increase in mortality or morbidity was reported in a small population of 1,3-butadiene monomer workers by Cowles et al. (1994), the exposure levels were low, with a mean of 3.5 ppm and most measurements below 1 ppm. A study of mortality of female SBR workers has been proposed (Sathiakumar and Delzell 2007), but results are not yet available.

3. HEALTH EFFECTS

No deaths were seen in B6C3F1 mice exposed to $\leq 8,000$ ppm 1,3-butadiene 6 hours/day, 5 days/week, for 2 weeks (NTP 1984). The majority of rabbits died when exposed to 250,000 ppm 1,3-butadiene for an average of 23 minutes (Carpenter et al. 1944). The LC_{50} values calculated for mice and rats exposed for 2 and 4 hours, respectively, was 122,000 and 129,000 ppm, respectively (Shugaev 1969).

Intermediate-duration exposures produced no deaths in rats exposed for 6 hours/day, 5/days/week, for 13 weeks to 8,000 ppm (Crouch et al. 1979), or in rats, guinea pigs, rabbits, and dogs during 8 months of exposure to 6,700 ppm (Carpenter et al. 1944). Increased mortality was seen in mice exposed to 5,000 ppm, but not 2,500 ppm, for 6 hours/day, 5 days/week, for 14 weeks (NTP 1984). The lowest intermediate-duration exposure resulting in death was observed in mice receiving 200 ppm for 6-hours/day, 5 days/week, for 40 weeks (NTP 1993), ostensibly from the early development of neoplasms.

During chronic exposure to 625 and 1,250 ppm of 1,3-butadiene for 61 weeks, significantly increased mortality, primarily due to cancer, was found in B6C3F1 mice (NTP 1984). Similar results were obtained in another study using a much lower concentration (20 ppm) (NTP 1993). Exposure of rats to 8,000 ppm 1,3-butadiene resulted in statistically significant increased mortality from cancer when compared with controls (Owen et al. 1987). The LC_{50} values and all reliable LOAEL values for death in each species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.

3.2.1.2 Systemic Effects

Respiratory Effects. Workers exposed to 1,3-butadiene gas during the manufacture of rubber complained of irritation of the eyes, nasal passages, throat, and lungs (Wilson 1944). In some, coughing, fatigue, and drowsiness developed. All symptoms disappeared on removal from the gas. The associated exposure levels were not reported.

No effects in respiratory tissues were observed in rats, guinea pigs, rabbits, or dogs inhaling up to 6,700 ppm 1,3-butadiene for 7.5 hours/day, 6 days/week, for 8 months (Carpenter et al. 1944) or in rats or mice exposed to 8,000 ppm 1,3-butadiene for 6 hours/day, 5 days/week, for 13–14 weeks (Crouch et al. 1979; NTP 1984). No effects were observed in lungs of mice exposed to up to 625 ppm for 6 hours/day, 5 days/week, for 9 months (NTP 1993).

Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation

Key to Figure ^a	Species (Strain)	Exposure/Duration/Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
ACUTE EXPOSURE								
Death								
1	Rat	1 d 4 h/d				129000	(LC50)	Shugaev 1969
2	Mouse	1 d 2h/d				122000	(LC50)	Shugaev 1969
3	Rabbit	1 d 23 min/d				250000	(death)	Carpenter et al. 1944
Neurological								
4	Human	1 d 6-8 hr/d		8000				Carpenter et al. 1944
5	Rabbit	1 d 23 min/d				250000	(anesthesia)	Carpenter et al. 1944
Reproductive								
6	Rat (Sprague-Dawley)	10 d 6 hr/d Gd 6-15		1000				DOE/NTP 1987a
7	Mouse (CD-1)	10 d 6 hr/d GD 6-15		1000				DOE/NTP 1987b
8	Mouse (B6C3F1)	5 d 6 h/d			1000 M (73% increase in number of abnormal sperm heads)			DOE/NTP 1988a
Developmental								
9	Rat (Sprague-Dawley)	10 d 6 hr/d Gd 6-15		1000				DOE/NTP 1987a

DRAFT FOR PUBLIC COMMENT

Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation

(continued)

Key to Figure	Species (Strain)	Exposure/Duration/Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
10	Rat	10 d 6 hr/d Gd 6-15		200	1000 (wavy ribs)	8000 (skeletal abnormalities)	Irvine 1981	
11	Mouse (CD-1)	10 d 6 hr/d GD 6-15			^b 40 M (fetal body weight 5% lower than controls)		DOE/NTP 1987b	
INTERMEDIATE EXPOSURE								
Death								
12	Mouse	14 wk 5 d/wk 6 hr/d				5000 (increased mortality)	NTP 1984	
13	Mouse (B6C3F1)	13-52 wk 6 hr/d 5 d/wk				200 (increased mortality from 40 weeks of exposure)	NTP 1993	
Systemic								
14	Rat	13 wk 5 d/wk 6 hr/d	Resp	8000			Crouch et al. 1979	
			Cardio	8000				
			Hemato	8000				
			Musc/skel	8000				
			Hepatic	8000				
			Renal	8000				
			Dermal	8000				
			Ocular	8000				

DRAFT FOR PUBLIC COMMENT

Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation

(continued)

Key to Figure	Species (Strain)	Exposure/Duration/Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments	
					Less Serious (ppm)	Serious (ppm)			
15	Mouse	3-24 wk 6 d/wk 6 hr/d	Hemato			1250 M (macrocytic megaloblastic anemia starting at 6 weeks)	Irons et al. 1986a, 1986b		
16	Mouse	14 wk 5 d/wk 6 hr/d	Resp	8000				NTP 1984	
			Cardio	8000					
			Gastro	8000					
			Musc/skel	8000					
			Hepatic	8000					
			Renal	8000					
			Dermal	8000					
			Bd Wt	1250	2500 M (13% decreased body weight)				
17	Mouse (B6C3F1)	13-52 wk 6 hr/d 5 d/wk	Resp		200 M (alveolar epithelial hyperplasia after 40 weeks)		NTP 1993		
			Cardio		200 M (endothelial hyperplasia after 40 weeks)				
			Ocular	200 M	625 M (Harderian gland hyperplasia after 26 weeks)				

DRAFT FOR PUBLIC COMMENT

Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation

(continued)

Key to Figure	Species (Strain)	Exposure/Duration/Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
18	Mouse (B6C3F1)	40 wk 6 hr/d 5 d/wk	Resp	200 M	625 M (alveolar epithelial hyperlasia)		NTP 1993	
			Cardio	625				
			Gastro	200	625 (forestomach epithelial hyperplasia)			
			Hemato		62.5 M (decreased erythrocyte counts, hemoglobin concentration, and red cell volume)	200 F (macrocytic megaloblastic anemia)		
			Musc/skel	625				
			Hepatic	625 F				
			Bd Wt	625				
Immuno/ Lymphoret								
19	Mouse (B6C3F1)	40 wk 6 hr/d 5 d/wk			625 F (19% reduction in relative thymus weight)		NTP 1993	
20	Mouse	6-24 wk 5 d/wk 6 hr/d			1250 (lymphoid organ histopathology)		Thurmond et al. 1986	
Neurological								
21	Rat	13 wk 5 d/wk 6 hr/d		8000			Crouch et al. 1979	

DRAFT FOR PUBLIC COMMENT

1,3-BUTADIENE

3. HEALTH EFFECTS

Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation

(continued)

Key to Figure	Species (Strain)	Exposure/Duration/Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
22	Mouse	14 wk 5 d/wk 6 hr/d		8000			NTP 1984	
Reproductive								
23	Mouse (CD)	10 wk 6 h/d 5 d/wk				12.5 M (increase in late fetal deaths, exencephalies, and skull abnormalities)	Anderson et al. 1996	
24	Mouse (CD)	4 wk 6 h/d 5 d/wk		12.5 M	65 M (increases in early fetal deaths)		Anderson et al. 1998	
25	Mouse (B6C3F1)	40 wk 6 hr/d 5 d/wk		62.5 F		200 F (ovarian atrophy)	NTP 1993	
Cancer								
26	Mouse (B6C3F1)	13-52 wk 6 hr/d 5 d/wk				200 M (CEL:lymphocytic lymphoma, histiocytic sarcoma, cardiac hemangiosarcoma, alveolar/bronchiolar adenoma/carcinoma, forestomach squamous cell papilloma/carcinoma, hepatocellular adenoma, Harderian gland adenoma/adenocarcinoma; preputial gland carcinoma)	NTP 1993	

DRAFT FOR PUBLIC COMMENT

Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/Duration/Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
CHRONIC EXPOSURE								
Death								
27	Rat	105-111 wk 5 d/wk 6 hr/d		1000		8000	(increased mortality)	Owen et al. 1987, Owen and Glaister 1990
28	Mouse	61 wk 5 d/wk 6 hr/d				625	(increased mortality)	NTP 1984
29	Mouse (B6C3F1)	2 yr 6 hr/d 5 d/wk				20	(increased mortality)	NTP 1993
Systemic								
30	Rat	105-111 wk 5 d/wk 6 hr/d	Resp	1000	8000		(increased organ weight, metaplasia)	Owen et al. 1987, Owen and Glaister 1990
			Cardio	8000				
			Gastro	8000				
			Hemato	8000				
			Hepatic	8000				
			Renal	1000		8000	(nephrosis)	
			Dermal	8000				
			Ocular	8000				

DRAFT FOR PUBLIC COMMENT

Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation

(continued)

Key to Figure	Species (Strain)	Exposure/Duration/Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
31	Mouse	61 wk 5 d/wk 6 hr/d	Resp	625		1250	(atrophy of nasal olfactory epithelium)	NTP 1984
			Cardio		625		(endothelial hyperplasia)	
			Gastro		625		(epithelial hyperplasia)	
			Musc/skel	1250				
			Hepatic		625		(hepatic necrosis)	
			Renal	1250				
			Dermal	1250				
32	Mouse (B6C3F1)	2 yr 6 hr/d 5 d/wk	Resp		6.25 M		(alveolar epithelial hyperplasia)	NTP 1993
			Cardio	200	625		(endothelial hyperplasia)	
			Gastro		625 F		(forestomach epithelial hyperplasia)	
					200 F		(forestomach epithelial hyperplasia)	
			Musc/skel	625				
			Hepatic		62.5		(liver necrosis)	
			Bd Wt	625				

DRAFT FOR PUBLIC COMMENT

Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation

(continued)

Key to Figure	Species (Strain)	Exposure/Duration/Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
33	Mouse (B6C3F1)	65 wk 6 hr/d 5 d/wk	Hemato	200		625 (macrocytic megaloblastic anemia)	NTP 1993	
			Bd Wt	625				
Neurological								
34	Rat	105-111 wk 5 d/wk 6 hr/d		8000			Owen et al. 1987, Owen and Glaister 1990	
35	Mouse	61 wk 5 d/wk 6 hr/d		1250			NTP 1984	
Reproductive								
36	Mouse	61 wk 5 d/wk 6 hr/d				625 (gonadal atrophy)	NTP 1984	
37	Mouse (B6C3F1)	2 yr 6 hr/d 5 d/wk				6.25 F (ovarian atrophy)	NTP 1993	
38	Mouse (B6C3F1)	65 wk 6 hr/d 5 d/wk		20 F		62.5 F (ovarian atrophy)	NTP 1993	

DRAFT FOR PUBLIC COMMENT

Table 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation

(continued)

Key to Figure ^a	Species (Strain)	Exposure/Duration/Frequency (Route)	System	NOAEL (ppm)	LOAEL		Reference Chemical Form	Comments
					Less Serious (ppm)	Serious (ppm)		
Cancer								
39	Rat	105-111 wk 5 d/wk 6 hr/d				1000	(CEL: mammary gland adenoma and sarcoma)	Owen et al. 1987, Owen and Glaister 1990
40	Mouse	61 wk 5 d/wk 6 hr/d				625	(CEL: alveolar/bronchiolar adenoma or carcinoma, malignant lymphoma, hemangiosarcoma, forestomach squamous cell papilloma or carcinoma, mammary gland carcinoma, ovarian granulosa cell tumor)	NTP 1984
41	Mouse (B6C3F1)	2 yr 6 hr/d 5 d/wk				6.25 F	(CEL: alveolar/bronchiolar adenoma/carcinoma)	NTP 1993

DRAFT FOR PUBLIC COMMENT

a The number corresponds to entries in Figure 3-1.

b Used to derive an acute-duration inhalation MRL of 0.1 ppm; human equivalent concentration divided by an uncertainty factor of 90 (3 for the use of a minimally adverse LOAEL, 3 for extrapolation from animals to humans using dosimetric conversion, and 10 for human variability).

Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; F = Female; Gastro = gastrointestinal; Gd = gestation day; Hemato = hematological; hr = hour(s); Immuno/Lymphoret = immunological/lymphoreticular; LOAEL = lowest-observed-adverse-effect level; M = male; min = minute(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; occup = occupational; Resp = respiratory; TWA = time-weighted average; x = time(s); wk = week(s); yr = year(s)

Figure 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation
Acute (≤14 days)





Figure 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation (Continued)

Intermediate (15-364 days)



DRAFT FOR PUBLIC COMMENT

Figure 3-1 Levels of Significant Exposure to 1,3-butadiene - Inhalation (Continued)
Intermediate (15-364 days)

DRAFT FOR PUBLIC COMMENT



3. HEALTH EFFECTS

An increase in chronic inflammation of the nasal cavity, fibrosis, cartilaginous metaplasia, osseous metaplasia, atrophy of the sensory epithelium, and hyperplasia of the respiratory epithelium were observed in mice exposed to 1,250 ppm for 2 years (NTP 1984). Lungs of rats exposed chronically to 8,000 ppm 1,3-butadiene exhibited metaplasia (Owen and Glaister 1990; Owen et al. 1987). Atrophy of the nasal olfactory epithelium was observed in mice exposed to up to 1,250 ppm 1,3-butadiene for 6 hours/day, 5 days/week, for 61 weeks (NTP 1993), while alveolar epithelial hyperplasia (a possible precancerous lesion) occurred in mice exposed to 6.25 ppm 6 hours/day, 5 days/week for 2 years (NTP 1993).

Cardiovascular Effects. In a retrospective epidemiological study of middle-aged workers in the rubber industry, excessive mortality was noted for certain types of cardiovascular diseases, mainly chronic rheumatic and arteriosclerotic heart diseases (McMichael et al. 1974). Furthermore, increased mortality for arteriosclerotic heart disease was reported among black males in the rubber industry (Matanoski and Schwartz 1987). This result was also reported in an update of the original study (Matanoski et al. 1988, 1990). However, increased mortality from cardiovascular disease was not observed in three other cohorts of SBR and 1,3-butadiene monomer workers (Cowles et al. 1994; Divine and Hartman 1996, 2001; Ward et al. 1995). Thus, it is unclear if cardiovascular disease is likely to be caused by 1,3-butadiene exposure.

No cardiovascular lesions were found in mice or rats exposed to 8,000 ppm 1,3-butadiene 6 hours/day, 5 days/week, for 13–14 weeks (Crouch et al. 1979; NTP 1984). Endothelial hyperplasia in the heart (an early preneoplastic lesion) was observed in mice after exposure to 200 ppm for 6 hours/day, 5 days/week for 40 weeks (NTP 1993) or 625 ppm 6 hours/day, 5 days/week for 61 weeks or 2 years (NTP 1984, 1993). No exposure-related histopathological cardiac lesions were found in rats exposed chronically to up to 8,000 ppm for 2 years (Owen et al. 1987).

Gastrointestinal Effects. No studies were located regarding non-cancer gastrointestinal effects in humans after inhalation exposure to 1,3-butadiene.

No significant incidences of gastrointestinal tract lesions were observed in mice following exposure to 8,000 ppm 1,3-butadiene for 6 hours/day, 5 days/week, for 14 weeks (NTP 1984) or 200 ppm for 6 hours/day, 5 days/week for 40 weeks (NTP 1993). In a chronic-duration study, high incidences of forestomach epithelial hyperplasia (a possible preneoplastic lesion) were observed in mice exposed to 625 ppm for 6 hours/day, 5 days/week for 61 weeks (Melnick et al. 1990a; NTP 1984) and for 2 years

3. HEALTH EFFECTS

(NTP 1993). No exposure-related nonneoplastic gastrointestinal lesions were found in rats exposed chronically to up to 8,000 ppm for 6 hours/day, 5 days/week for 2 years (Owen et al. 1987).

Hematological Effects. A hematological survey of workers at a styrene-butadiene rubber plant revealed little indication of bone marrow toxicity among the workers (Checkoway and Williams 1982). Styrene and 1,3-butadiene were the most significant chemicals in the atmosphere; benzene and toluene were present in much lower concentrations. A group of eight tank farm workers (workers who load and unload chemicals from storage tanks; mean level exposure of 20 ppm) demonstrated slightly lower levels of red blood cells, hemoglobin, platelets, and neutrophils compared with other workers, but these findings were within the normal range. Other epidemiological studies, however, implicated 1,3-butadiene as the possible cause of hematopoietic malignancies among styrene-butadiene rubber workers (McMichael et al. 1975) at exposure levels that may be lower than 20 ppm.

No signs of blood dyscrasias were found among 164 animals (rats, rabbits, guinea pigs, dogs) exposed to concentrations up to 6,700 ppm of 1,3-butadiene for 8 months (Carpenter et al. 1944). The results were supported by a 3-month study in which no effects on hematological indices were found in rats after exposure to 8,000 ppm of 1,3-butadiene (Crouch et al. 1979).

A treatment-related macrocytic megaloblastic anemia was observed in B6C3F1 and NIH mice exposed to 1,250 ppm 1,3-butadiene for 6 hours/day, 6 days/week for 6–24 weeks, but not after a 3-week exposure to the same concentration (Irons et al. 1986a, 1986b). The bone marrow damage was expressed as reduced numbers of red blood cells, decreased hemoglobin concentration and hematocrit, and increased mean corpuscular volume of circulating erythrocytes. The changes were observed in both strains, independently of the occurrence of murine leukemia viruses in the animals. Male mice exposed to ≥ 62.5 ppm for 6 hours/day, 5 days/week for 40 weeks exhibited decreased red blood cell counts, hemoglobin concentration, and hematocrit (NTP 1993). Leukopenia and lymphopenia occurred at ≥ 200 ppm. Females exhibited macrocytic megaloblastic anemia and bone marrow atrophy after exposure to 200 and 625 ppm, respectively, 6 hours/day, 5 days/week for 40 weeks (NTP 1993).

Macrocytic megaloblastic anemia and bone marrow hyperplasia was also observed in mice exposed chronically to 625 ppm 1,3-butadiene 6 hours/day, 5 days/week for 65 weeks (NTP 1993). Surviving females, but not males, in this study exhibited increased bone marrow cellularity.

3. HEALTH EFFECTS

In contrast to the findings in mice, no effects on hematology or blood chemistry of Sprague-Dawley rats were observed after exposure to 1,000 and 8,000 ppm of 1,3-butadiene for 105–111 weeks (Owen et al. 1987).

Musculoskeletal Effects. No studies were located regarding hepatic effects of 1,3-butadiene in humans after inhalation exposure.

No musculoskeletal effects were observed in mice and rats exposed to 8,000 ppm 1,3-butadiene 6 hours/day, 5 days/week for 13–14 weeks (Crouch et al. 1979; NTP 1984) or in mice exposed to 625 ppm 6 hours/day, 5 days/week from 40 or 65 weeks or 2 years (NTP 1993).

Hepatic Effects. No studies were located regarding hepatic effects of 1,3-butadiene in humans after inhalation exposure.

No histopathological changes in livers of rats (Crouch et al. 1979) or mice (NTP 1984) were found after intermediate-duration exposure to 1,3-butadiene. The relative liver weights of both sexes of Sprague-Dawley rats were elevated after the chronic exposure to 1,3-butadiene (1,000 and 8,000 ppm); however, this finding was not associated with any pathological changes (Owen et al. 1987). Mice exposed to ≥ 625 ppm 6 hours/day, 5 days/week for 61 weeks had a significant increase in liver necrosis (NTP 1984).

Renal Effects. No studies were located regarding renal effects in humans after inhalation exposure to 1,3-butadiene.

The results of urinalysis in 164 animals, including rats, guinea pigs, rabbits, and dogs were all normal after an 8-month exposure to concentrations up to 6,700 ppm of 1,3-butadiene (Carpenter et al. 1944), but the methods were poorly described. These results were supported, however, in rats after 13 weeks of exposure to concentrations up to 8,000 ppm of 1,3-butadiene (Crouch et al. 1979). Nephrosis was found among male rats after 111 weeks of exposure to 8,000 ppm, but not 1,000 ppm, of 1,3-butadiene (Owen et al. 1987). No non-neoplastic renal lesions were observed in mice exposed to 8,000 ppm 6 hours/day, 5 days/week for 14 weeks (NTP 1984) or 625 ppm 6 hrs/day, 5 days/week, for 40 weeks to 2 years.

Dermal Effects. No studies were located regarding dermal effects in humans after inhalation exposure to 1,3-butadiene.

3. HEALTH EFFECTS

No histopathological dermal changes were found in rats or mice after 13–14 weeks exposure to 8,000 ppm 1,3-butadiene (Crouch et al. 1979; NTP 1984), in rats after 111 weeks exposure to 8,000 ppm (Owen et al. 1987), or in mice after 40 weeks to 2 years exposure to 625 ppm (NTP 1993).

Ocular Effects. Two men reported slight irritation of the eyes and difficulty in focusing on instrument scales during 6–7 hours exposure to 2,000 and 4,000 ppm 1,3-butadiene (Carpenter et al. 1944).

Ophthalmologic examination of the eyes of dogs and rabbits disclosed no signs of injury during the course of exposure to up to 6,700 ppm 1,3-butadiene for 8 months (Carpenter et al. 1944). After the termination of the experiment, histological examination revealed that the sclera, cornea, and ciliary body were normal. Sections of the optic nerve with adjacent retina showed no myelin sheath degeneration. Although the ophthalmological examination was described in detail, the study was limited by the small number of animals used.

No histopathological ocular changes were found in rats or mice after 13–14 weeks exposure to 8,000 ppm (Crouch et al. 1979; NTP 1984) or in rats after 111 weeks exposure to 8,000 ppm 1,3-butadiene (Owen et al. 1987). Increased Harderian gland hyperplasia (a precancerous lesion) was observed in male mice exposed to ≥ 62.5 ppm 6 hours/day, 5 days/week for 65 weeks and 2 years (NTP 1993).

Body Weight Effects. Body weights were reduced by 13% in male mice exposed to 2,500 ppm 1,3-butadiene 6 hours/day, 5 days/week for 14 weeks, but were not significantly different from controls when exposed to 1,250 ppm 6 hours/day, 5 days/week for 61 weeks or when exposed to 625 ppm 6 hours/day, 5 days/week for 2 years (NTP 1993)

3.2.1.3 Immunological and Lymphoreticular Effects

No studies were located regarding immunological effects of 1,3-butadiene in humans after inhalation exposure.

After 3–21 weeks of exposure to 1,250 ppm 1,3-butadiene, an increased expression of murine leukemia virus (MuLV) was observed in hematopoietic tissues of B6C3F1 mice, but not in NIH mice (Irons et al. 1987a). Furthermore, altered regulation of the stem cell development in B6C3F1 mice was reported after a similar exposure (Leiderman et al. 1986).

3. HEALTH EFFECTS

Intermediate-duration exposure of female mice to 62.5 ppm 1,3-butadiene 6 hours/day, 5 days/week for 40 weeks resulted in a 17% reduction in relative spleen weight, while exposure to 625 ppm for the same duration resulted in a 19% reduction in thymus weight (NTP 1993). By 65 weeks, relative spleen weights in 625 ppm females had increased to 57% higher than controls.

Immunological changes were detected after evaluation of specific humoral and cell-mediated immunity in B6C3F1 mice exposed to 1,250 ppm 1,3-butadiene for 6, 12, or 24 weeks (Thurmond et al. 1986). Suppression of cytotoxic T-lymphocyte generation to mastocytoma cells was observed after 6 weeks, but recovered after 12 weeks of exposure. The histological examination of lymphoid organs showed depressed spleen cellularity after 24 weeks of exposure; this value is recorded as a LOAEL for immunological effects in Table 3-1 and plotted in Figure 3-1, although it is not known how these changes affect immunocompetency.

3.2.1.4 Neurological Effects

Inhalation of 1,3-butadiene is mildly narcotic in humans at low concentrations (not specified) and may result in a feeling of lethargy and drowsiness (Sandmeyer 1981). At very high concentrations (>10,000 ppm), 1,3-butadiene causes narcosis leading to respiratory paralysis, and death. The first signs observed in humans are blurred vision, nausea, paresthesia and dryness of the mouth, throat, and nose, followed by fatigue, headache, vertigo, decreased blood pressure and pulse rate, and unconsciousness (Sandmeyer 1981). Respiratory paralysis is likely to occur only after exposure to concentrations of 1,3-butadiene higher than 10,000 ppm (Sandmeyer 1981), such as after spills or leaks.

Psychomotor responses of two men inhaling 2,000, 4,000, or 8,000 ppm 1,3-butadiene for 6–8 hours/day on different days were evaluated by Carpenter et al. (1944). At the two higher concentrations, the subjects performed a steadiness test; at the highest concentration, a tapping rate test was also performed. Results after 1,3-butadiene exposure were identical to those obtained before exposure.

Rabbits exposed to 250,000 ppm of 1,3-butadiene went through all stages of anesthesia to death in the average time of 23 minutes (Carpenter et al. 1944). Less than 2 minutes of exposure was required for loss of motor and labyrinth reflexes.

No effects on erythrocyte or brain cholinesterase or on neuromuscular function tests were found in rats exposed to up to 8,000 ppm for 13 weeks (Crouch et al. 1979). In intermediate and chronic exposure

3. HEALTH EFFECTS

studies in mice and rats, no treatment-related histopathological lesions were found in organs and tissues of the nervous system (brain, spinal cord, sciatic nerves) (Crouch et al. 1979; NTP 1984; Owen and Glaister 1990; Owen et al. 1987). Tests results for neurological function (i.e., loss of balance on a rotating cone) were possibly confounded by the mammary tumors interfering with the mobility of rats (NTP, 1984). The highest NOAEL values and all reliable LOAEL values for neurological effects in each species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.

3.2.1.5 Reproductive Effects

No studies were located regarding reproductive effects in humans after inhalation exposure to 1,3-butadiene.

A concentration-related increase in the incidence of sperm-head abnormalities occurred in B6C3F1 mice after exposure to 1,000 (73% increase) and 5,000 ppm (129% increase) of 1,3-butadiene 6 hours/day for 5 days (DOE/NTP 1988a). No impairment of fertility was noted when groups of male and female rats, rabbits, or guinea pigs were exposed to $\leq 6,700$ ppm 1,3-butadiene, (Carpenter et al. 1944). No changes were observed in the number of implants, total resorptions, or live fetuses in pregnant mice (DOE/NTP 1987b) or rats (DOE/NTP 1987a) exposed to up to 1,000 ppm 6 hours/day for 10 days.

No treatment-related histopathological effects were seen in reproductive organs of rats or mice exposed to 8,000 ppm 1,3-butadiene 6 hours/day, 5 days/week for 13–14 weeks (Crouch et al. 1979; NTP 1984). Reduction in the number of round and elongated sperm head was seen in mice exposed to 130 ppm 6 hours/day, 5 days/week for 4 weeks, but this was not associated with changes in fertility (Anderson et al. 1998). Ovarian and uterine atrophy occurred in female mice exposed to 200 ppm 6 hours/day, 5 days/week for 40 weeks (NTP 1993), while testicular atrophy was seen in male mice exposed to 625 ppm for the same duration. Exposure of female mice to 62.5 or ≥ 6.25 ppm 1,3-butadiene 6 hours/day, 5 days/week for 65 weeks or 2 years, respectively, resulted in an increased incidence of ovarian atrophy (NTP 1993). Affected females had no evidence of oocytes, follicles, or corpora lutea. An increase in testicular atrophy and preputial gland hyperplasia was observed in males only after exposure to 625 ppm 6 hours/day, 5 days/week for 2 years (NTP 1993).

Fetal toxicity was observed following the mating of untreated female mice with males exposed to 12.5 ppm 1,3-butadiene 6 hours/day, 5 days/week for 10 weeks (Anderson et al. 1996). Observed effects included an increase in late fetal death, exencephaly, and skull abnormalities. Early fetal death occurred

3. HEALTH EFFECTS

in untreated female mice mated to males exposed to 65 ppm for 6 hours/day, 5 days/week for 4 weeks. All reliable LOAEL values for effects in the reproductive system in mice in each duration category are recorded in Table 3-1 and plotted in Figure 3-1.

3.2.1.6 Developmental Effects

No studies were located regarding developmental effects in humans after inhalation exposure to 1,3-butadiene.

When exposed to concentrations up to 8,000 ppm 1,3-butadiene for 6 hours/day, 5 days/week during GDs 6–15, Sprague-Dawley rats showed signs of dose-related maternal and fetal toxicity (Irvine 1981).

Depressed body weight gain among dams was observed at ≥ 200 ppm, and fetal growth was significantly decreased in the 8,000 ppm group. A significantly increased incidence of skeletal abnormalities (wavy ribs, irregular rib ossification) occurred in the 1,000 ppm group and major abnormalities (defects of the skull, spine, sternum, long bones, and ribs) were observed in the 8,000 ppm group. In a study in which female rats were exposed to 40–1,000 ppm during GDs 6–15 (DOE/NTP 1987a), some skeletal abnormalities and ossification reductions were found in the fetuses, but were not statistically significant and were not considered to be treatment-related. In mice, a 5–23% decrease in fetal body weight gain, primarily among male mice, was observed after exposure of dams during GDs 6–15 to 40–1,000 ppm 1,3-butadiene, and increased incidences of extra ribs and reduced ossification of sternbrae were found in fetuses from groups exposed to 200 ppm and 1,000 ppm, respectively (DOE/NTP 1987b). The reduction in fetal body weight gain by male mice observed at 40 ppm is the lowest LOAEL identified for acute-duration inhalation exposures and serves as the basis for derivation of the MRL.

The highest NOAEL value and all reliable LOAEL values for developmental effects in rats for the acute duration category are recorded in Table 3-1 and plotted in Figure 3-1.

3.2.1.7 Cancer

Retrospective epidemiological studies of mortality among workers in the rubber industry were conducted in SBR (polymer) production workers and 1,3-butadiene monomer workers. Matanoski et al. 1990 (in an update of the Matanoski and Schwartz 1987 cohort) found significant standardized mortality ratios (SMRs) of 532 (1 case), 656 (95% confidence interval [CI] 135–1,906), and 482 (95% CI 59–1,762) for lymphosarcoma, leukemia, and other lymphatic neoplasms, respectively, in black production workers; white workers exhibited an SMR of 230 (95% CI 92–473) for other lymphatic neoplasms. In white

3. HEALTH EFFECTS

maintenance workers, SMRs of 144 (95% CI 53–314) and 166 (95% CI 93–275) were observed for esophageal and stomach cancer, respectively. An odds ratio of 9.4 for leukemia was observed in SBR workers in a nested case-control study of the Matanoski and Schwartz (1987) cohort of SBR workers (Matanoski et al. 1989b). No such association was found for exposure to styrene. In a study of North American SBR workers, Delzell et al. (1996) found significant SMRs for leukemia of 265 (95% CI 141–453) for maintenance and 431 (95% CI 207–793) for laboratory workers. Using the same cohort, Macaluso et al. (1996) derived a relative rate value of 4.5 for leukemia development (no confidence interval reported) associated with a cumulative exposure of 80 ppm-years. In a recent updated analysis, Cheng et al. (2007) found a significant trend for the association of leukemia in SBR workers and increasing cumulative exposure or number of “peak” exposures (>100 ppm). They also reported a minimal association (relative rate of 1.03) of leukemia in SBR workers receiving an estimated 5 ppm 1,3-butadiene exposure for 20 years (100 ppm-years).

The association of cancer in SBR workers with 1,3-butadiene exposure is supported by studies in 1,3-butadiene monomer production workers. Downs et al. (1987) calculated an SMR of 235 (no confidence interval reported) for lymphosarcoma and reticular cell sarcoma. No increase in mortality from cancer of gastrointestinal, respiratory, urinary, and skeletal systems was associated with monomer exposure. Divine (1990) and Divine et al. (1993) reported similar results in a follow-up study of this cohort (SMR 452 [95% CI 165–984]) for lymphosarcoma. Divine and Hartman (2001) followed this cohort and found significant SMRs of 141 (95% CI 108–186), 129 (95% CI 77–204), and 148 (95% CI=89–231) for all lympho-hematopoietic cancers, leukemia, and non-Hodgkin’s lymphoma, respectively. Subcohort analyses showed that increases in lympho-hematopoietic cancers appear to be restricted to monomer workers employed before 1950 (Divine and Hartman 1996). Analysis of another cohort of 364 monomer workers, 277 of which worked in a U.S. Rubber Reserve plant during World War II, found an SMR of 577 (95% CI 157–1,480) for lymphosarcoma and reticulosarcoma (Ward et al. 1995). No significant association was found between 1,3-butadiene monomer exposure and all, lung, or lympho-hematopoietic cancers in a cohort of 614 monomer workers employed between 1948 and 1989 who were exposed to a relatively low mean concentration of 3.5 ppm, with many measurements below 1 ppm (Cowles et al. 1994).

The major limitations of the epidemiological studies described so far include the lack of precise historic exposure data to 1,3-butadiene, lack of adjustment for smoking, and possible exposure to other chemicals. Irons and Pyatt (1998) suggest that dithiocarbamates, such as dimethyldithiocarbamate (DMDTC), used in the SBR vulcanization process from 1950 to 1965, may have played a significant role in leukemia

3. HEALTH EFFECTS

development that was concentrated in workers employed during this period. However, Santos-Burgoa et al. (1992) and Delzell et al. (2001) and HEI (2006) used multivariate analysis to suggest that the estimates of 1,3-butadiene exposure provided the best correlation with the rates of lympho-hematopoietic cancers, even in the presence of styrene and DMDTC. Significant relative rate values of 1.0–2.9 were observed for leukemia and cumulative DMDTC and 1,3-butadiene exposure, but not styrene exposure, in 13,130 SBR workers employed between 1943 and 1991 (Delzell et al. 2001).

Several investigators have evaluated associations between childhood leukemias and ambient 1,3-butadiene emissions. Knox et al. (2005, 2006) associated the occurrence of childhood cancer with proximity of birthplace to industrial 1,3-butadiene and benzene emissions, and roads, railways, waterways, and bus, ferry, or train stations in Great Britain; however, no actual exposure data or estimates were available. Reynolds et al. (2003) calculated leukemia rate ratios (RR), adjusted for age, ethnicity, and sex, of 1.21 (95% CI: 1.03–1.42) and 1.32 (95% CI: 1.11–1.57) for children in California census tracts ranked highest for combined exposure to 25 hazardous air pollutants (HAPs, including 1,3-butadiene) and highest for point-source HAP exposures, respectively. Likewise, Whitworth et al. (2008) reported a significant association of childhood leukemia incidence with residence in census tracts close to the ship channel (which is in close proximity to petrochemical and chemical manufacturing facilities) in Houston, Texas. These studies do not indicate strong causality between 1,3-butadiene exposure and childhood leukemia, as many chemicals may have contributed to exposure and the actual exposure to 1,3-butadiene, if any, is unknown.

The rodent bioassay database corroborates the association of lympho-hematopoietic neoplasms and occupational exposure to 1,3-butadiene reported in the epidemiology literature. Mice were clearly more sensitive to 1,3-butadiene-mediated tumor development than rats. In rats, increased tumors were not observed following intermediate-duration exposures of up to 8,000 ppm 1,3-butadiene 6 hours/day, 5 days/week for 13 weeks (Crouch et al. 1979). Two-year exposure of rats to 1,000 or 8,000 ppm 6 hours/day, 5 days/week resulted in increased incidences of Leydig cell adenoma, pancreatic exocrine adenoma, uterine sarcoma, mammary gland adenoma and carcinoma, Zymbal gland carcinoma, and thyroid follicular cell tumors (Owen and Glaister 1990; Owen et al. 1987). In mice, exposure to 200 ppm for 40 weeks resulted in increased incidences of lymphocytic lymphoma, histiocytic sarcoma, cardiac hemangiosarcoma, alveolar/bronchiolar adenoma/carcinoma, forestomach squamous cell papilloma/carcinoma, hepatocellular adenoma, hardarian gland adenoma/adenocarcinoma, and preputial gland carcinoma (NTP 1993). These same tumors developed in mice in as little as 13 weeks after exposure to 625 ppm 6 hours/day, 5 days/week (NTP 1993). Chronic exposure of mice to lower

3. HEALTH EFFECTS

concentrations of 1,3-butadiene also resulted in multi-target organ neoplasm development. Two-year 6 hour/day, 5 day/week exposures of 20 ppm for male mice and 6.25 ppm (the lowest exposure level tested) for females resulted in increased incidences of lymphocytic lymphoma, histiocytic sarcoma, cardiac hemangiosarcoma, alveolar/bronchiolar adenoma/carcinoma, forestomach squamous cell papilloma/carcinoma, hepatocellular adenoma, hardarian gland adenoma/adenocarcinoma, mammary gland carcinoma, adenocanthoma, malignant mixed tumor, and malignant ovarian granulosa cell tumor.

The cancer effect levels (CELs) are recorded in Table 3-1 and plotted in Figure 3-1.

Using the Poisson regression analysis by Health Canada (2000) of the leukemia risk data from a cohort of 15,000 SBR production workers (Delzell et al. 1996), EPA derived a unit risk for inhalation exposure of 0.08 ppm^{-1} (IRIS 2009). This unit risk corresponds to upper bound individual lifetime cancer risks at 10^{-4} to 10^{-6} for exposure levels of 1×10^{-3} to 1×10^{-6} ppm, which are plotted in Figure 3-1.

The International Agency for Research on Cancer (IARC) has classified 1,3-butadiene as a Group 1 carcinogen (carcinogenic to humans) (IARC 2009). EPA has classified 1,3-butadiene as carcinogenic to humans (EPA 2002; IRIS 2009). The Department of Health and Human Services (NTP 2005) also identified 1,3-butadiene as a “known human carcinogen”.

3.2.2 Oral Exposure

No studies were located regarding health effects in humans or animals after oral exposure to 1,3-butadiene.

3.2.3 Dermal Exposure

Dermal contact with liquid 1,3-butadiene causes a sensation of cold followed by a sensation of burning, which is the result of rapid expansion of pressurized 1,3-butadiene from liquid to gas states (NIOSH, 2005). Although this may cause frostbite, it is specific to an unusual exposure scenario and is not a toxic endpoint. However, the possible toxic effects from dermal absorption of such a concentrated amount of 1,3-butadiene are unknown. High gas concentrations may cause mild skin irritation as well (NIOSH, 2005). No other studies were located regarding health effects in humans or animals following dermal exposure to 1,3-butadiene.

3. HEALTH EFFECTS

3.3 GENOTOXICITY

1,3-Butadiene has been tested for genotoxicity in a number of *in vitro* and *in vivo* studies (Tables 3-2 and 3-3). Positive results have been found in the reverse mutation assay in *Salmonella typhimurium* TA1530 and TA1535 in the absence or in the presence of metabolic activation system (de Meester et al. 1978; Madhusree et al. 2002). However, the interpretation of these results was confounded by the fact that the Petri dishes not containing S-9 mix were contaminated by volatile active metabolites. It was concluded that S-9 mix was necessary to activate 1,3-butadiene into mutagen(s) (De Meester 1988). TA1530 was the most sensitive strain, but 1,3-butadiene mutagenicity was detectable only with metabolic activation in the subsequent study (de Meester et al. 1980). No significant mutagenic effect on *S. typhimurium* strain TA100 with metabolic activation was observed (Victorin and Stahlberg 1988). A weak genotoxic activity was detected in strain TA1535 with rat S-9 (Arce et al. 1989). A weak increase in sister chromatid exchanges was observed in Chinese hamster ovary cells, but only with metabolic activation (Sasiadek et al. 1991). Increased mutations occurred in the hypoxanthione-guanine phosphoribosyl transferase (*hprt*) and *tk* gene loci of human TK6 lymphoblastoid cells (Cochrane and Skopek 1993). On the basis of these data, 1,3-butadiene appears to require metabolic activation to produce genotoxicity.

No significant alterations in the occurrence of chromosome aberrations and sister chromatid exchanges were observed in peripheral lymphocytes of SBR workers (Hayes et al. 2000; Zhou et al. 1986),

1,3-butadiene monomer workers exposed to 2 ppm (Kelsey et al. 1995), or petrochemical workers exposed to 0.7 ppm 1,3-butadiene (Lovreglio et al. 2006). However, significant increases in chromosome aberrations and sister chromatid exchange (1.1 and 30% increases, respectively, over controls), but no increases in micronuclei, were seen in peripheral lymphocytes of 1,3-butadiene production workers exposed to mean 1,3-butadiene levels of 0.2 ppm (Sram et al. 1998).

A number of cross-sectional studies provide dose-response data for *in vivo* peripheral lymphocyte mutations from occupational exposures to 1,3-butadiene. Ward et al. (1994) reported that 1,3-butadiene production workers exposed to a mean airborne concentration of 3.4 ppm (although most were at or below 1 ppm) exhibited an almost 4-fold higher frequency of *hprt* mutations than controls. In southeast Texas SBR workers exposed to airborne concentrations of 0.3 ppm 1,3-butadiene, *hprt* mutation frequencies were 2.5-fold higher than workers exposed to mean levels of 0.12 ppm (Ma et al. 2000; Ward et al. 1996), indicating good correlation between exposure and mutation frequency. A follow-up study of the southeast Texas SBR workers found a 3-fold increase in *hprt* mutation frequency in workers

3. HEALTH EFFECTS

Table 3-2. Genotoxicity of 1,3-Butadiene *In Vitro*

Species (test system)	End point	Results		Reference
		With activation	Without activation	
Prokaryotic organisms:				
<i>Salmonella typhimurium</i>				
TA1530	Gene mutation	+	–	de Meester et al. 1980
TA100	Gene mutation	–	–	Victorin and Stahlberg 1988
TA1535	Gene mutation	+	–	Arce et al. 1989; Madhusree et al. 2002
Eukaryotic organisms:				
Chinese hamster ovary	SCE	+	–	Sasiadek et al. 1991
Human TK6 lymphoblastoid cells	<i>hprt</i> and <i>tk</i> loci mutations	NA	NA	Cochrane and Skopek 1993

– = negative result; + = positive result; NA = not applicable; SCE = sister chromatid exchange

3. HEALTH EFFECTS

Table 3-3. Genotoxicity of 1,3 Butadiene *In Vivo*

Species (test system)	End point	Results	Reference
Mammalian cells: B6C3F1 mice (inhalation)	Bone marrow: Dose-dependent increase in SCEs	+	Cunningham et al. 1986
Sprague-Dawley rats (inhalation)		-	
B6C3F1 mice (inhalation)	Bone marrow: increase in CA, SCEs, AGT and depression of MI	+	Tice et al. 1987
B6C3F1 mice (inhalation)	Macrocytic-megaloblastic anemia. bone marrow: 44% increase in proliferative index	+	Irons et al. 1986a
Swiss mice (inhalation)	Macrocytic-megaloblastic anemia 8-fold increase in circulating micronuclei, bone marrow damage	+	Irons et al. 1986b
B6C3F1 mice (inhalation)	Bone marrow: alteration of hematopoietic stem cell development	+	Leiderman et al. 1986
B6C3F1 mice (inhalation)	Peripheral blood erythrocytes: induction of micronuclei	+	Jauhar et al. 1988
B6C3F1 mice (inhalation)	Induction of MN; induction of SCEs; chromosomal aberrations	+	Tice et al. 1988
B6C3F1 mice (inhalation)	Sperm abnormalities; dominant lethality	+	DOE/NTP 1988a
C57B1/6 mice (intraperitoneal injection)	Bone marrow increase in CA, SCE	+	Sharief et al. 1986
B6C3F1 mice (inhalation)	<i>lacZ</i> mutant frequency in lung	+	Recio et al. 1992
B6C3F1 mice (inhalation)	<i>lacZ</i> mutant frequency in liver and bone marrow	-	Recio et al. 1992
B6C3F1 mice and F344 rats (inhalation)	<i>hprt</i> loci mutations in splenic T lymphocytes	+	Cochrane and Skopek 1993; Meng et al. 1999, 2000, 2004, 2007
B6C3F1 mice (inhalation)	Peripheral blood erythrocytes and bone marrow: induction of micronuclei	+	Autio et al. 1994
Wistar rats	Peripheral blood erythrocytes and bone marrow: induction of micronuclei	-	Autio et al. 1994
C3H mice (inhalation)	Heritable spermatid chromosomal translocations; dominant lethality	+	Adler et al. 1998
C3H mice (inhalation)	Spermatocytes: induction of micronuclei	+	Xiao and Tates 1995
CD-1 mice (inhalation)	Dominant lethality	-	Brinkworth et al. 1998
Humans (inhalation)	CA; SCE	+	Sram et al. 1998
Humans (inhalation)	CA; SCE	-	Lovreglio et al. 2006
Humans (inhalation)	<i>hprt</i> loci in peripheral lymphocytes	-	Hayes et al. 1996, 2000
Humans (inhalation)	<i>hprt</i> loci in peripheral lymphocytes	-	Tates et al. 1996
Humans (inhalation)	<i>hprt</i> loci in peripheral lymphocytes	-	Albertini et al. 2001, 2007; HEI 2003

3. HEALTH EFFECTS

Table 3-3. Genotoxicity of 1,3 Butadiene *In Vivo*

Species (test system)	End point	Results	Reference
Humans (inhalation)	<i>hprt</i> loci in peripheral lymphocytes	-	Liu et al. 2008
	<i>hprt</i> exon deletion	+	Liu et al. 2008
Humans (inhalation)	<i>hprt</i> loci in peripheral lymphocytes	+	Ward et al. 1994
Humans (inhalation)	<i>hprt</i> loci in peripheral lymphocytes		Abdel-Rahman et al. 2001, 2003, 2005; Ma et al. 2000; Ward et al. 1996, 2001
Humans (inhalation)	<i>hprt</i> loci in peripheral lymphocytes	+	Wickliffe et al. 2009
Humans (inhalation)			
C3H mice (inhalation)	Induction of spermatid micronuclei	+	Tommasi et al. 1998
B6C3F1 mice (inhalation)	H- and K- <i>ras</i> mutation frequency	+	Sills et al. 2001
NMRI mice (inhalation)	Bone marrow: induction of micronuclei	+	Vodicka et al. 2006

– = negative result; + = positive result; AGT = average generation time; CA = chromosomal aberration; MI = mitotic index; MN = micronucleated cell; SCEs = sister chromatid exchange

3. HEALTH EFFECTS

exposed to 1.7 ppm, compared to workers exposed to 0.07 ppm (Ward et al. 2001). A 3-fold increase in *hprt* mutation frequency was reported in another group of SBR workers exposed to 1.5 ppm compared to low-exposure workers exposed to 0.15 ppm (Ammenheuser et al. 2001). In these workers, individuals with a polymorphism for microsomal epoxide hydrolase (EH), an enzyme important for the hydrolysis of epoxide metabolites of 1,3-butadiene (see Section 3.4.3), exhibited a 3-fold higher *hprt* mutation frequency than workers without the polymorphism (Abdel-Rahman et al. 2001). Further, polymorphisms in the glutathione-S-transferase (another important enzyme in epoxide metabolite metabolism) genotypes GSTM1 or GSTT1 did not impact *hprt* mutation rates, but a combination of EH and GST polymorphism did result in an increase in *hprt* mutation frequency (Abdel-Rahman et al. 2001, 2003, 2005). Analysis of other cohorts did not find an association between *hprt* mutation and 1,3-butadiene exposure. No significant difference in *hprt* gene mutation frequency was observed in Chinese rubber production workers exposed to an average of 1.0–3.5 ppm or up to 45 ppm (6-hour TWA) during occasional pump repairs (Hayes et al. 1996, 2000). Likewise, *hprt* mutation frequencies in Chinese petrochemical workers exposed to mean levels of 10 ppm were higher, but were not significantly different than unexposed controls, while the percentage of workers exhibiting *hprt* exon deletions (27%) was significantly higher than levels found in controls (13%) (Liu et al. 2008). No significant increases in *hprt* mutation frequency were seen in Czech Republic monomer or polymer workers exposed to a mean airborne concentration of 0.6–2 ppm (range: 0.002–40 ppm) (Albertini et al. 2001, 2007; HEI 2003; Tates et al. 1996).

The reasons for disparate correspondence in lymphocyte *hprt* gene mutation and 1,3-butadiene exposure in SBR and monomer and polymer workers are not clear, but may be the result of varying experimental techniques in exposures assessment (active vs. passive sampling) and mutation analysis (autoradiography vs. cloning *hprt* assays). Another reason may be related to the longevity of worker exposure. SBR workers with current exposure to a mean airborne concentration of 0.09 ppm 1,3-butadiene did not show a significant association of *hprt* mutation frequency with current exposure or age, but did indicate significant (although weakly correlated, $R^2 = 0.1$) association with ≥ 30 years of employment, suggesting that chronic exposure may result in a lasting *hprt* mutation signature (Wickliffe et al. 2009).

A number of rodent inhalation studies report genotoxic effects. Mice and rats exhibited increased *hprt* locus mutations in splenic T cells (Cochrane and Skopek 1993; Meng et al. 1999, 2000, 2004, 2007). Inhaled 1,3-butadiene also induce an increase in micronucleus induction in erythrocytes (Jauhar et al. 1988; Tice et al. 1987; Vodicka et al. 2006), spermatocytes (Tommasi et al. 1998; Xiao and Tates 1995), and bone marrow cells (Autio et al. 1994), increased frequency of sister chromatid exchanges (Tice et al. 1987) and chromosomal aberration frequencies (Cunningham et al. 1986; Irons et al. 1987b; Tice et al.

3. HEALTH EFFECTS

1987) in mice. Transgenic B6C3F1 mice exhibited an increased *lacZ* mutant frequency in the lungs (Recio et al. 1992). Increased percentages of H- and K-*ras* proto-oncogene mutations were found in forestomach neoplasms from mice inhaling 1,3-butadiene for 2 years (83% in exposed mice compared to 24% in spontaneous neoplasms from controls) (Sills et al. 2001). No genotoxic effects (micronucleus induction, chromosomal aberrations, or sister chromatid exchanges) were found in bone marrow of rats or liver of mice exposed by inhalation to 1,3-butadiene (Autio et al. 1994; Cunningham et al. 1986; Recio et al. 1992).

In a dominant lethal study in which male CD-1 mice inhaled 1,3-butadiene for 5 days and were mated to nonexposed females, an increased number of dead implantations per pregnancy occurred at 200 and 1,000 ppm, but not at 5,000 ppm during the first 2 weeks postexposure (DOE/NTP 1988b). These results were considered to be inconclusive because of the lack of a strict dose-response relationship. Increased numbers of dead fetuses were also observed in offspring of CH3 males inhaling 130 ppm (Adler et al. 1998), but not in CD-1 mice exposed to 125 ppm (Brinkworth et al. 1998). Heritable spermatid chromosomal translocations occurred in F₁ offspring of male CH3 mice inhaling 1,3-butadiene (Adler et al. 1995a, 1998).

Although cytogenetic monitoring of 1,3-butadiene rubber workers for chromosomal aberrations revealed no or slight differences between exposed and control groups (Lovreglio et al. 2006; Sram et al. 1998; Zhou et al. 1986), 1,3-butadiene is clearly genotoxic in mice. As discussed in Section 3.4.3, species differences exist in the metabolism of 1,3-butadiene, and data suggest that humans may metabolize this compound at different metabolic rates than do rodents. If the genotoxic and clastogenic response of 1,3-butadiene requires activation to an active metabolite that is formed more slowly or deactivated more rapidly in humans than in rats and mice, the genotoxicity observed in animals may only be observed after much higher exposures in humans. The data in humans are too limited, however, to rule out the possibility of a genotoxic potential in humans exposed to 1,3-butadiene.

3.4 TOXICOKINETICS

3.4.1 Absorption

3.4.1.1 Inhalation Exposure

In human volunteers inhaling 2 ppm 1,3-butadiene for 20 minutes, the absorbed fraction varied from 18 to 74% (Lin et al. 2001). Neither sex nor age (30±8 years for males, 29±9 years for females) were factors in

3. HEALTH EFFECTS

this variation. Fractional absorption in Asian volunteers was about 20% greater than in Caucasians, African-Americans, or Hispanics. Blood triglyceride levels may influence absorption, as blood:air partition coefficients increased 20–40% in humans having borderline higher triglyceride levels after ingestion of fat in the diet (Lin et al. 2002).

In close-chamber studies, the uptake of inhaled 1,3-butadiene in mice and rats was linear to 2,000 and 1,000 ppm, respectively, above which metabolism is saturated (Kohn and Melnick 2001). The distribution coefficient for 1,3-butadiene between rabbit blood and air was 0.603 *in vitro* and 0.654 *in vivo*, suggesting simple passive diffusion of the gas from the alveoli to the blood (Carpenter et al. 1944). After 9 minutes of exposure of rabbits to 250,000 ppm, the concentration of 1,3-butadiene was 0.26 mg/mL in the femoral artery and 0.18 mg/mL in the femoral vein. Pulmonary absorption, therefore, appears to be rapid. Distribution studies in rats and mice following inhalation exposure to 1,3-butadiene indicate that it is absorbed from the lungs in these species as well (see Section 3.4.2.1). When *Macaca fascicularis* monkeys were exposed to radioactively labeled 1,3-butadiene, the uptake was calculated as 16.40 $\mu\text{mol}/\text{hour}/10$ ppm of inhaled and 3.20 $\mu\text{mol}/\text{hour}/10$ ppm of retained 1,3-butadiene (Dahl et al. 1990).

3.4.1.2 Oral Exposure

No studies were located regarding absorption in humans or animals after oral exposure to 1,3-butadiene.

3.4.1.3 Dermal Exposure

No studies were located regarding absorption in humans or animals after dermal exposure to 1,3-butadiene.

3.4.2 Distribution

3.4.2.1 Inhalation Exposure

In human volunteers inhaling 2 ppm 1,3-butadiene for 20 minutes, blood levels approached equilibrium by 5 minutes (Smith et al. 2001). In mice and rats inhaling up to 625 ppm 1,3-butadiene, equilibrium in blood concentrations was reached by 2 hours, with blood levels in mice being three- to 4-fold higher than in rats at all times (Himmelstein et al. 1994). The distribution of 1,3-butadiene in several tissues in rats was measured following a 1-hour inhalation exposure to 129,000 ppm (Shugaev 1969). Perinephric fat

3. HEALTH EFFECTS

contained 152 mg 1,3-butadiene/100 cc tissue, compared to levels of 36–51 mg 1,3-butadiene /100 mL in the brain, liver, septum, and kidney.

Species differences in the distribution of inhaled 1,3-butadiene were studied in Sprague-Dawley rats and B6C3F1 mice (Bond et al. 1986, 1987). When normalized for amount of inhaled ¹⁴C-1,3-butadiene, molar tissue concentrations of radioactive material at 1 hour postexposure were 17-fold (thyroid) to 80-fold higher (lung) in mice than in rats. In blood, the normalized radioactivity concentration was 57-fold higher in mice than rats, while 110- to 120-fold more radioactivity was found in mouse intestine than in rat intestine.

In vitro measurements of tissue: blood equilibrium partition coefficients suggest that 1,3-butadiene distributes to a variety of tissues. Partition coefficients in humans were highest in fat (18.4) and were similar in well- and poorly-perfused tissues (0.69 and 0.72, respectively) (Brochot et al. 2007). In rats, partition coefficients were highest for fat (21.9), similar for liver, kidney, muscle, and spleen (0.87–0.94), and lowest in brain (0.43) (Johanson and Filser 1993).

3.4.2.2 Oral Exposure

No studies were located regarding distribution in humans or animals after oral exposure to 1,3-butadiene.

3.4.2.3 Dermal Exposure


No studies were located regarding distribution in humans or animals after dermal exposure to 1,3-butadiene.

3.4.3 Metabolism

The metabolism of 1,3-butadiene has been observed in the liver, lung, and kidneys. The liver is the predominant site of 1,3-butadiene metabolism (Elfarrar et al. 2001; Schmidt and Loeser 1985, 1986). 1,3-Butadiene is initially oxidized (Figure 3-2) by cytochrome P450 (CYP) to 2-butenal or 3,4-epoxy-1-butene (EB) (Bolt et al. 1983; Csanady et al. 1992; Duescher and Elfarrar 1994; Himmelstein et al. 1994, 1995; Malvoisin and Roberfroid 1982; Malvoisin et al. 1979; Thornton-Manning et al. 1995, 1997). Approximately 2–5% 1,3-butadiene is converted to the aldehyde, while the remaining 95–98% is oxidized to the epoxide (Elfarrar et al. 1996). Metabolism of EB is mediated by three competing oxidative, hydrolytic, or conjugation pathways. The flux of 1,3-butadiene through the various pathways is

3. HEALTH EFFECTS

Figure 3-2. Metabolism of 1,3-Butadiene



Source: Hurst 2007

3. HEALTH EFFECTS

concentration- and species-dependent. Successive oxidation steps of EB result in 1,2:3,4-diepoxbutane (DEB) and 3,4-epoxy-1,2-diol (EBdiol). EB can also be conjugated to glutathione by glutathione-S-transferase (GST) to form 1-glutathionyl-3-buten-2-ol, or can be hydrolyzed via epoxide hydrolase (EH) to 3-butene-1,2-diol (BDdiol). BDdiol is metabolized via CYP or aldehyde dehydrogenase (ADH) to the ketone 1-hydroxy-3-buten-2-one (hydroxymethylvinyl ketone, or HMVK) or EBdiol. GST can conjugate glutathione to HMVK and EBdiol to form 4-glutathionyl-1-hydroxy-2-butanone and 4-glutathionyl-butane-1,2,3-triol.

Several isoforms of CYP have been implicated in the oxidative metabolism of 1,3-butadiene and resulting epoxides in various tissues. In human liver microsomes, CYP2E1 dominates metabolism at low concentrations (i.e., 0.16 mM), while CYP2A6 dominates at higher concentrations (i.e., 4.4 mM) (Elfarra et al. 1996). In mice, CYP2E1 and 2A5 are active in 1,3-butadiene oxidation in lung and liver microsomes, but CYP4B1 dominates metabolism in the kidneys (Elfarra et al. 2001).

In vitro studies indicate that mouse lung and liver have a higher capacity than other species, including humans, to oxidize 1,3-butadiene to EB and DEB, but have much less ability to detoxify the epoxides via the EH pathway (Jackson et al. 2000b). Female mouse tissue homogenates resulted in higher EB generation than in males or in rat, human, or monkey tissues, while human and monkey tissues hydrolyzed the epoxides to diols approximately 20-fold more extensively than rodents (Schmidt and Loeser 1985, 1986). In studies of liver microsomes, mice had intrinsic clearance (V_{max}/K_m) values of 57.5 and 0.77 minute^{-1} for oxidation of 1,3-butadiene to EB and EB to DEB, respectively. These values are 3–4-fold higher than the respective rat values of 1,637 and 0.21 minute^{-1} (Elfarra et al. 2001). Conversely, intrinsic clearance via EH-mediated hydrolysis of EB was 34.4 minute^{-1} in rats, compared to 12.4 minute^{-1} in mice. Clearance by EB conjugation with GSH was similar (21.0 and 22.0 minute^{-1}) in both species. These *in vitro* findings comport with metabolic differences observed between rats and mice after inhalation exposure to EB (Kreiling et al. 1987; Laib et al. 1990). A limited rate of EB removal and its subsequent accumulation was observed in mice at 500 ppm exposure, but not in rats at exposures up to 5,000 ppm. This may partially account for the differing levels of toxicity and carcinogenicity between rats and mice in long-term studies.

Differences were noted between rodents and monkeys in 1,3-butadiene metabolism (Dahl et al. 1990; Sun et al. 1989a). At 10 ppm, blood levels of EB, DEB, and EBdiol were lower in monkeys inhaling 10 ppm than in rodents. The difference was not so great at 8,000 ppm (Sun et al. 1989a). Similar exposures of 10 ppm 1,3-butadiene resulted in blood concentrations of total 1,3-butadiene metabolites in monkeys that

3. HEALTH EFFECTS

were about 5–50 times lower than in mice and about 4–14 times lower than in rats (Dahl et al. 1991). The results indicated possible lower susceptibility to toxic effects of low levels of 1,3-butadiene in primates.

3.4.4 Elimination and Excretion

3.4.4.1 Inhalation Exposure

The monoepoxide metabolite, EB, can be conjugated to glutathione by GST to form monohydroxybutenylmercaptic acid (MHBMA, or M2), a mixture of N-acetyl-S-([1-hydroxymethyl]-2-propenyl)cysteine and N-acetyl-S-([2-hydroxymethyl]-3-propenyl)cysteine. EBdiol, formed by hydrolysis of EB, may also be conjugated by GST to glutathione to form N-acetyl-S-(3,4-dihydroxy-butyl)cysteine (DHBMA, or M1). Both mercaptic acids are excreted in the urine (Boogaard et al. 2001a; McDonald et al. 2004). These excretion products have been used as biomarkers of 1,3-butadiene exposures in both environmental and occupational settings (Albertini et al. 2001, 2007; Ammenheuser et al. 2001; Boogaard et al. 2001a) (see Section 3.8). The relative abundance of MHBMA and DHBMA in urine indicates the flux of EB through the competing GST and EH metabolic pathways. In humans, >97% of urinary mercaptic acid measured following 1,3-butadiene inhalation is DHBMA, indicating that most EB proceeds to hydrolysis via EH rather than to formation of the diepoxide (Henderson et al. 1996). Albertini et al. (2007) showed that women excrete lower levels of both mercaptic acids than men; however, they maintain the ratio of M1 and M2, suggesting sex differences in metabolic activity, but not pathway flux.

In rats exposed to 1,3-butadiene, 1,2-epoxybutene-3 and acetone were exhaled as suspected metabolites of the administered compound (Bolt et al. 1983). The pharmacokinetic profile of inhaled 1,3-butadiene was studied in mice (Kreiling et al. 1986b) and in rats (Bolt et al. 1984; Filser and Bolt 1984). Following exposure of mice and rats to ¹⁴C-1,3-butadiene, the elimination of radioactivity was rapid, and 77–99% of the initial tissue amount was eliminated with half-lives of between 2 and 10 hours (Bond et al. 1987). At concentrations of approximately ≤1,000 ppm, the elimination of 1,3-butadiene followed first-order kinetics in both species. The first-order metabolic clearance of inhaled 1,3-butadiene per kg body weight was 4,500 mL/hour for rats (Laib et al. 1988) and 7,300 mL/hour for mice (Kreiling et al. 1986b). The maximal metabolic elimination rate was calculated as 220 μmol/hour/kg for rats (Laib et al. 1988) and 400 μmol/hour/kg for mice (Kreiling et al. 1986b). With increasing concentrations of ¹⁴C-1,3-butadiene, exhalation of radiolabeled carbon was a major pathway for elimination of ¹⁴C in mice and rats (Bond et al. 1986). Similar results were observed in mice and rats following inhalation of 62.5 ppm 1,3-butadiene for 6 hours (Himmelstein et al. 1996). Blood 1,3-butadiene concentrations in mice fell from about 3 μM at

3. HEALTH EFFECTS

the end of exposure to 0.03 μM 15 minutes later. Rat elimination of 1,3-butadiene from blood was slower, falling from a post-exposure maximum of about 1.5–0.1 μM 30 minutes later.

About 2% of the total inhaled amount of 1,3-butadiene was excreted as metabolites in *Cynomolgus* monkeys (Sun et al. 1989a). Carbon dioxide was the major exhalation product at 10 ppm, while epoxy-metabolites (specific compounds not determined) were predominant in exhaled breath at 300 and 8,000 ppm. Urinary excretion of total metabolites was not influenced by exposure levels. In *Macaca fascicularis* monkeys, about 39% of metabolite radioactivity (specific compounds not determined) were eliminated in the urine, 0.8% in feces, and 56% were exhaled as carbon dioxide during the first 70 hours postexposure (Dahl et al. 1990).

3.4.4.2 Oral Exposure

No studies were located regarding excretion in humans or animals after oral exposure to 1,3-butadiene.

3.4.4.3 Dermal Exposure

No studies were located regarding excretion in humans or animals after dermal exposure to 1,3-butadiene.

3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models

Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and disposition of chemical substances to quantitatively describe the relationships among critical biological processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry models. PBPK models are increasingly used in risk assessments, primarily to predict the concentration of potentially toxic moieties of a chemical that will be delivered to any given target tissue following various combinations of route, dose level, and test species (Clewell and Andersen 1985). Physiologically based pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to quantitatively describe the relationship between target tissue dose and toxic end points.

PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to delineate and characterize the relationships between: (1) the external/exposure concentration and target tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and Krishnan 1994; Andersen et al. 1987). These models are biologically and mechanistically based and can be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from

3. HEALTH EFFECTS

route to route, between species, and between subpopulations within a species. The biological basis of PBPK models results in more meaningful extrapolations than those generated with the more conventional use of uncertainty factors.

The PBPK model for a chemical substance is developed in four interconnected steps: (1) model representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 1994; Leung 1993). PBPK models for a particular substance require estimates of the chemical substance-specific physicochemical parameters, and species-specific physiological and biological parameters. The numerical estimates of these model parameters are incorporated within a set of differential and algebraic equations that describe the pharmacokinetic processes. Solving these differential and algebraic equations provides the predictions of tissue dose. Computers then provide process simulations based on these solutions.


The structure and mathematical expressions used in PBPK models significantly simplify the true complexities of biological systems. If the uptake and disposition of the chemical substance(s) are adequately described, however, this simplification is desirable because data are often unavailable for many biological processes. A simplified scheme reduces the magnitude of cumulative uncertainty. The adequacy of the model is, therefore, of great importance, and model validation is essential to the use of PBPK models in risk assessment.

PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste sites) based on the results of studies where doses were higher or were administered in different species. Figure 3-3 shows a conceptualized representation of a PBPK model.

If PBPK models for 1,3-butadiene exist, the overall results and individual models are discussed in this section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations.

3. HEALTH EFFECTS

Figure 3-3. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance



Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a hypothetical chemical substance. The chemical substance is shown to be absorbed via the skin, by inhalation, or by ingestion, metabolized in the liver, and excreted in the urine or by exhalation.

Source: Adapted from Krishnan and Andersen 1994

3. HEALTH EFFECTS

Johanson and Filser 1993

Description of the Model. The Johanson and Filser (1993) model simulates absorption and disposition of 1,3-butadiene and the metabolite, 3,4-epoxy-1-butene, in the mouse and rat. The hepatic conjugation of 3,4-epoxy-1-butene to GSH is also simulated. Tissue compartments include the blood/lung, liver, fat, and muscle/richly-perfused tissues. Both the exchange of 1,3-butadiene and 3,4-epoxy-1-butene between blood and tissue or lung air is assumed to be first-order and flow-limited. *In vitro* derivation of tissue:air and tissue:blood partition coefficients was performed by the model authors and reported in the study. Michaelis-Menten expressions were included for 1,3-butadiene oxidation, 3,4-epoxy-1-butene hydrolysis, and 3,4-epoxy-1-butene conjugation to GSH, all occurring in the liver compartment. Values for physiological (alveolar, pulmonary, and tissue perfusion rates, organ weights) and metabolic parameters (V_{max} , K_m , and GSH content and elimination rates) were taken from the literature, except for the affinity constant (K_m) for 1,3-butadiene oxidation, which was fit to blood 1,3-butadiene timecourse data. Elimination of 1,3-butadiene and 3,4-epoxy-1-butene was represented as either metabolism or as exchange passage back to the lung air.

Risk Assessment. This model has not been used in risk assessment.

Validation of the Model. The K_m for 1,3-butadiene oxidation and 3,4-epoxy-1-butene hydrolysis were the only parameters optimized against close-chamber gas uptake data for 1,3-butadiene or 3,4-epoxy-1-butene (1,000–5,000 ppm) in rats (Filser and Bolt 1984) and mice (Kreiling et al. 1987). Model predictions were evaluated against the concentration of 3,4-epoxy-1-butene appearing in the chambers (due to metabolism and exhalation from the animals) during the 1,3-butadiene exposures, and were found to predict 3,4-epoxy-1-butene levels that were similar to observations.

Target Tissues. The model simulates concentrations of 1,3-butadiene and 3,4-epoxy-1-butene in liver, a target tissue for 1,3-butadiene metabolites, as well as in blood, fat, and a lumped compartment for muscle and richly-perfused tissues.

Species Extrapolation. The model has been developed for simulations of rats and mice. Extrapolation to other species would require species-specific physiological and metabolism parameter values and blood-tissue partition coefficients.

3. HEALTH EFFECTS

High-low Dose Extrapolation. The model has been evaluated for simulating inhalation exposures in mice and rats ranging from 500 to 5,000 ppm.

Interroute Extrapolation. The model simulates inhalation exposures only and would require additional parameterization to simulate exposures by other routes.

Strengths and Limitations. Strengths of the model are that it simulates disposition and clearance of inhaled 1,3-butadiene, as well as production and clearance of 3,4-epoxy-1-butene, the major oxidative metabolite formed in rodents. Limitations include: (1) the model has not been evaluated for inhalation exposures below 500 ppm; (2) the model does not simulate the appearance and disposition of other metabolites, such as the diepoxide, diols, and GSH-conjugate products eliminated in the urine; and (3) the model does not simulate 1,3-butadiene disposition in humans.

Kohn and Melnick 1993, 1996, 2000

Description of the Model. The Kohn and Melnick (1993, 1996, 2000) model simulates absorption of 1,3-butadiene and the disposition of 1,3-butadiene and the metabolite, 3,4-epoxy-1-butene, in the mouse and rat. The body is represented by discrete compartments for venous and arterial blood, lung, liver, kidney, fat, the GI tract, and lumped compartments for richly- and poorly perfused tissues (viscera and muscle, respectively). Values for physiological flow rates, tissue volumes, and tissue:blood partition coefficients were taken from the literature. 1,3-Butadiene is eliminated by exhalation to lung air or oxidative metabolism to 3,4-epoxy-1-butene in the lung, liver, and kidney, while oxidation metabolism of 3,4-epoxy-1-butene to 1,2:3,4-diepoxibutane occurs in the liver and kidney. The hydrolysis of 3,4-epoxy-1-butene occurs in the lung, liver, and kidney. GSH conjugation occurs in the lung, liver, kidney, and blood. All of these pathways are described as saturable Michaelis-Menten processes, with V_{max} and K_m values optimized against published closed-chamber 1,3-butadiene and 3,4-epoxy-1-butene uptake data (Bolt et al. 1984; Filser and Bolt 1984; Kreiling et al. 1986b, 1987). Epoxide hydrolysis was modeled such that dissociation of the diepoxide from P450 in the microsome is followed by preferential binding of the epoxide hydrolase, replicating the so-called privileged access model for epoxide hydrolysis.

Risk Assessment. This model has not been used in risk assessment.

3. HEALTH EFFECTS

Validation of the Model. The model predicted similar profiles of 1,3-butadiene and 3,4-epoxy-1-butene uptake data (100–4,000 ppm) in mice and rats against which it was optimized. Further, it predicted single time point concentrations of 1,3-butadiene in mice and rats similar to observations from nose-only exposures to 7–1,250 ppm (Bond et al. 1986; Himmelstein et al. 1994). Additionally, it predicted similar percentages of GSH depletion in mouse and rat lung and liver observed following 7-hour 1,3-butadiene exposures of 50–2,000 ppm (Deutschmann and Laib 1989).

Target Tissues. The model simulates concentrations of 1,3-butadiene and 3,4-epoxy-1-butene in lung, liver, and kidney, all target tissues for 1,3-butadiene metabolite intoxication, as well as in blood, fat, GI tract, and lumped compartments for muscle and viscera.

Species Extrapolation. The model has been developed for simulations of rats and mice. Extrapolation of predictions to humans would require additional species-specific values for physiology and metabolism, as well as human data to verify the accuracy of the predictions.

High-low Dose Extrapolation. The model has been evaluated for simulating inhalation exposures ranging from 7 to 4,000 ppm.

Interroute Extrapolation. The model simulates inhalation exposures only and would require additional parameterization to simulate exposures by other routes.

Strengths and Limitations. Strengths of the model are that it simulates disposition and clearance of inhaled 1,3-butadiene, as well as production and clearance of 3,4-epoxy-1-butene and 1,2:3,4-diepoxybutane, the major oxidative epoxide metabolites formed in rodents. It also predicts depletion of GSH by 3,4-epoxy-1-butene metabolism in the lung and liver. Limitations include: (1) the model has not been evaluated against data for inhalation exposures in humans, and (2) the model does not simulate the appearance and disposition of other metabolites, such as the diepoxide, diols, and GSH-conjugate products eliminated in the urine.

Brochot et al. 2007

Description of the Model. The Brochot et al. (2007) model simulates absorption of 1,3-butadiene and the disposition of 1,3-butadiene, 1,2-epoxy-3-butene, and 1,2:2,3-diepoxybutane in the blood, fat, and lumped compartments for richly- and poorly-perfused tissues in humans. In addition, the disposition and

3. HEALTH EFFECTS

clearance of 3-butene-1,2-diol and 3,4-epoxy-1,2-butanediol was modeled for the blood and richly- and poorly-perfused tissues. Tissue:blood partition coefficients were taken from the literature. 1,3-Butadiene is eliminated by exhalation to lung air or oxidative metabolism, epoxide hydrolysis, or GSH conjugation in the richly-perfused tissues to mono- and diepoxide and the two diols. Since the model was intended to direct further study design for low-ppm human exposures, all of the metabolic steps are described as 1st-order processes, governed by a rate constant for each pathway. The metabolic rate constants and physiological parameters were optimized using Bayesian techniques against 133 datasets from individual subjects inhaling 2 ppm 1,3-butadiene for 20 minutes (Lin et al. 2001).

Risk Assessment. This model has not been used in risk assessment.

Validation of the Model. The model fit well against the human data from which it was calibrated. It's performance has not been evaluated against other independent human inhalation data.

Target Tissues. The model predicts parent compound, mono- and diepoxide, and vicinal thiol (including the epoxydiol) concentrations in the blood, but not in other tissues.

Species Extrapolation. The model was optimized for humans. Extrapolation of predictions to animals would require additional species-specific values for physiology and metabolism, as well as animal data (available in the literature) to verify the accuracy of the predictions

High-low Dose Extrapolation. The model was calibrated for low (2 ppm) exposures in humans. Extrapolation to higher doses will require that the metabolic expression be modified to account for saturation of the oxidative, hydrolytic, and conjugating pathways described.

Interoute Extrapolation. The model was designed to simulate inhalation exposures. Additional parameters and absorption expressions must be added (and optimized with oral or dermal data) in order to extrapolate internal dosimetry from inhalation exposures across other routes of exposure.

Strengths and Limitations. The model is the first PBTK model to simultaneously predict blood levels of 1,3-butadiene and its epoxide and vicinal diol metabolites in humans. Limitations include: (1) the model has not been evaluated against data for inhalation exposures in animals, and (2) the model does not account for saturation of metabolic pathways that may occur in humans (and have been observed in rodents) exposed to higher inhalation concentrations of 1,3-butadiene.

3. HEALTH EFFECTS

3.5 MECHANISMS OF ACTION**3.5.1 Pharmacokinetic Mechanisms**

Inhaled 1,3-butadiene is extensively absorbed across alveolar tissues into the blood and distributed throughout the body. Data are not available to determine the extent of absorption from oral or dermal routes of exposure. 1,3-Butadiene enters the lung blood via passive diffusion. It is unknown whether 1,3-butadiene binds to blood constituents such as albumins, but its monoepoxide metabolite forms stable adducts with hemoglobin (see Section 3.8.1). *In vitro* partition coefficient data suggest that 1,3-butadiene would accumulate in fatty tissues, although no *in vivo* data are available to support this notion (Johanson and Filser 1993; Kohn and Melnick 1993). Oxidative metabolism of 1,3-butadiene to EB, DEB, or EBdiol appears to be required for genotoxicity, as a 30–56% reduction in induction of erythrocyte micronuclei was observed in mice pretreated with various P450 inhibitors (Jackson et al. 2000b). *In vitro* human and animal data suggest that the flux of 1,3-butadiene through the P450-mediated oxidation, epoxide hydrolase, or GSH conjugation pathways may determine the sensitivity of a species or individual to toxicity. As discussed in Section 3.4.3, mice have a relatively greater 1,3-butadiene oxidation capacity and lower epoxide hydrolase activity compared to rats and primates. Upon depletion of GSH, this could result in metabolic accumulation of epoxides available for systemic distribution and reactive interactions with cellular macromolecules and DNA. Differences between mouse and rat metabolism were observed in the ability of 1,3-butadiene to deplete nonprotein sulfhydryl (NPSH) (Deutschmann and Laib 1989; Kreiling et al. 1988). The depletion of NPSH content was greater in mice than in rats after 1,3-butadiene exposure, suggesting that detoxification of active metabolites in mice proceeds mainly via glutathione-S-transferase-mediated pathways. Further differences were noted between 1,3-butadiene metabolism in rodents and in monkeys (Dahl et al. 1990; Sun et al. 1989a). At 10 ppm, blood levels of EB, DEB, and EBdiol were lower in monkeys than in rodents. The difference was not so great at 8,000 ppm (Sun et al. 1989a). Similar exposures of 10 ppm 1,3-butadiene resulted in blood concentrations of total 1,3-butadiene metabolites in monkeys that were about 5–50 times lower than in mice and about 4–14 times lower than in rats (Dahl et al. 1991). The results indicated possible lower susceptibility to toxic effects of low levels of 1,3-butadiene in primates.

3.5.2 Mechanisms of Toxicity

The mechanism(s) of reproductive, developmental, and hematological toxicity for 1,3-butadiene are not well understood. For cancer, direct binding of reactive mono- and diepoxides and epoxydiols to DNA or

3. HEALTH EFFECTS

nucleoproteins may be responsible for the observed genotoxicity. Similar mechanism may be responsible for non-cancer toxicity, as these effects are seen at the lowest exposures in mice (NTP 1993), which have a greater capacity to oxidize 1,3-butadiene to EB and DEB than do rats (see Section 3.4.3).

Differences were observed between mice and Wistar rats in the ability of 1,3-butadiene to bind covalently to hepatic nucleoproteins and DNA (Kreiling et al. 1986a). In correspondence with the higher metabolic rate of 1,3-butadiene in mice, the formation rate of reactive protein-binding metabolites was about twice as high in this species as noted in rats. In lung tissues from mice inhaling 1,3-butadiene, over 98% of the detected N7-guanine adducts resulted from DNA interaction with 3,4-epoxy-1,2-diol (Koivisto and Peltonen 2001). Other experiments demonstrated protein-DNA and DNA-DNA crosslinks in the liver tissues in B6C3F1 mice, but not in Wistar rats following exposure to ¹⁴C-1,3-butadiene (Jelitto et al. 1989). The crosslinking was due to the reaction of 1,3-butadiene metabolites (1,2-epoxybutene-3 and diepoxybutane) with guanine resulting in a N7-guanine adduct. A number a malignant gliomas and neuroblastomas in mice chronically exposed to 625 ppm exhibited mutations of the p53 gene and H- and K-*ras* oncogenes (Kim et al. 2005), which have also been observed in forestomach tumors of chronically exposed mice (Sills et al. 2001).

Human CD34+ bone marrow cells CD4+ lymphocytes were resistant to chromosomal aberrations from *in vitro* exposure to 1,3-butadiene metabolites (except for the diepoxide) at concentrations likely to be encountered *in vivo* (1–10 μM) (Irons et al. 2001). Exposure of mouse, rat, or human splenic or peripheral lymphocytes to EB resulted in minimal changes in the frequency of chromosomal aberrations or sister chromatid exchanges (Kligerman et al. 1999). However, exposure to DEB was a potent inducer of both effects. Mice and rat cells were equally sensitive to DEB, but human cells were less sensitive, ostensibly due to the activity of GST-T1, allowing for GSH conjugation of either epoxide. *In vitro* exposure of rats to EB, DEB, or EBdiol all resulted in induction of micronuclei in developing spermatocytes (Lahdetie et al. 1997).

3.5.3 Animal-to-Human Extrapolations

Bioassay and toxicokinetic data in animals suggest that the flux of 1,3-butadiene through P450-mediated oxidation, epoxide hydrolysis, or GSH conjugation may determine the extent of accumulation and distribution of reactive epoxide metabolites and, thus, determine sensitivity to toxic effects (see Section 3.5.1). *In vitro* data suggest that humans may be less sensitive than mice to 1,3-butadiene due primarily to quantitative differences in toxicokinetics. In rats and mice exposed to up to 625 ppm

3. HEALTH EFFECTS

1,3-butadiene, the DNA-DNA cross-links 1,4-bis-(guan-7-yl)-2,3-butanediol (bis-N7G-BD) and 1-(guan-7-yl)-4-(aden-1-yl)-2,3-butanediol (N7G-N1A-BD), were identified as specific to DEB formation (Goggin et al. 2009). Mice exhibited 4–10-fold higher levels than rats of these cross-links. Further, higher levels of bis-N7G-BD were measured in females compared to males. This comports with greater cancer susceptibility of female mice than male mice or rats (see Section 3.2.1.7). This also suggests that rats, which produce relatively lower formation of DEB than mice, may be a more appropriate model for human toxicity than mice. PBTK models are capable of exploring species differences in the internal dosimetry of 1,3-butadiene and its reactive metabolites EB, DEB, and EBdiol (see Section 3.4.5). However, the models have not been developed sufficiently to quantify human dosimetry (and derive risks) while taking into account the variability in expression of key metabolic enzymes, such as P450 and epoxide hydrolase.

3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS

Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine system because of the ability of these chemicals to mimic or block endogenous hormones. Chemicals with this type of activity are most commonly referred to as *endocrine disruptors*. However, appropriate terminology to describe such effects remains controversial. The terminology *endocrine disruptors*, initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to develop a screening program for “...certain substances [which] may have an effect produced by a naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning *endocrine disruptors*. In 1999, the National Academy of Sciences released a report that referred to these same types of chemicals as *hormonally active agents*. The terminology *endocrine modulators* has also been used to convey the fact that effects caused by such chemicals may not necessarily be adverse. Many scientists agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to the health of humans, aquatic animals, and wildlife. However, others think that endocrine-active chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist in the natural environment. Examples of natural hormone mimics are the isoflavonoid phytoestrogens (Adlercreutz 1995; Livingston 1978; Mayr et al. 1992). These chemicals are derived from plants and are similar in structure and action to endogenous estrogen. Although the public health significance and descriptive terminology of substances capable of affecting the endocrine system remains controversial, scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or

3. HEALTH EFFECTS

elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, development, and/or behavior (EPA 1997). Stated differently, such compounds may cause toxicities that are mediated through the neuroendocrine axis. As a result, these chemicals may play a role in altering, for example, metabolic, sexual, immune, and neurobehavioral function. Such chemicals are also thought to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; Giwercman et al. 1993; Hoel et al. 1992).

No *in vivo* or *in vitro* studies were located regarding endocrine disruption in humans and/or animals after exposure to 1,3-butadiene.

3.7 CHILDREN'S SUSCEPTIBILITY

This section discusses potential health effects from exposures during the period from conception to maturity at 18 years of age in humans, when all biological systems will have fully developed. Potential effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect effects on the fetus and neonate resulting from maternal exposure during gestation and lactation. Relevant animal and *in vitro* models are also discussed.

Children are not small adults. They differ from adults in their exposures and may differ in their susceptibility to hazardous chemicals. Children's unique physiology and behavior can influence the extent of their exposure. Exposures of children are discussed in Section 6.6, Exposures of Children.

Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is a difference depends on the chemical (Guzelian et al. 1992; NRC 1993). Children may be more or less susceptible than adults to health effects, and the relationship may change with developmental age (Guzelian et al. 1992; NRC 1993). Vulnerability often depends on developmental stage. There are critical periods of structural and functional development during both prenatal and postnatal life, and a particular structure or function will be most sensitive to disruption during its critical period(s). Damage may not be evident until a later stage of development. There are often differences in pharmacokinetics and metabolism between children and adults. For example, absorption may be different in neonates because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants and young children (Ziegler et al. 1978). Distribution of xenobiotics may be different; for example, infants have a larger proportion of their bodies as extracellular water, and their brains and livers are

3. HEALTH EFFECTS

proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 1966; Widdowson and Dickerson 1964). The infant also has an immature blood-brain barrier (Adinolfi 1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975). Many xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages of growth and development, levels of particular enzymes may be higher or lower than those of adults, and sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and Kearns 1997; NRC 1993; Vieira et al. 1996). Whether differences in xenobiotic metabolism make the child more or less susceptible also depends on whether the relevant enzymes are involved in activation of the parent compound to its toxic form or in detoxification. There may also be differences in excretion, particularly in newborns who all have a low glomerular filtration rate and have not developed efficient tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948). Children and adults may differ in their capacity to repair damage from chemical insults. Children also have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly relevant to cancer.

Certain characteristics of the developing human may increase exposure or susceptibility, whereas others may decrease susceptibility to the same chemical. For example, although infants breathe more air per kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their alveoli being less developed, which results in a disproportionately smaller surface area for alveolar absorption (NRC 1993).

No human data are available to determine whether children are more sensitive than adults to 1,3-butadiene toxicity. Mechanistic data in animals suggest that the ratio of 1,3-butadiene oxidation:epoxide hydrolysis may be a significant determinant of 1,3-butadiene sensitivity (see Section 3.5.1 and 3.5.2). It is not known if the ratio of 1,3-butadiene oxidation:epoxide hydrolysis is different in children than adults. Unborn children may be more sensitive to 1,3-butadiene toxicity than adults, as changes in fetal body weight and developmental effects have been identified at the lowest LOAELs in mice exposed to acute- and intermediate-duration inhalation exposures (Anderson et al. 1996; DOE/NTP 1987b). Several studies have associated the development of childhood leukemia to close proximity of birthplace to industrial point sources of 1,3-butadiene (and other high-volume industrial chemicals, including benzene) (Knox et al. 2005, 2006; Reynolds et al. 2003; Whitworth et al. 2008). Although these study authors suggest that *in utero* exposure to 1,3-butadiene may have significantly contributed to cancer risks in these populations, there are no estimates of actual prenatal or postnatal exposures of mothers or children, respectively.

3. HEALTH EFFECTS

3.8 BIOMARKERS OF EXPOSURE AND EFFECT

Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 1989).

A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta. However, several factors can confound the use and interpretation of biomarkers of exposure. The body burden of a substance may be the result of exposures from more than one source. The substance being measured may be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic compounds). Depending on the properties of the substance (e.g., biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the body by the time samples can be taken. It may be difficult to identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as copper, zinc, and selenium). Biomarkers of exposure to 1,3-butadiene are discussed in Section 3.8.1.

Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an organism that, depending on magnitude, can be recognized as an established or potential health impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung capacity. Note that these markers are not often substance specific. They also may not be directly adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers of effects caused by 1,3-butadiene are discussed in Section 3.8.2.

A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability to respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic or other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are discussed in Section 3.10, Populations That Are Unusually Susceptible.

3. HEALTH EFFECTS

3.8.1 Biomarkers Used to Identify or Quantify Exposure to 1,3-Butadiene

Two urinary metabolites of 1,3-butadiene have been identified in tollbooth workers. Sapkota et al. (2006) measured 258–378 ng/mL 1,2-dihydroxy-4-(N-acetylcysteiny)butane and 6–9.7 ng/mL of the isomeric mixture of 1-hydroxy-2-(N-acetylcysteiny)-3-butene and 1-(N-acetylcysteiny)-2-hydroxy-3-butene in workers' urine following average ambient 1,3-butadiene exposures of 0.4–1 ppb. These biomarkers are quite specific to 1,3-butadiene exposure, but the measured levels were not significantly associated with exposure, although this may have been due to the small sample size used or the low (0.0005 ppm) exposure levels studied. N-acetyl-S-((1-hydroxymethyl)-2-propenyl)cysteine and N-acetyl-S-((2-hydroxymethyl)-3-propenyl)cysteine, the isomeric mixture known as MHBMA (or M2), are the GST conjugation products of EB found in human urine following 1,3-butadiene exposure. Another urinary metabolite, N-acetyl-S-(3,4-dihydroxybutyl)cysteine, or DHBMA (M1), is formed by EBdiol conjugation with glutathione via GST (Boogaard et al. 2001a; McDonald et al. 2004). These urinary metabolites have been used as biomarkers of 1,3-butadiene exposures in several human studies (Albertini et al. 2001, 2007; Ammenheuser et al. 2001; Boogaard et al. 2001a; Fustinoni et al. 2004) (see Section 3.8).

The determination of 1,3-butadiene-derived adducts in hemoglobin was proposed as a method to detect and estimate prior exposures. The hemoglobin adducts *N*-(2-dihydroxy-3-butenyl)valine (HB-val) and *N*-(2,3,4-trihydroxybutyl)valine (THB-val) were well correlated with 1,3-butadiene exposure in 1,3-butadiene monomer workers (Albertini et al. 2001, 2007; Begemann et al. 2001a, 2001b; Osterman-Golkar et al. 1996) and Chinese polymer workers (Hayes et al. 2000; HEI 2000). The adduct *N,N*-(2,3-dihydroxy-1,4-butadyl)valine (*pyr*-val) is very specific for the diepoxide DEB. However, it was not detected in blood of male and female Czech workers exposed to 0.2–0.4 ppm (Albertini et al. 2007)

Zhao et al. (2000) found a significant linear relationship of DNA adduction and 1,3-butadiene exposure between 1,3-butadiene workers and controls. The levels of N1-(2,3,4-trihydroxybutyl)adenine adduct in lymphocytes of 1,3-butadiene workers (mean exposure: 0.3 ppm; range: <0.005–7.7 ppm) were 5-fold higher than controls (mean exposure: 0.01 ppm; range: <0.001–0.07 ppm).

1,3-Butadiene-specific urinary metabolites and hemoglobin and DNA adducts have also been observed in animals. Excretion of 1,3-butadiene metabolites was reported to be high in the urine of exposed monkeys (Dahl et al. 1990). A linear accumulation of the hemoglobin adducts, HB-val and THB-val, was observed in B6C3F1 mice and Sprague-Dawley rats after intraperitoneal (Sun et al. 1989b) and inhalation (HEI

3. HEALTH EFFECTS

2000) exposures. The lifetimes of these adducts were in agreement with the expected lifetimes for red blood cells in these animals. DNA adducts were detected in the livers of mice and rats exposed to radiolabeled 1,3-butadiene (Kreiling et al. 1986b). In mice exposed to 1,3-butadiene by nose-only inhalation, the N7-guanine adduct (N7-(1-(hydroxymethyl)-2,3-dihydroxypropyl)guanine) from interaction with 3,4-epoxy-1,2-diol, was the major DNA adduct measured (Boogaard et al. 2001b).

1,3-Butadiene has been measured in expired air of forestry workers living in mountain villages (Perbellini et al. 2003); however, the levels measured (median of 1.2 ng/L) were not correlated with any exposure to 1,3-butadiene.

3.8.2 Biomarkers Used to Characterize Effects Caused by 1,3-Butadiene

Dermal, ocular, and/or upper respiratory irritation can occur following 1,3-butadiene exposure (NIOSH 2005) and may alert the exposed individual. However, the effects are not specific for 1,3-butadiene exposure and may be caused by several other chemicals.

Given the genotoxic (Section 3.3) and carcinogenic (Section 3.2.1.7) activity of 1,3-butadiene, a useful biomarker of effect would correlate a quantifiable measure of genetic mutation with 1,3-butadiene exposure. 1,4-Bis-(guan-7-yl)-2,3-butanediol (bis-N7G-BD) and 1-(guan-7-yl)-4-(aden-1-yl)-2,3-butanediol (N7G-N1A-BD) are DEB-specific DNA-DNA cross-links identified in rats and mice inhaling up to 625 ppm 1,3-butadiene (Goggin et al. 2009). Mice exhibited 4–10-fold higher levels than rats of these cross-links. Further, higher levels of bis-N7G-BD were measured in females, compared to males. The sensitivity of female mice to these biomarkers and to 1,3-butadiene-induced carcinogenicity suggests that: (1) DEB is the putative carcinogenic metabolite of 1,3-butadiene, and (2) bis-N7G-BD and N7G-N1A-BD levels may quantitatively inform on genotoxicity leading to tumor development.

Another biomarker of genetic change is the mutation frequency of the *hprt* gene locus in human peripheral lymphocytes, which has been used in multiple studies of 1,3-butadiene SBR, monomer, and polymer workers in the United States, China, and Czech Republic. These studies are discussed in detail in Section 3.3. Several of these studies demonstrated good correlation between the increase in *hprt* mutation frequency and 1,3-butadiene exposure (Abdel-Rahman et al. 2001, 2003, 2005; Ammenheuser et al. 2001; Ma et al. 2000; Ward et al. 1994, 1996, 2001), as well as correlation with urinary and hematological biomarkers of exposure. Others did not find a significant correlation between exposure and mutation frequency (Albertini et al. 2001, 2007; Hayes et al. 1996, 2000; HEI 2003; Liu et al. 2008;

3. HEALTH EFFECTS

Tates et al. 1996). The reasons for the differences in sensitivity of the *hprt* mutation as a biomarker may include the very low exposures that were studied and differences in assay procedures (as discussed in Section 3.3). It is unclear at this time which *hprt* mutation frequency assay is most adequate for risk assessment.

Two biomarkers for carcinogenic effect have been consistently found in multiple tumor sites in rodent chronic bioassays. A number of malignant gliomas and neuroblastomas in mice chronically inhaling 1,3-butadiene exhibited mutations of the p53 gene and H- and K-*ras* oncogenes (Kim et al. 2005), which have also been observed in forestomach tumors (Sills et al. 2001), hemangiosarcomas (Hong et al. 2000), and lymphomas (Zhuang et al. 1997) of chronically exposed mice.

3.9 INTERACTIONS WITH OTHER CHEMICALS

No animal studies were located regarding toxic effects of 1,3-butadiene in coexposure with other chemicals. In addition to 1,3-butadiene, workers in the rubber industry are exposed to other chemicals, including styrene and its mutagenic metabolite, styrene oxide (Loprieno et al. 1978; Norppa et al. 1980; Pohlova et al. 1985; Watabe et al. 1978), as well as dithiocarbamates (Irons and Pyatt 1998). It is unclear whether these other chemicals or their active metabolites have a synergistic harmful effect in humans, but a multivariate analysis of an SBR worker cohort (HEI 2006) did not detect interactive effects of co-exposure to 1,3-butadiene, styrene, and DMDTC. Since 1,3-butadiene exposure reduced GSH levels in rodents (see Section 3.5.1), co-exposure to other chemicals that also deplete GSH levels may increase the toxicity of 1,3-butadiene.

3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE

A susceptible population will exhibit a different or enhanced response to 1,3-butadiene than will most persons exposed to the same level of 1,3-butadiene in the environment. Reasons may include genetic makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke). These parameters result in reduced detoxification or excretion of 1,3-butadiene, or compromised function of organs affected by 1,3-butadiene. Populations who are at greater risk due to their unusually high exposure to 1,3-butadiene are discussed in Section 6.7, Populations with Potentially High Exposures.

The human and animal data do not identify a gender-specific susceptibility to 1,3-butadiene. Human *in vivo* data do not identify specific populations that may be sensitive to the effects of 1,3-butadiene. Polymorphisms in metabolic enzymes may affect the toxicokinetics of 1,3-butadiene and render some

3. HEALTH EFFECTS

individuals more sensitive to toxicity, based on increased sensitivity to genetic changes seen in these groups. Lymphocytes from GSTT1-null 1,3-butadiene workers in Texas had higher induction of sister chromatid exchange following *in vitro* DEB exposure (Kelsey et al. 1995), while GSTT1-null Czech workers exhibited higher rates of chromosomal aberrations (Sorsa et al. 1996). However, no such effects were observed in other Czech (Sram et al. 1998) or Chinese (Hayes et al. 2000) workers that were GSTT1 or GSTM1 deficient. Increased *hprt* mutation frequencies have been reported in U.S. 1,3-butadiene workers with various polymorphisms in EH (Abdel-Rahman et al. 2001, 2003, 2005)

Animals studies indicate that the predominant factor in species sensitivity is related to the toxicokinetics of 1,3-butadiene, specifically, the ratio of P450-mediated oxidation:epoxide hydrolase activity (see Section 3.4.3). Human populations that have a higher ratio of 1,3-butadiene oxidation:hydrolysis metabolism may also be more sensitive, although such populations have not been identified. In terms of absorption capacity, Asian volunteers had about 20% greater fractional absorption of inhaled 1,3-butadiene than did Caucasians, African-Americans, or Hispanics (Lin et al. 2001). However, it is not known if this results in higher internal doses of the putative epoxide toxicants.

3.11 METHODS FOR REDUCING TOXIC EFFECTS

This section will describe clinical practice and research concerning methods for reducing toxic effects of exposure to 1,3-butadiene. However, because some of the treatments discussed may be experimental and unproven, this section should not be used as a guide for treatment of exposures to 1,3-butadiene. When specific exposures have occurred, poison control centers and medical toxicologists should be consulted for medical advice.

3.11.1 Reducing Peak Absorption Following Exposure

No specific antidotes for 1,3-butadiene are available; however, recommendations have been made for general treatment of intoxicated persons (Bronstein and Currance 1988; Stutz and Janusz 1988). First, the exposed individual should be removed from the contaminated area and contaminated clothing should be taken away (Currance et al. 2007; Leikin and Paloucek 2002). It has been suggested that exposed skin should be washed with soapy water and contaminated eyes should be flushed with water. Inhalation exposure to high 1,3-butadiene concentrations may result in narcosis leading to respiratory paralysis and death. Data have shown that neurological effects, including anesthesia, may occur in humans exposed to >10,000 ppm (Sandmeyer 1981) and have been observed in animals exposed to 250,000 ppm (Carpenter

3. HEALTH EFFECTS

et al. 1944). Therefore, administration of oxygen has been used and ventilation has been assisted as needed in cases of 1,3-butadiene poisoning.

3.11.2 Reducing Body Burden

No information is available regarding displacing or removing absorbed 1,3-butadiene prior to metabolism to reactive metabolites.

3.11.3 Interfering with the Mechanism of Action for Toxic Effects

Toxicity studies found mice to be extremely sensitive (DOE/NTP 1987b; Melnick et al. 1989, 1990b; NTP 1993). Studies on the metabolism of 1,3-butadiene demonstrated that the chemical is converted to its epoxy derivatives by P450 isoforms in lung, liver, kidney (see Section 3.4.3), and possibly other tissues. The epoxides may be responsible for most toxic and carcinogenic effects caused by 1,3-butadiene exposure. The epoxides are detoxified by hydrolysis or conjugation with glutathione (Kreiling et al. 1988). A higher rate of epoxide formation and a greater depletion of hepatic nonprotein sulfhydryl content in mice is probably responsible for their higher susceptibility to 1,3-butadiene toxicity. Since the macromolecular covalent binding is enhanced only after a substantial decrease of glutathione levels (Kreiling et al. 1988), sufficient availability of glutathione should mitigate the effects of 1,3-butadiene exposure.

Interference with the oxidative metabolism of 1,3-butadiene may also be effective in allowing pulmonary clearance of the parent compound to occur before reactive epoxides are formed. In mice, a 30–56% reduction in induction of erythrocyte micronuclei was observed in mice pretreated with various P450 inhibitors (Jackson et al. 2000b). However, the side effects of systemically inhibiting P450s in humans is unknown.

3.12 ADEQUACY OF THE DATABASE

Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate information on the health effects of 1,3-butadiene is available. Where adequate information is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the initiation of a program of research designed to determine the health effects (and techniques for developing methods to determine such health effects) of 1,3-butadiene.

3. HEALTH EFFECTS

The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, NTP and EPA. They are defined as substance-specific informational needs that if met would reduce the uncertainties of human health assessment. This definition should not be interpreted to mean that all data needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed.

3.12.1 Existing Information on Health Effects of 1,3-Butadiene

The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 1,3-butadiene are summarized in Figure 3-4. The purpose of this figure is to illustrate the existing information concerning the health effects of 1,3-butadiene. Each dot in the figure indicates that one or more studies provide information associated with that particular effect. The dot does not necessarily imply anything about the quality of the study or studies, nor should missing information in this figure be interpreted as a “data need”. A data need, as defined in ATSDR’s *Decision Guide for Identifying Substance-Specific Data Needs Related to Toxicological Profiles* (Agency for Toxic Substances and Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public health assessments. Generally, ATSDR defines a data gap more broadly as any substance-specific information missing from the scientific literature.

As seen from Figure 3-4, information regarding acute systemic effects (respiratory tract irritation and narcotic effect), chronic systemic effects (respiratory irritation), genotoxicity, and cancer exists for inhalation exposure in humans. No information was located regarding oral or dermal exposure of humans to 1,3-butadiene.

Inhalation studies in animals provide data on death, systemic effects, immunologic effects, neurologic effects, reproductive and developmental effects, genotoxicity, and carcinogenicity. No information was located regarding effects in animals after oral or dermal exposure to 1,3-butadiene.

3.12.2 Identification of Data Needs

Acute-Duration Exposure. Acute inhalation exposure to very high concentrations (>10,000 ppm) of 1,3-butadiene may lead to narcosis and death by respiratory paralysis in both humans and animals (Carpenter et al. 1944; Shugaev 1969). No studies were located that correlated the level of exposure with the first signs of toxicity in humans or animals. Developmental effects were seen in mice after exposure

3. HEALTH EFFECTS

Figure 3-4. Existing Information on Health Effects of 1,3-Butadiene

	Systemic									
	Death	Acute	Intermediate	Chronic	Immunologic/Lymphoretic	Neurologic	Reproductive	Developmental	Genotoxic	Cancer
Inhalation	●		●		●			●	●	
Oral										
Dermal										

Human

	Systemic									
	Death	Acute	Intermediate	Chronic	Immunologic/Lymphoretic	Neurologic	Reproductive	Developmental	Genotoxic	Cancer
Inhalation	●	●	●	●	●	●	●	●	●	●
Oral										
Dermal										

Animal

● Existing Studies

3. HEALTH EFFECTS

to concentrations as low as 40 ppm (DOE/NTP 1987b; Irvine 1981). The LOAEL of 40 ppm (DOE/NTP 1987b) was used as the basis for the derivation of an acute inhalation MRL. No studies were located regarding effects following oral or dermal exposure, and no pharmacokinetic studies by the oral or dermal routes were located; therefore, it is not possible to predict if effects following oral or dermal exposure would be similar to those observed after inhalation exposure. Because 1,3-butadiene exists primarily as a gas and has been detected in soil off-gases at hazardous waste sites, inhalation exposure appears to be the greatest concern. However, it is not known if 1,3-butadiene is present in groundwater or soil at these hazardous waste sites because it is difficult to analyze these media for the compound. 1,3-Butadiene has been detected in industrial waste water and drinking water, and is poorly soluble in water (735 ppm). Therefore, oral and dermal routes of exposure cannot be ruled out. Information concerning 1,3-butadiene toxicity by these routes of exposure would be useful. Because people living at or near these hazardous waste sites may be exposed for brief periods of time, more dose-response data for acute exposures by oral and inhalation routes is considered to be important.

Intermediate-Duration Exposure. No information is available regarding effects of 1,3-butadiene during intermediate-duration exposure in humans. No studies were located regarding effects in humans or animals following oral or dermal exposure to 1,3-butadiene, and pharmacokinetic data for these routes of exposure are insufficient to predict whether the disposition or toxicity of 1,3-butadiene following oral or dermal exposure would be similar to that following inhalation exposure. Therefore, information regarding the toxicity of 1,3-butadiene by the oral route of exposure would be useful. Several studies on intermediate-duration inhalation exposure to 1,3-butadiene have been conducted in animals (Anderson et al. 1996, 1998; Crouch et al. 1979; Irons et al. 1986a; NTP 1984, 1993; Thurmond et al. 1986). Atrophy of reproductive organs, anemia, precancerous hyperplasia in multiple organs, and cancer occurred in mice exposed to ≥ 200 ppm (Irons et al. 1986a; NTP 1984, 1993). The observed hematological changes (macrocytic megaloblastic anemia) were similar to those found in human preleukemic syndrome (Biemer 1983), suggesting that 1,3-butadiene exposure might interfere with normal bone marrow cell development. Further investigation of this topic could be valuable since epidemiological studies in humans indicate that hematopoietic tissue may be a possible target for 1,3-butadiene toxicity (Checkoway and Williams 1982; McMichael et al. 1975). Developmental effects were observed at lowest exposures tested. Skeletal malformations and fetal death were seen at 12.5 ppm, the lowest exposure level tested for this duration (Anderson et al. 1996, 1998). For this reason, an MRL was not derived. More data is needed to understand the mechanism of developmental toxicity in animals to determine if it is relevant to human exposures. Further developmental studies in animals at exposure levels < 12.5 ppm are needed to identify a NOAEL for this effect.

3. HEALTH EFFECTS

Chronic-Duration Exposure and Cancer. Possible risk for hematological disorders was reported in humans after chronic inhalation exposure to 1,3-butadiene in occupational settings, but exposure levels are lacking, and exposure to other chemicals occurs in these settings (Checkoway and Williams 1982; McMichael et al. 1976). Well-conducted inhalation studies identified respiratory effects, liver necrosis, gonadal atrophy, multi-site cancer, and increased mortality in mice at exposures as low as 6.25 ppm (Melnick et al. 1989, 1990a; NTP 1984, 1993), while renal pathology, cancer, and increased mortality were observed in rats exposed to $\geq 1,000$ ppm (Owen et al. 1987). Because a serious LOAEL of severe ovarian atrophy (with complete destruction of oocytes, follicles, and corpora lutea) was found at 6.25 ppm, with no associated NOAEL, no chronic MRL has been derived. Chronic-duration studies are needed that identify a NOAEL in mice for gonadal atrophy. Oral studies are lacking, and toxicokinetic data are insufficient to predict toxicity across routes of exposure. Therefore, information concerning the possible toxicity of 1,3-butadiene by this route would be useful to identify the target organs and the thresholds for toxic effects.

Epidemiological studies in humans indicate a possible increase in carcinogenic risk from occupational exposure to 1,3-butadiene (Cheng et al. 2007; Delzell et al. 1996; Divine 1990; Divine and Hartman 2001; Divine et al. 1993; Downs et al. 1987; Macaluso et al. 1996; Matanoski and Schwartz 1987; Matanoski et al. 1982, 1989a, 1989b, 1990; McMichael et al. 1974, 1975, 1976; Meinhardt et al. 1982; Ward et al. 1995). This is supported by the information about mutagenic activity of 1,3-butadiene metabolites (de Meester 1988) and by well-conducted chronic inhalation studies that provide information on carcinogenic effects of 1,3-butadiene in mice and rats (Melnick et al. 1989; NTP 1984, 1993; Owen et al. 1987). IARC (2009) and EPA (EPA 2002; IRIS 2009) concluded that there is sufficient evidence for the carcinogenicity of 1,3-butadiene in animals. IARC has classified 1,3-butadiene in group 1, carcinogenic to humans. EPA has classified 1,3-butadiene as a human carcinogen. The Department of Health and Human Services (NTP 2005) also identified 1,3-butadiene as a “known human carcinogen”. Further epidemiological investigations that more precisely estimate exposure for possible correlation with specific hematological and cancer effects would be useful. Also, data are needed on 1,3-butadiene exposure to urban populations living in close proximity to major roadways and intersections, as well as on long-term follow-up of health effects, particularly the detection of diminishment in reproductive capability and prevalence of lympho-hematopoietic cancers.

No chronic oral or dermal carcinogenicity studies in animals were located, and pharmacokinetic data are insufficient to predict a carcinogenic potential of 1,3-butadiene by these routes.

3. HEALTH EFFECTS

Genotoxicity. Studies of chromosomal aberrations, sister chromatid exchanges, and *hprt* mutation frequencies among petrochemical and 1,3-butadiene monomer workers exposed to low levels (≤ 2 ppm) provide conflicting results (Albertini et al. 2001, 2007; Ammenheuser et al. 2001; Hayes et al. 1996, 2000; HEI 2003; Lovreglio et al. 2006; Sram et al. 1998; Tates et al. 1996; Ward et al. 1996, 2001; Zhou et al. 1986). 1,3-Butadiene has caused increases in micronuclei induction, chromosomal aberration frequency, and mutations of proto-oncogenes in *in vivo* studies of rats and mice following inhalation exposure (Autio et al. 1994; Cochrane and Skopek 1993; Cunningham et al. 1986; Irons et al. 1987b; Jauhar et al. 1988; Meng et al. 1999, 2000, 2004, 2007; Recio et al. 1992; Sills et al. 2001; Tice et al. 1987; Vodicka et al. 2006). Information on the genotoxic effects of 1,3-butadiene was also obtained from *in vitro* studies in prokaryotic (Arce et al. 1989; de Meester 1988, de Meester et al. 1980; Victorin and Stahlberg 1988) and eukaryotic (Cochrane and Skopek 1993; Sasiadek et al. 1991) organisms. These data sufficiently characterize the mutagenic potential of 1,3-butadiene metabolites. However, reliable cytogenetic studies among exposed workers would be useful. These studies would provide the opportunity to determine if a correlation exists between the induction of chromosomal aberrations and sister chromatid exchanges in individuals and the concentration of 1,3-butadiene to which they are exposed.

Reproductive Toxicity. The atrophy of gonads in mice after chronic inhalation exposures as low as 6.25 ppm 1,3-butadiene was reported (Melnick et al. 1989; NTP 1984, 1993). The fertility of rats, guinea pigs, or rabbits was reported to be unaltered by acute- and intermediate-duration inhalation exposure to 1,3-butadiene (Anderson et al. 1996, 1998; Carpenter et al. 1944). Sperm head abnormalities were found in male mice exposed to 1,3-butadiene by inhalation (DOE/NTP 1988b). Further information regarding the reproductive effects of 1,3-butadiene in animals such as multigeneration studies would be useful to estimate the possible risk for reproductive effects in humans. An epidemiological study among exposed populations concentrating on reproductive effects would be useful.

No studies were located regarding reproductive toxicity of 1,3-butadiene by the oral or dermal routes in humans or animals, and pharmacokinetic data were insufficient to suggest the potential for 1,3-butadiene to cause reproductive effects by these routes of exposure. The potential for exposure of humans by the oral and dermal routes, however, is not known.

Developmental Toxicity. No information on developmental toxicity in humans was located. A developmental study by the inhalation route indicated growth retardation in rat fetuses and an increase in

3. HEALTH EFFECTS

major skeletal abnormalities at a concentration of 1,000 ppm of 1,3-butadiene (Irvine 1981). Furthermore, fetotoxicity was observed in mice at acute-duration exposures of 40 ppm and intermediate-duration exposures of 12.5 ppm 1,3-butadiene (DOE/NTP 1987b). More data on developmental toxicity in other species (at least one of them nonrodent) would be useful to identify the possible developmental risk for humans. The developmental effects following other routes of exposure have not been studied, and pharmacokinetic data are insufficient to predict that responses would be similar to those by the inhalation route. Therefore, studies of oral exposures in animals to determine the possible developmental effects of 1,3-butadiene and the thresholds for these effects would be useful.

Immunotoxicity. Reduction in thymus weight and lymphoid histopathology was seen after the intermediate-duration exposure of mice to ≥ 625 ppm 1,3-butadiene (NTP 1993; Thurmond et al. 1986). The indications of disturbances in hemato- and lymphatopoietic stem cell regulations were observed after inhalation exposure of mice to 1,3-butadiene (Liederman et al. 1986). The high incidence of lymphoma among mice after the chronic exposure (NTP 1984, 1993) also indicates that the immune system is a target. A battery of immune function tests has not been performed in humans or animals. More data regarding humans and animals would be useful for determining potential human immunotoxicity of 1,3-butadiene. Studies regarding skin sensitization with 1,3-butadiene are lacking.

Neurotoxicity. Narcosis has been reported in humans (Sandmeyer 1981) and demonstrated in animals after acute inhalation exposure to very high levels of 1,3-butadiene (250,000 ppm) (Carpenter et al. 1944; Shugaev 1969). No reliable information was located regarding neurotoxicity due to chronic inhalation exposure or to oral or dermal exposure for any duration. Information regarding early, subtle signs of possible neurological effects with correlation to the exposure levels is lacking. A battery of neurological and neurobehavioral tests would be useful to better define the neurological end points.

Epidemiological and Human Dosimetry Studies. Several epidemiological studies on health effects of 1,3-butadiene have been conducted (Case and Hosker 1954; Fox et al. 1974; Matanoski and Schwartz 1987; Matanoski et al. 1989a, 1989b; McMichael et al. 1974, 1975, 1976; Meinhardt et al. 1982). The limitation of these studies is that the cohorts of exposed workers were recruited from the rubber industry, in which the people were exposed to a mixture of various chemicals. Some genotoxicity studies have been conducted among 1,3-butadiene manufacturing workers and petrochemical workers exposed to low (≤ 2 ppm) exposures, but have reported conflicting results (Albertini et al. 2001, 2007; Ammenheuser et al. 2001; Hayes et al. 1996, 2000; HEI 2003; Kelsey et al. 1995; Lovreglio et al. 2006; Tates et al. 1996; Ward et al. 1996, 2001; Wickliffe et al. 2009; Zhou et al. 1986). Reliable dosimetry

3. HEALTH EFFECTS

data on the exposed populations would be useful for good epidemiological comparisons. Efforts to improve estimates of past exposures and to more accurately define current exposure levels to 1,3-butadiene would be valuable. Epidemiological studies should concentrate on the possible carcinogenic effect of 1,3-butadiene in humans and on changes in hemato- and lymphatopoietic systems as possible targets for 1,3-butadiene induced toxicity. The data obtained from workers exposed occupationally to low concentrations of 1,3-butadiene could possibly be extrapolated to populations living near hazardous waste sites.

Biomarkers of Exposure and Effect.

Exposure. The determination of 1,3-butadiene-derived urinary metabolites (Albertini et al. 2001, 2007; Ammenheuser et al. 2001; Bechtold et al. 1994; Dahl et al. 1990; Hayes et al. 1996, 2000; Sapkota et al. 2006; Ward et al. 1994, 1996), DNA adducts (Kreiling et al. 1986b; Sun et al. 1989b; Zhao et al. 2001), and hemoglobin adducts (Albertini et al. 2001, 2007; Begemann et al. 2001a, 2001b; Boogaard et al. 2001b; Hayes et al. 2000; HEI 2000; Osterman-Golkar et al. 1996) of rats, mice, and humans exposed to 1,3-butadiene has been performed. Continued efforts to devise more specific early biomarkers of disease, especially hematological and oncological, would be valuable. Data are needed that accurately correlate the level of biomarkers measured in the body with the exposure to 1,3-butadiene, as well as the variability in this correlation between sexes and ethnicity.

Effect. Conflicting data exist for the sensitivity of human lymphocyte *hprt* mutation frequencies resulting from occupational exposures (Albertini et al. 2001, 2007; Ammenheuser et al. 2001; Hayes et al. 1996, 2000; HEI 2003; Kelsey et al. 1995; Lovreglio et al. 2006; Tates et al. 1996; Ward et al. 1996, 2001; Wickliffe et al. 2009; Zhou et al. 1986). In mice and rats, levels of DEB-specific DNA-DNA cross-links correlated well with 1,3-butadiene inhalation and relative sensitivity of female mice to toxicity (Goggin et al, 2009). Two biomarkers for carcinogenic effect have been consistently found in multiple tumors sites in rodent chronic bioassays. A number of malignant gliomas and neuroblastomas in mice chronically inhaling 1,3-butadiene exhibited mutations of the p53 gene and H- and K-*ras* oncogenes (Kim et al. 2005), which have also been observed in forestomach tumors (Sills et al. 2001), hemangiosarcomas (Hong et al. 2000), and lymphomas (Zhuang et al. 1997) of chronically exposed mice. Data for reliable and specific biomarkers indicating onset of developmental effects in animals would be useful to determine if comparable exposure may lead to these effects in humans.

3. HEALTH EFFECTS

Absorption, Distribution, Metabolism, and Excretion. The timecourse of 1,3-butadiene and its primary metabolite, EB, in human blood has been investigated in volunteers inhaling 2 ppm for 20 minutes (Lin et al. 2001). *In vitro* studies have characterized some of the metabolism dynamics of 1,3-butadiene in animals (Bolt et al. 1983; Csanady et al. 1992; Duescher and Elfarra 1994; Elfarra et al. 1996, 2001; Himmelstein et al. 1994, 1995; Jackson et al. 2000a; Kreiling et al. 1987; Laib et al. 1990; Malvoisin and Roberfroid 1982; Malvoisin et al. 1979; Schmidt and Loeser 1985, 1986; Thornton-Manning et al. 1995, 1997). Several toxicokinetic studies on 1,3-butadiene metabolism *in vivo* have been conducted in rats and mice following inhalation exposure (Bolt et al. 1983; Bond et al. 1987; Himmelstein et al. 1994; Kohn and Melnick 2001; Kreiling et al. 1986b; Shugaev 1969), but not following exposure by other routes. Thus, further studies in animals by the oral route to determine possible target organs by this route could be useful. Ethical considerations limit the testing of humans, but the development of methods to determine urinary and breath excretion of 1,3-butadiene and its metabolites by humans with known exposure to 1,3-butadiene may provide a means of monitoring humans for exposure.

Comparative Toxicokinetics. The study by Schmidt and Loeser (1985) indicated that there is a difference between the capability of mouse and rat liver postmitochondrial fractions to produce 1,2-epoxybutene-3 after incubation with 1,3-butadiene. Furthermore, monkey and human postmitochondrial liver preparations catalyzed the formation of only a small amount of the epoxide. Higher levels of the toxic epoxides were found in blood of mice following 1,3-butadiene exposure as compared to monkeys (Bolt et al. 1983; Csanady et al. 1992; Dahl et al. 1990; Duescher and Elfarra 1994; Elfarra et al. 1996, 2001; Jackson et al. 2000a; Sun et al. 1989a). Species differences in the toxicokinetics of a chemical may account for differences in toxic responses. Analysis of the blood, breath, and urine of humans exposed to 1,3-butadiene for parent compound and metabolites over time would provide a greater knowledge of the human metabolic pathways. Qualitative and quantitative comparison of human metabolites with those of animals could help identify the most appropriate species to serve as a model for predicting toxic effects and mechanisms of action in humans.

Methods for Reducing Toxic Effects.

Children's Susceptibility. Data needs relating to both prenatal and childhood exposures, and developmental effects expressed either prenatally or during childhood, are discussed in detail in the Developmental Toxicity subsection above.

3. HEALTH EFFECTS

The sensitivity of children to 1,3-butadiene toxicity, if any, is unknown. In mice, acute- and intermediate-duration inhalation exposures resulted in *in utero* fetal effects at exposure levels of 21.5–40 ppm (Anderson et al. 1996; DOE/NTP 1987b). No information is available for interfering with effects of 1,3-butadiene toxicity *in utero*.

Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs: Exposures of Children.

3.12.3 Ongoing Studies

The following ongoing studies were identified in the Federal Research in Progress database (FEDRIP 2009).

E. Struble is being funded by EPA HEERL to use environmental irradiation chambers (smog chambers) to induce the natural photochemically stimulated transformations of environmental pollutants. The synthetic urban smog mixture is composed of 55 hydrocarbon species representative of the ambient air of an average city in the United States. In this study, A549 cells were exposed simultaneously to irradiated and non-irradiated chamber mixtures for 5 hours. Post exposure, adverse health effects were determined by measures of increased cellular stress cytokine release and cytotoxicity. Exposure to the photochemically-generated products of 1,3-butadiene, toluene, and methanol induced increases in both cytotoxicity and IL-8 gene expression compared to 1,3-butadiene, toluene, or methanol alone. The exposure design was used to investigate the toxicity of chemicals after photochemical reactions and interactions with the urban atmosphere on healthy and susceptible individuals using representative *in vitro* samples. This research informs the toxicity from exposures to multiple environmental pollutants found in urban settings.

James A. Swenberg is being funded by NIEHS to examine the molecular dose of previously unexplored DNA adducts in rodents exposed to 1,3-butadiene and 3-butene-1, 2-diol (BD-diol). The data will be compared with mutation frequencies and mutational spectra to determine (1) if a particular adduct could be used as a mutagenic indicator, and (2) to determine the effects of exposure on gene expression. First, it will be determined if hydroxymethylvinyl ketone (HMVK) is formed *in vivo* during exposure to 1,3-butadiene and BD-diol in a sex-, species-, and exposure concentration-dependent manner, resulting in mutagenicity. Secondly, promutagenic N1 adenine adducts will be observed to see if they are converted to more stable inosine adducts, which may accumulate in tissues during chronic exposures. Several

3. HEALTH EFFECTS

specific aims will be accomplished while addressing these questions. Specific Aim 1 is to examine the formation of potentially mutagenic DNA adducts (specifically 1, N2-propanodeoxyguanosine) by HMVK in vivo. Specific Aim 2 is to determine the utility of the N-terminal valine adduct of HMVK (HMVK-Val) as a biomarker of HMVK formation by BD and BD-diol. Specific Aim 3 is to develop methods for detecting N1- inosine, N1 - and N6 adenine adducts derived from BD metabolites in vivo. Specific Aim 4 is to determine the mutagenic responses induced by BD exposures and characterize the impact of BD-diol-derived metabolites on the spectra of mutations induced by BD exposure in the B6C3F1 mouse and F344 rat to identify which adducts studied in Aims 1 and 3 are quantitative indicators of mutagenesis. Specific Aim 5 will examine the effects of exposure to BD and BD-diol on gene expression and DNA repair pathways. Collectively, these experiments have been designed to inform on adduct formation, DNA repair, mutagenicity, and genomic alterations in rodents exposed to 1,3-butadiene and BD-diol, as well as the impact of glutathione depletion and DNA repair deficiency.

Elaine Symanski is being funded by the National Cancer Institute to evaluate an association between lymphohematopoietic (LH) cancer incidence and air pollution in the Houston metropolitan area, with particular emphasis on three compounds: benzene, 1,3-butadiene, and styrene. Data from the Texas Cancer Registry (TCR) from 1995 to 2005 and the Texas Commission on Environmental Quality (TCEQ) from 1992 to 2003 will be analyzed to: (1) investigate the spatial and temporal distribution of LH cancer incidence in Harris and surrounding counties; (2) evaluate the association between distance from industrial sources and LH cancer incidence; (3) identify optimal methods for assessing ambient levels of benzene, 1,3-butadiene, and styrene using existing TCEQ monitoring data; and (4) evaluate the association between ambient levels of benzene, styrene, and 1,3-butadiene and LH cancer incidence using Poisson regression in single and multi-pollutant models. This will be the first study to examine this association in Harris and seven surrounding counties (Texas) and is among the first to utilize monitored levels of hazardous air pollutants (HAPs) to assess increased risks of LH cancer associated with air pollution. This work will also correlate cancer rates with proximity to industrial facilities as well as ambient levels of benzene, styrene, and 1,3-butadiene. This study will address a gap in the literature by examining the association between HAPs and cancer incidence in Harris County, Texas and will further explore innovative methods to evaluate this association utilizing existing data sources.

Natalia Y. Tretyakova is being funded by the National Cancer Institute to evaluate the role of DNA-DNA cross-linking in the genotoxicity of diepoxybutane and 1,3-butadiene. DEB-DNA cross-links will be structurally characterized and formation sequence preferences will be determined. The hydrolytic stability of DEB-DNA cross-links will be evaluated for their recognition by the *E. coli* UvrABC repair

3. HEALTH EFFECTS

complex. DEB-DNA cross-links in rodent tissues will be quantified by capillary HPLC-ESI-MS/MS methods. This research will provide valuable information on the molecular mechanisms underlying the genotoxic activity of diepoxybutane.

4. CHEMICAL AND PHYSICAL INFORMATION

4.1 CHEMICAL IDENTITY


Information regarding the chemical identity of 1,3-butadiene is located in Table 4-1. This information includes synonyms, chemical formula and structure, and identification numbers.

4.2 PHYSICAL AND CHEMICAL PROPERTIES

Information regarding the physical and chemical properties of 1,3-butadiene is located in Table 4-2.

4. CHEMICAL AND PHYSICAL INFORMATION

Table 4-1. Chemical Identity of 1,3-Butadiene^a

Characteristic	Information
Chemical name	1,3-Butadiene
Synonyms and trade names	Butadiene; buta-1,3-diene; biethylene; bivinyl; divinyl; vinylethylene; erythrene; alpha,-gamma-butadiene; pyrrolylene ^b
Chemical formula	C ₄ H ₆
Chemical structure	
Identification numbers:	
CAS registry	106-99-0
NIOSH RTECS	EI9275000 ^c
EPA hazardous waste	R0377-0754 ^d
DOT/UN/NA/IMDG shipping	1010
EINECS	203-450-8
HSDB	181
NCI	C50602

^aAll information obtained from HSDB 2009 and ChemID Plus Advanced 2009 except where noted.

^bO'Neil et al. 2006

^cNIOSH 2005

^dMiller 1978

CAS = Chemical Abstracts Service; DOT/UN/NA/IMDG = Department of Transportation/United Nations/North America/International Maritime Dangerous Goods Code; EINECS = European Inventory of Existing Commercial chemical Substances; EPA = Environmental Protection Agency; HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for Occupational Safety and Health; RTECS = Registry of Toxic Effects of Chemical Substances

4. CHEMICAL AND PHYSICAL INFORMATION

Table 4-2. Physical and Chemical Properties of 1,3-Butadiene

Property	1,3-Butadiene	Reference
Molecular weight	54.09	O'Neil et al. 2006
Color	Colorless	Lewis 2007
Physical state	Gas	Lewis 2007
Melting point	-108.966 °C	O'Neil et al. 2006
Boiling point	-4.5 °C	O'Neil et al. 2006
Density:		
at 25 °C (g/cm ³)	0.6149	Lide 2008
Vapor density	1.88 (air=1)	NIOSH 2005
Odor	Mildly aromatic; gasoline-like	Lewis 2007
Water	Not applicable ^a	Amoore and Hautala 1983
Air	1.6 ppm	Amoore and Hautala 1983
Odor threshold		
Solubility:		
Water at 25 °C	735 mg/L	McAuliffe 1966
Organic solvent(s)	Soluble in ether, ethanol and benzene; very soluble in acetone	Lide 2008
Partition coefficients:		
Log K _{ow}	1.99	Hansch et al. 1995
K _{oc}	288 (estimated) ^b	HSDB 2009
Vapor pressure at 25 °C	2.11x10 ³ mm Hg	AICHE 2000
Henry's law constant at 25 °C	7.4x10 ⁻² atm·m ³ /mol (estimated) ^c	HSDB 2009
Autoignition temperature	414 °C	Lewis 2007
Flashpoint	-76 °C	Lewis 2007
Explosive limits	2.0-11.5%	O'Neil et al. 2006
Conversion factors	1 ppm=2.21 mg/m ³ 1 mg/m ³ =0.452 ppm	NIOSH 2005

^aAmoore and Hautala (1983) reported an odor threshold of 0.0014 ppm for 1,3-butadiene in water; however, these authors state that this solution lacks enough persistence for this value to be used for reference purposes.

^bThis K_{oc} value was estimated using the measured log K_{ow} value (1.99) and a regression derived equation.

^cThis Henry's Law constant value was calculated from the measured vapor pressure (2.11x10³ mm Hg at 25 °C) and water solubility (735 mg/L).

4. CHEMICAL AND PHYSICAL INFORMATION

This page is intentionally blank.

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL

5.1 PRODUCTION

1,3-Butadiene was discovered in the nineteenth century and its use in the development of rubber-like polymers was explored during the early 1900s (Grub and Loser 2005; Sun and Wristers 2002). Large volume production of 1,3-butadiene in the United States began during World War II as a result of the nation's synthetic rubber program (American Chemical Society 2007; Dolnick and Potash 1948). U.S. production rose to 2.7 billion pounds in 1965 as new plants were started to meet the increasing butadiene-rubber demand of the auto industry (Chemical Market Reporter 2006; Grub and Loser 2005; Kirshenbaum 1978). Production reached 3.7 billion pounds (1,674 metric tons) by 1974 and then fluctuated through the 1980s as a response to market pressures (Grub and Loser 2005; Kirshenbaum 1978; Sun and Wristers 2002). Production growth resumed during the 1990s, reaching 4.5 billion pounds (2,020 metric tons) in 1998 (Grub and Loser 2005). Actual production volumes of 1,3-butadiene manufactured in the United States during more recent years are not available; however, the annual U.S. production capacity was reported to be 6 billion pounds (2,800 metric tons) during 2008 (Chemical Week 2008; SRI 2008).

The 1,3-butadiene market is heavily dependent on the synthetic rubber demand of the auto industry, which accounts for approximately 60% of the total consumption of this substance (Chemical Market Reporter 2006). Also, since most 1,3-butadiene is produced through steam cracking, the supply of this chemical has been largely influenced by the demand for ethylene, the primary product from steam cracking (Sun and Wristers 2002). The current global economic downturn and weakening of the U.S. auto industry are expected to lead to a decline in U.S. production of 1,3-butadiene for 2009 (ICIS 2009a, 2009b).

The companies that produced 1,3-butadiene in the United States, their production sites, and their annual capacities during 2008 (the most recent year for which figures are available) are shown in Table 5-1 (SRI 2008). Table 5-2 summarizes the number of facilities in each state that manufactured or processed 1,3-butadiene in 2007, the ranges of maximum amounts on site, if reported, and the activities and uses as reported in the Toxics Release Inventory (TRI) (TRI07 2009). The data listed in this table should be used with caution since only certain types of facilities are required to report. This is not an exhaustive list.

Except for a small amount of 1,3-butadiene produced by the oxydehydrogenation of n-butene, all the 1,3-butadiene produced in the United States is a co-product of ethylene manufacture (Chemical Market

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL

Table 5-1. Companies that Produce 1,3-Butadiene in the United States and Annual Capacities During 2008

Company	Location	Capacity (million pounds/year)	Capacity (metric tons)
Equistar Chemicals, LP	Alvin, Texas	150	68,060
	Channelview, Texas	865	392,500
	Corpus Christi, Texas	200	90,740
ExxonMobil Chemical Company	Baton Rouge, Louisiana	385	
	Baytown, Texas	325	147,500
INEOS Americas, LLC			
INEOS Olefins & Polymers USA	Alvin, Texas	235	106,600
Sabina Petrochemicals LLC	Port Arthur, Texas	900	
Shell Chemical LP	Deer Park, Texas	360	163,300
	Norco, Louisiana	575	260,900
Texas Petrochemicals, Inc.	Houston, Texas	1,080	490,000
	Port Neches, Texas	925	419,700
Total		6,000	2,722,000

Source: SRI 2008

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL

Table 5-2. Facilities that Produce, Process, or Use 1,3-Butadiene

State ^a	Number of facilities	Minimum amount on site in pounds ^b	Maximum amount on site in pounds ^b	Activities and uses ^c
AL	7	0	9,999,999	1, 3, 5, 6, 8, 13, 14
AR	6	1,000	999,999	1, 2, 3, 6, 9, 12
AZ	1	10,000	99,999	9
CA	68	0	999,999,999	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14
CO	12	0	9,999,999	1, 3, 5, 6, 12, 13
CT	3	1,000,000	9,999,999	2, 3, 6
DE	10	1,000	9,999,999	1, 2, 3, 5, 6, 7, 12, 13
GA	4	100,000	9,999,999	1, 5, 6
HI	6	1,000	99,999	1, 3, 5, 6, 13, 14
IA	4	100,000	9,999,999	1, 3, 4, 6
IL	36	0	49,999,999	1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14
IN	19	0	999,999	1, 3, 4, 5, 6, 7, 8, 12, 13, 14
KS	8	100	499,999,999	1, 3, 6, 10, 13
KY	16	10,000	9,999,999	1, 3, 4, 5, 6, 7, 9, 12, 13
LA	92	0	10,000,000,000	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14
MI	25	0	49,999,999	1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 13
MN	10	0	9,999,999	1, 2, 3, 5, 6, 7, 12, 13
MO	6	0	9,999	1, 5, 7, 12, 14
MS	12	1,000	499,999,999	1, 2, 3, 4, 5, 6, 7, 9, 13, 14
MT	18	100	999,999	1, 3, 5, 6, 8, 12, 13, 14
NC	9	0	49,999,999	2, 3, 6, 7, 8, 10
ND	4	0	9,999	1, 2, 3, 4, 6
NE	2	0	9,999	3, 8, 11, 12
NH	1	1,000	9,999	6
NJ	16	0	99,999	1, 3, 4, 5, 6, 7, 12, 13
NM	2	0	9,999	1, 3, 5, 7, 11
NY	7	10,000	999,999	2, 3, 4, 6, 8, 11
OH	30	0	49,999,999	1, 2, 3, 5, 6, 7, 8, 12, 13, 14
OK	21	0	9,999,999	1, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13
PA	16	0	9,999,999	1, 2, 3, 5, 6, 7, 8, 12, 13
PR	1	10,000,000	49,999,999	1, 5, 7
SC	3	0	99,999	1, 5, 6, 13, 14
TN	21	0	9,999,999	1, 2, 3, 5, 6, 7, 8, 9, 10, 12, 13, 14
TX	211	0	10,000,000,000	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
UT	13	100	999,999	1, 3, 4, 5, 6, 7, 8, 9
VA	6	100	9,999	1, 3, 4, 5, 6, 13
VI	5	100	99,999	1, 2, 3, 6, 13

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL

Table 5-2. Facilities that Produce, Process, or Use 1,3-Butadiene

State ^a	Number of facilities	Minimum amount on site in pounds ^b	Maximum amount on site in pounds ^b	Activities and uses ^c
WA	25	0	9,999,999	1, 2, 3, 4, 5, 6, 7, 11, 12, 13
WI	2	100,000	9,999,999	6
WV	9	0	99,999,999	1, 5, 6, 7, 8, 12
WY	5	0	99,999	1, 3, 4, 6

^aPost office state abbreviations used

^bAmounts on site reported by facilities in each state

^cActivities/Uses:

- | | | |
|--------------------------|--------------------------|-----------------------------|
| 1. Produce | 6. Impurity | 11. Chemical Processing Aid |
| 2. Import | 7. Reactant | 12. Manufacturing Aid |
| 3. Onsite use/processing | 8. Formulation Component | 13. Ancillary/Other Uses |
| 4. Sale/Distribution | 9. Article Component | 14. Process Impurity |
| 5. Byproduct | 10. Repackaging | |

Source: TRI07 2009 (Data are from 2007)

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL

Reporter 2006; Sun and Wristers 2002). In this process, feed streams ranging from light hydrocarbons to heavy gas oils are cracked in the presence of steam at 700–900 °C (Grub and Loser 2005; Kirshenbaum 1978; Sun and Wristers 2002). The fraction of 1,3-butadiene produced by this process varies widely with the type of feedstock used and is lowest with low-boiling input streams (Grub and Loser 2005; Kirshenbaum 1978).

Purification of the crude C4 stream resulting from the steam cracking process cannot be achieved by a simple distillation due to the close boiling point of the various products and the fact that 1,3-butadiene forms an azeotrope with butane (Grub and Loser 2005; Kirshenbaum 1978). 1,3-Butadiene can be removed from the hydrocarbon stream by liquid-liquid extraction or extractive distillation. The selective solvents used in these processes include aqueous cupric ammonium acetate, acetonitrile, furfural, dimethylformamide, N,N-dimethylacetamide, and N-methylpyrrolidinone (Grub and Loser 2005; Sun and Wristers 2002).

The oxidative dehydrogenation of n-butene, used in the production of 1,3-butadiene, is a highly selective, irreversible process that involves heating the starting material, air, and a suitable catalyst together at 400–450 °C (Grub and Loser 2005; Kirshenbaum 1978; Sun and Wristers 2002). The hydrogen released in the dehydrogenation step combines with oxygen, producing large amounts of heat, which makes this process energy-efficient (Grub and Loser 2005; Kirshenbaum 1978; Sun and Wristers 2002). As indicated above, oxidative dehydrogenation of n-butene has not been competitive with the steam cracking process for manufacture of 1,3-butadiene (Chemical Market Reporter 2006; Grub and Loser 2005). Rather, this method has been used on a campaign basis when there is a large enough differential between feedstock and 1,3-butadiene prices (Grub and Loser 2005).

5.2 IMPORT/EXPORT

Large amounts of 1,3-butadiene are imported into the United States as consumption typically exceeds production (Chemical Market Reporter 2006; Chemical Week 2008; Sun and Wristers 2002). U.S. imports of 1,3-butadiene in 2005 were approximately 600 million pounds (Chemical Market Reporter 2006). More recent import data are not available. U.S. Exports of 1,3-butadiene are considered to be negligible (Chemical Market Reporter 2006).

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL

5.3 USE

1,3-Butadiene is used as a monomer in the production of rubber and plastics; approximately 60% of the 1,3-butadiene consumed in the United States is used in the production of synthetic rubbers (Chemical Market Reporter 2006). 1,3-Butadiene uses can be broken down into the following categories: synthetic rubber, 61% (styrene butadiene rubber [SBR], 30%; polybutadiene elastomer, 25%; polychloroprene elastomer, 4%; nitrile elastomer, 2%) adiponitrile/hexamethylene diamine (HMDA), 11%; styrene-butadiene latex, 12%; ABS resins, 5%; and other uses, 11% (Chemical Market Reporter 2006).

Automobile tires are the major end-use product (Chemical Market Reporter 2006; ICIS 2009a). Both styrene butadiene rubber and polybutadiene are used heavily for this purpose. 1,3-Butadiene is also used for other automotive applications such as high-impact polystyrene and ABS resin plastics (Chemical Market Reporter 2006; ICIS 2009a). 1,3-Butadiene is a precursor in the production of adiponitrile (used to make nylon) and chloroprene (used to make neoprene) (Chemical Market Reporter 2006; ICIS 2009a).

5.4 DISPOSAL

The recommended method of disposal of 1,3-butadiene is by incineration within a suitable combustion chamber or in a safe area (HSDB 2009). Gaseous 1,3-butadiene can be burned directly; however, liquefied 1,3-butadiene (in a compressed cylinder) must be atomized before burning (HSDB 2009). Kennedy et al. (2008) report that burning off 1,3-butadiene, also referred to as flaring, is commonly practiced at facilities where excess amounts of this substance need to be destroyed (Kennedy et al. 2008).

6. POTENTIAL FOR HUMAN EXPOSURE

6.1 OVERVIEW

1,3-Butadiene has been identified in at least 13 of the 1,699 hazardous waste sites that have been proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2007). However, the number of sites evaluated for 1,3-butadiene is not known. The frequency of these sites can be seen in Figure 6-1.

1,3-Butadiene is a high-volume, volatile hydrocarbon used in the production of commercial plastics and synthetic rubbers (Chemical Market Reporter 2006; ICIS 2009a). The chemical reactivity of this monomer is utilized in its transformation into polymeric materials (Sigsby et al. 1987).

1,3-Butadiene may be released to the environment as an intentional or fugitive emission during its production, use, storage, transport, or disposal. Large amounts of this hydrocarbon are released to the atmosphere from commercial processes (TRI07 2009). Data on the detection of 1,3-butadiene in soil and water are scarce. In the past, it has been qualitatively detected in drinking water (EPA 1978; Kraybill 1980); however, more recent measurements are not available.


1,3-Butadiene is a highly volatile gas; therefore, it is expected to partition predominantly to the atmosphere. In the atmosphere, 1,3-butadiene is expected to undergo rapid destruction, primarily by photo-initiated reactions. The reaction with photochemically produced hydroxyl radicals has a calculated half-life of approximately 6 hours and is expected to be the dominant pathway for atmospheric removal (Atkinson 1989). Destruction of atmospheric 1,3-butadiene by the gas-phase reaction with tropospheric ozone and by the night-time reaction with nitrate radicals in urban areas is also expected to be significant (Atkinson and Carter 1984; Atkinson et al. 1984).

Limited data have been located on the fate of 1,3-butadiene in soil or water. Based on its physical properties, rapid volatilization of 1,3-butadiene from either soil or water to the atmosphere is expected to dominate over all other potential environmental processes. Based on estimated soil adsorption coefficient values, 1,3-butadiene is not expected to adsorb significantly to soil or sediment, nor is it expected to bioconcentrate in fish or aquatic organisms based on estimated bioconcentration and bioaccumulation factors.

Although 1,3-butadiene undergoes rapid photooxidation in the atmosphere, it is almost always present at very low concentrations in urban and suburban areas (Curren et al. 2006; Grant et al. 2007; Oguz et al.

6. POTENTIAL FOR HUMAN EXPOSURE

Figure 6-1. Frequency of NPL Sites with 1,3-Butadiene Contamination



Derived from HazDat 2007

6. POTENTIAL FOR HUMAN EXPOSURE

2003; Reiss 2006; Reiss and Griffin 2004; Sax et al. 2004). Automobile exhaust is a constant source of 1,3-butadiene release to the atmosphere. Because of the compound's ubiquity in the urban/suburban atmosphere, the general population is exposed to low ppb levels of 1,3-butadiene through inhalation (Higashino et al. 2007; Hughes et al. 2003). Exposure to 1,3-butadiene may also occur from the inhalation of cigarette smoke or the smoke from wood fires (Adam et al. 2006; Bartle et al. 1969; Blomberg and Widmark 1975; Brunnemann et al. 1990; Carmella et al. 2009; Counts et al. 2006; Gustafson et al. 2007; Lofroth et al. 1989; Pankow et al. 2004, 2007; Penn and Snyder 2007; Stump et al. 1989; Thweatt et al. 2007; Vainiotalo et al. 2008). Ingestion of contaminated food or drinking water may also lead to low levels of exposure, although current levels of this compound in food and water samples are not known, nor is there a good understanding of their frequency of detection (EPA 1978; Hughes et al. 2003; Kraybill 1980; Leber 2001; McNeal and Breder 1987; Startin and Gilbert 1984). The levels of 1,3-butadiene in soil are not known. Elevated levels of exposure for the general population may occur for those near its site of manufacture or facilities where it is made into polymeric materials.

Occupational exposure to 1,3-butadiene is expected to be limited to those working at facilities that manufacture 1,3-butadiene or convert it into commercial polymers (Anttinen-Klemetti et al. 2006; Begemann et al. 2001a; Fustinoni et al. 2004; Jones and Harris 1983; Lovreglio et al. 2006; Meinhardt et al. 1982; Sathiakumar et al. 2007; Tsai et al. 2001, 2005; Ward et al. 2001). Exposure by inhalation is expected to be the dominant pathway for exposure. Dermal exposure to liquified 1,3-butadiene could occur during an explosion of a pressurized storage tank or some other catastrophic event.

6.2 RELEASES TO THE ENVIRONMENT

The Toxics Release Inventory (TRI) data should be used with caution because only certain types of facilities are required to report (EPA 2005). This is not an exhaustive list. Manufacturing and processing facilities are required to report information to the TRI only if they employ 10 or more full-time employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to facilities that combust coal and/or oil for the purpose of generating electricity for distribution in commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces,

6. POTENTIAL FOR HUMAN EXPOSURE

imports, or processes $\geq 25,000$ pounds of any TRI chemical or otherwise uses $>10,000$ pounds of a TRI chemical in a calendar year (EPA 2005).

6.2.1 Air

Estimated releases of 1.78 million pounds (809 metric tons) of 1,3-butadiene to the atmosphere from 197 domestic manufacturing and processing facilities in 2007 accounted for about 99% of the estimated total environmental releases from facilities required to report to the TRI (TRI07 2009). These releases are summarized in Table 6-1.

The dominant sources for the release of 1,3-butadiene to the atmosphere are fugitive or accidental emissions during its manufacture, use, transport, and storage. Low levels of 1,3-butadiene are continuously emitted to the atmosphere from many sources including exhaust from motor vehicle engines using petroleum-based fuels.

EPA's National Emission Inventory database (NEI) contains detailed information about sources that emit criteria air pollutants and their precursors, and hazardous air pollutants for the 50 United States, Washington DC, Puerto Rico, and the U.S. Virgin Islands. Emission data for 1,3-butadiene in 2005 is presented in Table 6-2 and suggests that automobile usage accounts for approximately one-third of all emissions.

1,3-Butadiene was measured in the exhaust of typical automobiles and light trucks using both winter and summer gasoline formulations and accounted for up to 0.12% of total hydrocarbon emissions (Stump et al. 1989). An earlier study determined that the concentration of 1,3-butadiene in automobile exhaust was 20–60 ppb (Neligan 1962). 1,3-Butadiene has also been detected in the exhaust of diesel engines (Hayano et al. 1985) and high-altitude jet aircraft engines operating under simulated conditions (Katzman and Libby 1975).

There are several minor sources for the release of 1,3-butadiene to the atmosphere, all of which involve the thermal breakdown of other materials. 1,3-Butadiene has been detected as a component of the sidestream smoke from cigarettes (Adam et al. 2006; Bartle et al. 1969; Blomberg and Widmark, 1975; Carmella et al. 2009; Penn and Snyder 2007; Vainiotalo et al. 2008). The average amount of 1,3-butadiene in sidestream cigarette smoke is 205–361 $\mu\text{g}/\text{cigarette}$ (Brunnemann et al. 1990), with an average airborne yield of 400 $\mu\text{g}/\text{cigarette}$ (Lofroth et al. 1989).

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-1. Releases to the Environment from Facilities that Produce, Process, or Use 1,3-Butadiene^a

State ^c	RF ^d	Reported amounts released in pounds per year ^b					Total release		
		Air ^e	Water ^f	UI ^g	Land ^h	Other ⁱ	On-site ^j	Off-site ^k	On- and off-site
AL	2	6,700	0	0	250	0	6,700	250	6,950
AR	1	1,138	No data	0	0	0	1,138	0	1,138
AZ	1	277	No data	0	0	0	277	0	277
CA	16	5,035	0	0	0	0	5,035	0	5,035
CO	3	1,835	0	0	0	0	1,835	0	1,835
CT	2	49	0	0	0	0	49	0	49
DE	2	5,384	0	0	0	0	5,384	0	5,384
GA	3	11,086	0	0	0	0	11,086	0	11,086
HI	1	1,401	No data	0	0	0	1,401	0	1,401
IA	2	20,429	No data	0	0	0	20,429	0	20,429
IL	7	57,247	10	0	0	0	57,257	0	57,257
IN	5	386	0	0	0	0	386	0	386
KS	3	316	0	0	0	0	316	0	316
KY	5	30,709	0	0	625	0	30,709	625	31,334
LA	22	323,402	62	0	387	0	323,464	387	323,851
MI	3	32,691	0	0	0	0	32,691	0	32,691
MN	1	13,705	2	0	0	0	13,707	0	13,707
MS	1	813	0	0	0	0	813	0	813
MT	3	824	0	0	0	0	824	0	824
NC	3	3,815	0	0	0	0	3,815	0	3,815
ND	1	93	No data	0	0	0	93	0	93
NJ	4	79	0	0	0	0	79	0	79
OH	12	57,381	17	0	2,707	6	60,104	7	60,111
OK	5	8,421	0	0	0	0	8,421	0	8,421
PA	5	634	0	0	255	0	634	255	889
SC	1	8,200	No data	0	0	0	8,200	0	8,200
TN	4	5,036	0	0	0	0	5,036	0	5,036
TX	67	1,175,836	45	925	229	37	1,176,737	335	1,177,071
UT	2	1,500	No data	0	0	0	1,500	0	1,500
VA	1	1,323	No data	0	0	0	1,323	0	1,323
VI	1	983	0	0	0	0	983	0	983
WA	4	491	0	0	0	0	491	0	491
WI	1	840	0	0	0	0	840	0	840

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-1. Releases to the Environment from Facilities that Produce, Process, or Use 1,3-Butadiene^a

State ^c	RF ^d	Air ^e	Reported amounts released in pounds per year ^b						
			Water ^f	UI ^g	Land ^h	Other ⁱ	Total release		
							On-site ^j	Off-site ^k	On- and off-site
WV	1	4,200	No data	0	15	0	4,215	0	4,215
WY	2	255	No data	0	0	0	255	0	255
Total	197	1,782,512	136	925	4,468	43	1,786,225	1,859	1,788,084

^aThe TRI data should be used with caution since only certain types of facilities are required to report. This is not an exhaustive list. Data are rounded to nearest whole number.

^bData in TRI are maximum amounts released by each facility.

^cPost office state abbreviations are used.

^dNumber of reporting facilities.

^eThe sum of fugitive and point source releases are included in releases to air by a given facility.

^fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal and metal compounds).

^gClass I wells, Class II-V wells, and underground injection.

^hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface impoundments, other land disposal, other landfills.

ⁱStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for disposal, unknown

^jThe sum of all releases of the chemical to air, land, water, and underground injection wells.

^kTotal amount of chemical transferred off-site, including to POTWs.

RF = reporting facilities; UI = underground injection

Source: TRI07 2009 (Data are from 2007)

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-2. 1,3-Butadiene Emission Data for 2005^a

Category name	Type	Annual emissions (tons)	Percentage
Fuel comb, residential fireplaces	Nonpoint	3,352.17	6.35
On-road vehicles, gasoline	Onroad	16,008.77	30.32
Miscellaneous sources	Nonpoint	17,627.65	33.39
On-road vehicles, diesel	Onroad	1,058.86	2.01
Agricultural field burning	Nonpoint	339.31	0.64
Fuel comb, residential woodstoves	Nonpoint	315.31	0.60
Graphic arts	Point	0.00	0.00
Gas stations	Point	0.01	0.00
Wildfires	Nonpoint	3,340.53	6.33
Bulk gasoline terminals	Point	5.11	0.01
Fuel comb, commercial/institutional	Nonpoint	0.07	0.00
Planes, trains, and ships	Nonroad	109.07	0.21
Prescribed fires	Nonpoint	164.95	0.31
Industrial process, storage and transfer	Nonpoint	2.61	0.00
Industrial process, NEC	Point	129.88	0.25
Surface coating, industrial	Point	16.81	0.03
Non-road equipment, diesel	Nonroad	364.74	0.69
Non-road equipment, gasoline	Nonroad	8,062.72	15.27
Industrial process, petroleum refineries	Nonpoint	1.30	0.00
Industrial process, petroleum refineries	Point	22.15	0.04
Industrial process, cement manufacturing	Point	64.37	0.12
Logging slash burning	Nonpoint	211.34	0.40
Fuel comb, electric utility	Point	2.30	0.00
Waste disposal, open burning	Point	0.03	0.00
Waste disposal, open burning	Nonpoint	123.52	0.23
Fuel comb, commercial/institutional	Point	0.78	0.00
Industrial process, oil and gas production	Point	7.71	0.01
Waste disposal	Nonpoint	1.52	0.00
Industrial process, chemical manufacturing	Point	603.65	1.14
Degreasing	Point	0.01	0.00
Industrial process, chemical manufacturing	Nonpoint	1.44	0.00
Solvent, NEC	Point	0.24	0.00
Planes, trains, and ships	Point	323.90	0.61
Fuel comb, industrial boilers, ICES	Nonpoint	2.86	0.01
Fuel comb, industrial boilers, ICES	Point	111.72	0.21
Waste disposal	Point	37.16	0.07
Industrial process, oil and gas production	Nonpoint	0.18	0.00
Industrial process, storage and transfer	Point	217.59	0.41

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-2. 1,3-Butadiene Emission Data for 2005^a

Category name	Type	Annual emissions (tons)	Percentage
Industrial process, pulp and paper	Point	0.30	0.00
Industrial process, metals	Point	161.81	0.31

^aEmission estimates are subject to updates for subsequent revised versions of the 2005 National Emissions Inventory data. These numbers may be different than values published for previous versions of the 2005 data and may also be different than values for subsequent revisions of the data as generated by EPA.

ICEs = internal combustion engines; NEC = not elsewhere classified

Source: EPA 2008

6. POTENTIAL FOR HUMAN EXPOSURE

The burning of plastics or rubber has been shown to release small amounts of 1,3-butadiene (Miller 1978). In a test designed to simulate a real-life electrical overload condition, 1,3-butadiene was detected when polyurethane coated wire was heated to 250 °C for 40 minutes (Rigby 1981). 1,3-Butadiene has also been measured as a component of the smoke from brush fire (Stephens and Burleson 1969), and as a stack emission from waste incinerators (Junk and Ford 1980). The concentrations of 1,3-butadiene were not presented in these studies. The mean, minimum, and maximum concentrations of 1,3-butadiene measured in the air of nine municipal structural fires were 1.03, 0.03, and 4.84 ppm, respectively (Austin et al. 2001). The sources of 1,3-butadiene were considered to be both the combustion of wood and the thermal degradation of polymeric materials. Forest fires are considered to be a natural source of 1,3-butadiene in the atmosphere (Curren et al. 2006). Detection of 1,3-butadiene while heating rapeseed oil indicates that the heating of cooking oils may be a source of 1,3-butadiene in indoor air (Pellizzari et al. 1995).

1,3-Butadiene has been identified in air samples collected at 8 of the 13 NPL hazardous waste sites where it was detected in some environmental media (HazDat 2007).

6.2.2 Water

Estimated releases of 136 pounds (0.06 metric tons) of 1,3-butadiene to surface water from 197 domestic manufacturing and processing facilities in 2007, accounted for about 0.01% of the estimated total environmental releases from facilities required to report to the TRI (TRI07 2009). An additional 1,860 pounds (0.84 metric tons) were transferred off-site which includes releases to publicly owned treatment works (POTWs) (TRI07 2009). These releases are summarized in Table 6-1.

Additional information regarding the release of 1,3-butadiene to water was not located in the available literature. 1,3-Butadiene has been identified in groundwater samples collected at 1 of the 13 NPL hazardous waste sites where it was detected in some environmental media (HazDat 2007). It was not identified in surface water at any of the NPL sites.

6.2.3 Soil

Estimated releases of 4,470 pounds (2.03 metric tons) of 1,3-butadiene to soils from 197 domestic manufacturing and processing facilities in 2007, accounted for about 0.25% of the estimated total environmental releases from facilities required to report to the TRI (TRI07 2009). An additional

6. POTENTIAL FOR HUMAN EXPOSURE

925 pounds (0.42 metric tons), constituting about 0.05% of the total environmental emissions, were released via underground injection (TRI07 2009). These releases are summarized in Table 6-1.

Additional information regarding the release of 1,3-butadiene to soil was not located in the available literature. 1,3-Butadiene has been identified in soil samples collected at 2 of the 13 NPL hazardous waste sites where it was detected in some environmental media (HazDat 2007). It was not identified in sediment at any of the NPL sites.

6.3 ENVIRONMENTAL FATE

6.3.1 Transport and Partitioning

1,3-Butadiene's high volatility suggests that it will partition predominantly to the atmospheric compartment, where it is not expected to be adsorbed to particulate matter to any significant extent (Eisenreich et al. 1981).

Based on the calculated Henry's Law constant of 7.4×10^{-2} atm-m³/mol, the half-life for volatilization of 1,3-butadiene is 2.2 hours from a model river (1 m deep, flowing at 1 m/second, with a wind velocity of 3 m/second) and 2.9 days from a model lake (1 m deep, flowing at 0.05 m/second, with a wind velocity of 0.5 m/second) (Lyman et al. 1990). Based on an experimental log octanol/water partition coefficient of 1.99 (Hansch et al. 1995), a calculated soil adsorption coefficient of 288 (Lyman et al. 1990) suggests that adsorption to sediment and suspended organic matter will not be a significant fate process. From the log octanol/water partition coefficient, a calculated bioconcentration factor of 19 (Lyman et al. 1990) indicates that 1,3-butadiene will not bioconcentrate in fish and aquatic organisms to any significant extent. However, no experimental data have been located to verify these theoretical values.

If released to soil, 1,3-butadiene is expected to volatilize rapidly from either moist or dry soil to the atmosphere. This follows from the estimated lack of any appreciable adsorption to soil, and consideration of 1,3-butadiene's calculated Henry's law constant for moist soil or its vapor pressure, 2,100 mm Hg at 25 °C (AIChE 2000), for dry soil. Both values suggest a rapid rate of volatilization from their respective media.

The calculated soil adsorption coefficient of 288 (Hansch et al. 1995; Lyman et al. 1990) suggests that 1,3-butadiene may display moderate mobility in soil (Swann et al. 1983). However, the expected rapid rate of volatilization and the possibility of rapid degradation in soil suggest that there is little potential for

6. POTENTIAL FOR HUMAN EXPOSURE

1,3-butadiene to leach into groundwater. But until adequate groundwater monitoring for 1,3-butadiene has been performed, the partitioning of 1,3-butadiene in soil cannot be adequately addressed.

6.3.2 Transformation and Degradation

6.3.2.1 Air

Butadiene is a reactive, electron-rich chemical that is expected to undergo rapid reactions with the electrophilic oxidants typically present in the atmosphere: ozone, photochemically produced hydroxyl radicals, nitrate radicals, and molecular oxygen. Among these, the most rapid reaction in the atmosphere is with photochemically produced hydroxyl radicals.

The atmospheric degradation of 1,3-butadiene by photo-initiated processes has been established empirically by early studies. These studies typically involved irradiating urban air samples in atmospheric chambers of varying complexity and monitoring the disappearance of each constituent. Using this technique, 1,3-butadiene, at an average concentration of 12.4 ppb, disappeared in 6 hours when irradiated with natural sunlight during October (Kopczynski et al. 1972). In another study, a half-life of 2 hours was determined for the atmospheric removal of 1,3-butadiene using natural sunlight in October or November (Altshuller et al. 1970). In smog chamber studies, the sunlight oxidation of 1,3-butadiene led to the formation of fairly potent eye irritants, suggesting destruction of this compound with concomitant formation of oxygenated species (Dimitriades et al. 1975; Heuss and Glasson 1968). It is believed that the destruction of 1,3-butadiene occurs by photo-initiated bimolecular processes rather than direct photochemical degradation (Kopczynski et al. 1972). It is important to note that the rate of destruction of 1,3-butadiene when it was irradiated with natural light depended on the time of day in which the irradiation occurred. Furthermore, these studies were performed in October and November, when the amount and the intensity of available sunlight is diminished over that of summer months; thus, these values probably represent the high end of the compound's atmospheric lifetime. The individual processes responsible for the destruction of 1,3-butadiene in the atmosphere are discussed below.

Numerous studies have determined the rate constant for the gas-phase reaction of 1,3-butadiene with photochemically produced hydroxyl radicals (Atkinson 1985; Atkinson and Aschmann 1984; Atkinson et al. 1977, 1979; Maldotti et al. 1980). The experimental rate constant 6.85×10^{-11} cm³/molecule-second at 26 °C (Atkinson et al. 1977) is representative. Given an average hydroxyl radical concentration of 5×10^5 molecule/cm³ (Atkinson 1985), the half-life for this second-order process is 5.6 hours. Major products of this reaction include acrolein and formaldehyde (Baker et al. 2005).

6. POTENTIAL FOR HUMAN EXPOSURE

Gas-phase 1,3-butadiene also reacts with ozone in the atmosphere. Rate constants ranging from 6.7×10^{-18} to 8.4×10^{-18} $\text{cm}^3/\text{molecule-second}$ at 25°C have been published in the literature (Atkinson and Carter 1984; Jaspar et al. 1974). Using an average atmospheric ozone concentration of 7×10^{11} molecules/ cm^3 (Atkinson and Carter 1984), half-lives ranging from 1.4 to 1.7 days can be calculated for this second-order process. Therefore, the reaction of 1,3-butadiene with ozone is expected to contribute to the overall destruction of atmospheric 1,3-butadiene. The initial products from the reaction of 1,3-butadiene with ozone are acrolein, formaldehyde, acetylene, ethylene, and formic anhydride (Niki et al. 1983). All of these products are susceptible to secondary reactions with ozone and other atmospheric oxidants.

The night-time degradation of 1,3-butadiene is also expected to occur via the gas-phase reaction with nitrate radicals; this tends to be significant in urban areas, where the concentration of this oxidant is typically higher than in rural areas (Altshuller and Cohen 1964; Gay and Bulfalini 1971; Maldotti et al. 1980). A rate constant of 5.4×10^{-14} $\text{cm}^3/\text{molecule-second}$ at 22°C has been determined for this reaction. This corresponds to a half-life of 14.9 hours using an average atmospheric nitrate radical concentration of 2.4×10^8 molecule/ cm^3 (Atkinson et al. 1984), typical of mildly polluted urban centers. Acrolein has been identified as a primary product of this reaction.

In summary, there are three gas-phase pathways that degrade 1,3-butadiene in the troposphere. Depending on local conditions, any one or all of these reactions may occur. Destruction of atmospheric 1,3-butadiene by the gas-phase reaction with photochemically produced hydroxyl radicals is expected to be the dominant photo-initiated pathway. Degradation via nitrate radicals is expected to be a significant night-time process in urban areas.

6.3.2.2 Water

Data on the degradation of 1,3-butadiene in aquatic systems are limited. Experimental data are restricted to microbial degradation studies performed under aerobic conditions. The bulk of these data were obtained from isolated bacterial strains (pure cultures), not with mixed microbial populations typically found in natural systems, and are not considered to be representative of the biodegradation of 1,3-butadiene in the environment. However, results from these studies suggest that biodegradation of 1,3-butadiene proceeds through oxidation to form 3,4-epoxybutene (Hou et al. 1979, 1980, 1983; Patel et al. 1982a; Watkinson and Somerville 1976). Watkinson and Somerville (1976) reported further degradation.

6. POTENTIAL FOR HUMAN EXPOSURE

6.3.2.3 Sediment and Soil

As is the case for the degradation of 1,3-butadiene in water, very limited data on the destruction of this compound in soil could be located in the available literature. Results from pure culture studies suggest a similar aerobic biodegradation pathway for 1,3-butadiene in soil compared to the pathway in water (Hou et al. 1979; Patel et al. 1979, 1982a, 1982b; VanGinkel et al. 1987; Watkinson and Somerville 1976).

6.3.2.4 Other Media

Specific information regarding the transformation or degradation of 1,3-butadiene in other environmental media was not located.

6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT

Reliable evaluation of the potential for human exposure to 1,3-butadiene depends in part on the reliability of supporting analytical data from environmental samples and biological specimens. Concentrations of 1,3-butadiene in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits of current analytical methods. In reviewing data on 1,3-butadiene levels monitored or estimated in the environment, it should also be noted that the amount of chemical identified analytically is not necessarily equivalent to the amount that is bioavailable. The analytical methods available for monitoring 1,3-butadiene in a variety of environmental media are detailed in Chapter 7.

6.4.1 Air

1,3-Butadiene is widely detected at low ppb levels in urban air samples. Reported average concentrations range from 0.1 to 2 $\mu\text{g}/\text{m}^3$ (0.04–1 ppb) (Curren et al. 2006; Grant et al. 2007; Oguz et al. 2003; Reiss 2006; Reiss and Griffin 2004; Sax et al. 2004). A major source of 1,3-butadiene in urban air is automobile engine exhaust (Broderick and Marnane 2002; Sigsby et al. 1987; Stump and Dropkin 1985; Stump et al. 1989). Atmospheric emissions from industrial facilities that produce or use 1,3-butadiene are another major source of the compound in areas located near these facilities. Concentrations as high as 40 $\mu\text{g}/\text{m}^3$ (18 ppb) have been measured in the air near industrial sites (Grant et al. 2007). Curren et al. (2006) analyzed 3,267 air samples collected at eight rural locations in Canada and reported a mean 1,3-butadiene concentration of 0.02 $\mu\text{g}/\text{m}^3$ at these sites. EPA (2003a) estimated that the average background concentration of 1,3-butadiene in the air of the United States is 0.13 $\mu\text{g}/\text{m}^3$. McCarthy et al.

6. POTENTIAL FOR HUMAN EXPOSURE

(2006) provided a lower estimate ($<0.02 \mu\text{g}/\text{m}^3$) of 1,3-butadiene in the background air of North America. Table 6-3 lists reported concentrations of 1,3-butadiene measured in outdoor air.

1,3-Butadiene has also been detected in indoor air samples. Mean concentrations of 1,3-butadiene measured in indoor air of homes in New York were $1.0 \mu\text{g}/\text{m}^3$ during the winter and $1.2 \mu\text{g}/\text{m}^3$ during the summer (Sax et al. 2004). In Los Angeles, mean concentrations were $0.5 \mu\text{g}/\text{m}^3$ during the winter and $0.2 \mu\text{g}/\text{m}^3$ during the fall. The concentrations of 1,3-butadiene measured in a tavern were 11 and $19 \mu\text{g}/\text{m}^3$ (4.98 and 8.60 ppb) in two separate studies, while the outside air concentration was $\leq 1 \mu\text{g}/\text{m}^3$ (0.45 ppb) at the same time (Lofroth et al. 1989). The difference in the indoor versus outdoor concentration may be ascribed to the presence of 1,3-butadiene in cigarette smoke. The concentration of 1,3-butadiene in a smoke-filled bar was $2.7\text{--}4.5 \mu\text{g}/\text{m}^3$ (1.2–2.0 ppb) (Brunnemann et al. 1990). Higher 1,3-butadiene levels have been observed in air samples collected from the smoking areas of restaurants and pubs than in air samples collected from the nonsmoking areas of these buildings (Kim et al. 2001; Vainiotalo et al. 2008). Mean 1,3-butadiene concentrations measured in the indoor air of 32 smoking homes and 32 nonsmoking homes were 1.7 and $0.5 \mu\text{g}/\text{m}^3$, respectively (Kim et al. 2001). Mean 1,3-butadiene levels were $0.31\text{--}0.38 \mu\text{g}/\text{m}^3$ in the air of wood burning homes and $0.114 \mu\text{g}/\text{m}^3$ in non-wood burning homes in Hagfors, Sweden (Gustafson et al. 2007). Table 6-4 lists reported concentrations of 1,3-butadiene measured in indoor air.

6.4.2 Water

No current information on the occurrence of 1,3-butadiene in water was located in the available literature.

1,3-Butadiene was found in 1 of 204 water samples taken in 1975–1976 from surface waters near known industrialized areas across the United States. The single positive sample was obtained in the Carquinez Strait, Posta Corta, California, at an approximate concentration of 2 ppb (Ewing et al. 1977).

No specific data on its presence in drinking water, such as monitoring dates or concentration, were located; however, 1,3-butadiene has been qualitatively detected in U.S. drinking water in the past (EPA 1978; Kraybill 1980).

6.4.3 Sediment and Soil

No data on the occurrence of 1,3-butadiene in soil were located in the available literature.

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-3. 1,3-Butadiene Concentrations in Outdoor Air

Location	Concentration ($\mu\text{g}/\text{m}^3$)						Reference
	n	>LOD	LOD	Mean	Median	Maximum	
Urban							
New York City							Sax et al. 2004
Winter	31	14%	0.06	0.1	ND	0.7	
Summer	27	11%	0.06	0.1	ND	2.0	
Los Angeles							Sax et al. 2004
Winter	35	24%	0.06	0.2	ND	1.7	
Fall	32	3%	0.06	0.01	ND	0.3	
Houston							Reiss 2006
16 Locations	4,374	61%	0.02 ^a	1.3	—	7.2	
Texas							Grant et al. 2007
47 Urban/ industrial sites	—	<30–74%	0.61	0.5	—	40	
Baltimore							Sapkota and Buckley 2003
Toll booth	56	100%	0.46	—	2–13.5 ^b	19	
Baltimore							Kim et al. 2007
Parking garage	24 ^c	—	—	—	0.2–0.5 ^d	8	
Canada							Curren et al. 2006
30 Locations	5,160	—	0.001–0.02	0.22	0.17	2.58	
Rural							
Canada							Curren et al. 2006
8 Locations	3,267	—	0.001–0.02	0.02	—	—	
Background estimate							
United States	—	—	—	0.13	0.10	2.2	EPA 2003a
North America	—	—	—	<0.02	<0.02	<0.02	McCarthy et al. 2006

^aValue is referred to as the reporting limit.

^bLower and upper median values correspond to measurements taken during 12–3 a.m. and 6–9 a.m., respectively.

^cSeven-hour samples were collected on 18 week days and 6 weekend days.

^dLower and upper median values correspond to measurements taken on weekends and weekdays, respectively.

LOD = limit of detection; n = number of samples; ND = not detected

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-4. 1,3-Butadiene Concentrations in Indoor Air

Location	Concentration ($\mu\text{g}/\text{m}^3$)						Reference
	n	>LOD	LOD	Mean	Median	Maximum	
New York City							Sax et al. 2004
Winter	36	64%	0.06	1.0	0.7	5.8	
Summer	30	44%	0.06	1.2	ND	12	
Los Angeles							Sax et al. 2004
Winter	40	60%	0.06	0.5	0.5	1.8	
Fall	32	38%	0.06	0.2	ND	1.5	
Arizona NHEXAS							Gordon et al. 1999
Home indoor	24	4%	0.38	ND	ND	0.6	
Home outdoor	14	0%	0.38	ND	ND	ND	
Ottawa, Canada							Graham et al. 2004
House background	17	65%	0.1	0.51	0.36	1.63	
Cold-start house ^a	17	100%	0.1	5.76	2.69	28.6	
Cold-start garage ^a	17	100%	0.1	82.8	84.7	166	
Birmingham, United Kingdom							Kim et al. 2001
6 smoking homes	32	100%	0.11	1.7	0.7	10.8	
6 nonsmoking homes	32	<100%	0.11	0.5	0.4	1.1	
Restaurants	6	—	0.11	1.5	—	—	
Pubs	6	—	0.11	3.0	—	—	
Other indoor ^b	43	—	0.11	0.2–0.9	—	—	
Helsinki, Finland							Vainiotalo et al. 2008
10 Restaurants							
Smoking area	20	100%	0.02	4.3	—	10.1	
Non-smoking area	20	100%	0.02	1.1	—	3.9	
Hagfors, Sweden							Gustafson et al. 2007
Wood burning homes	14	NR	0.03–0.15	0.31–0.38	0.20–0.23	0.90–1.54 ^c	
Reference homes	10	NR	0.03–0.15	0.11	0.10–0.11	0.18–0.24 ^c	
Area outdoor	9	NR	0.03–0.15	0.12	0.11	—	

^aConcentrations measured in the house and garage after a cold vehicle engine was started in the attached garage.

^bIncludes offices, department stores, cinemas, perfume shop, libraries, and laboratories.

^c90th percentile values.

LOD = limit of detection; n = number of samples; ND = not detected; NHEXAS = National Human Exposure Assessment Survey; NR = not reported

6. POTENTIAL FOR HUMAN EXPOSURE

6.4.4 Other Environmental Media

1,3-Butadiene is used to manufacture synthetic rubber and plastics that are frequently used for food packaging. Because residual 1,3-butadiene may be present in the polymers used to make the containers, both the packaging and the food contained therein have been analyzed. In one study, 1,3-butadiene at a concentration of 8–9 ng/g (ppb) was detected in three of three brands of olive oil packaged in 1,3-butadiene rubber-modified acrylonitrile-acrylic bottles (McNeal and Breder 1987). Analysis of the bottles themselves found 1,3-butadiene residues as high as 6,600 ng/g (ppb). Soft-plastic packaging tubs used as containers for potato salad, cottage cheese, and yogurt had residual 1,3-butadiene levels in the range of 21–1,700 ng/g (ppb). However, no 1,3-butadiene was detected in any of the food packed in these containers (detection limit 1 ppb). Chewing gum made with a 1,3-butadiene rubber base did not show residual traces of this diene (McNeal and Breder 1987). Soft-plastic margarine tubs from five major name brands in the United Kingdom contained 1,3-butadiene residues ranging from 5 to 310 µg/kg (ppb), but none of the monomer was detected in the margarine samples themselves (detection limit 0.2 µg/kg) (Startin and Gilbert 1984). The authors concluded that migration of the 1,3-butadiene monomer from plastic packaging to food is unlikely to present a problem. Residual levels of 1,3-butadiene in food containers are closely regulated by the Food and Drug Administration.

Pellizzari et al. (1995) measured 0.1 mg of 1,3-butadiene in rapeseed oil emissions during 20 minutes of heating the oil in a wok at 260 °C. The presence of 1,3-butadiene was attributed to the pyrolytic decomposition of unsaturated fatty acids in the oil.

6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE

1,3-Butadiene is almost always present in the air at low levels due to its emission from motor vehicles. Therefore, the general population is probably routinely exposed to ppb levels of this compound. Exposure to 1,3-butadiene by the general population is expected to be dominated by inhalation (Higashino et al. 2007; Hughes et al. 2003). Reported mean concentrations of 1,3-butadiene measured in urban air generally range from 0.1 to 2 µg/m³ (0.4–1 ppb) (Curren et al. 2006; Grant et al. 2007; Oguz et al. 2003; Reiss 2006; Reiss and Griffin 2004; Sax et al. 2004). Sapkota et al. (2006) measured mean 1,3-butadiene personal air exposure levels of 1.22 µg/m³ for suburban-weekend exposure, 1.47 µg/m³ for urban-week day exposure, and 2.88 µg/m³ for tollbooth worker exposure in the Baltimore, Maryland area.

Inhalation of 1,3-butadiene by the general population may also occur due to other sources. 1,3-Butadiene has been identified in cigarette smoke; therefore, smokers and those nearby are exposed to this compound

6. POTENTIAL FOR HUMAN EXPOSURE

(Adam et al. 2006; Bartle et al. 1969; Blomberg and Widmark 1975; Brunnemann et al. 1990; Carmella et al. 2009; Counts et al. 2006; Lofroth et al. 1989; Pankow et al. 2004, 2007; Penn and Snyder 2007; Thweatt et al. 2007; Vainiotalo et al. 2008). Reported delivery levels of 1,3-butadiene in the mainstream smoke of cigarettes range from 1.3 to 100 $\mu\text{g}/\text{cigarette}$ (Pankow et al. 2004; Thweatt et al. 2007). Nazaroff and Singer (2004) calculated a 1,3-butadiene inhalation intake of 16–37 $\mu\text{g}/\text{day}$ for nonsmokers who live with a smoker. This value was based on an exposure relevant emission factor of 515 μg 1,3-butadiene/cigarette and a 1,3-butadiene exposure concentration of 1.4–3.1 $\mu\text{g}/\text{m}^3$ (Nazaroff and Singer 2004). Counts et al. (2006) measured 1,3-butadiene concentrations ranging from 11.2 to 59.3 $\mu\text{g}/\text{cigarette}$ in the mainstream smoke of 26 different commercial cigarettes sold in the United States.

1,3-Butadiene is present in the smoke from brush fires, wood fires, and municipal structural fires (Austin et al. 2001; Gustafson et al. 2007; Stephens and Burleson 1969), suggesting that inhalation of the smoke from wood fires will lead to low-level exposure to 1,3-butadiene. Gustafson et al. (2007) reported a mean 1,3-butadiene concentration of 0.33 $\mu\text{g}/\text{m}^3$ in the personal air of individuals living in wood-burning homes and 0.14 $\mu\text{g}/\text{m}^3$ in the personal air of a reference group. Its presence in waste incinerator emissions (Junk and Ford 1980) suggests that exposure to the general population may occur for those living nearby. Small amounts of 1,3-butadiene are produced by the thermal degradation of polyurethane-coated wire, an event that may occur during an electrical overload (Rigby 1981). The thermal degradation of other 1,3-butadiene-based plastics or rubbers may produce 1,3-butadiene (Miller 1978), also leading to low-level exposure of the general population by inhalation.

If the mean daily urban air concentration of 1,3-butadiene is 0.29 ppb, as determined in an analysis and compilation of experimental reports of ambient monitoring data obtained from 1970 to 1987 (Shah and Heyerdahl 1988), a nonoccupational daily intake of 12.8 μg per person can be obtained based on an average human intake of 20 m^3 air/day. Marshall et al. (2006) calculated a 1,3-butadiene intake rate of 7.3 $\mu\text{g}/\text{day}$ based on an exposure concentration of 0.55 $\mu\text{g}/\text{m}^3$ and a mean breathing rate of 13.1 m^3/day . Kim et al. (2002) measured mean personal air exposure concentrations of 1.1 $\mu\text{g}/\text{m}^3$ during the night time and 0.8 $\mu\text{g}/\text{m}^3$ during the day time for 12 residents of Birmingham, United Kingdom who were nonsmokers.

No data are available that quantify general population exposure to 1,3-butadiene by other routes of intake, such as ingestion of contaminated drinking water. Low-level exposure by ingestion of contaminated drinking water may occur as 1,3-butadiene has been qualitatively detected in U.S. drinking water supplies (EPA 1978; Kraybill 1980). Given that residues of 1,3-butadiene have been found in plastic and rubber

6. POTENTIAL FOR HUMAN EXPOSURE

food containers and in a few samples of the food contained in these containers (McNeal and Breder 1987), very low-level exposure to the general population may occur by ingestion of contaminated foods packaged in these containers (Hughes et al. 2003; Leber 2001). Leber (2001) estimated an upper-bound 1,3-butadiene intake of 44 ng/day from food contact sources which include styrene butadiene rubber-containing chewing gum, polymeric coatings, closures with sealing gaskets, and other indirect additives. According to the National Occupational Exposure Survey (NOES) conducted by NIOSH between 1980 and 1983, 9,456 workers, of which 286 are women, were estimated to be exposed to 1,3-butadiene (NIOSH 1989). The NOES database does not contain information on the frequency, concentration, or duration of exposure of workers to any chemicals listed therein. These surveys provide only an estimate of the number of workers potentially exposed to chemicals in the workplace. During a study involving 13,130 men who had been employed for at least 1 year at any of eight synthetic rubber plants in the United States or one in Canada between 1943 and 1992, it was estimated that 10,429 (79%) of these individuals had occupational exposure to 1,3-butadiene (Delzell et al. 2001; Macaluso et al. 2004). Occupational exposure to 1,3-butadiene is expected to be limited to inhalation of this compound, although dermal contact with liquified 1,3-butadiene may occur during a large spill, tank explosion, pipeline rupture, or similar catastrophic event. Specific industrial classifications or job descriptions involving exposure to 1,3-butadiene are provided below.

Levels of 1,3-butadiene measured in the air at styrene-butadiene rubber (SBR) plants have been reported (Anttinen-Klemetti et al. 2006; Jones and Harris 1983; Meinhardt et al. 1982; Sathiakumar et al. 2007; Ward et al. 2001). Table 6-5 lists 1,3-butadiene air concentrations associated with typical SBR operations. These concentrations were measured in air samples collected at different times between 1977 and 1991 at a synthetic rubber plant in Canada (Sathiakumar et al. 2007). These data show that individuals directly involved in the production of styrene-butadiene rubber have the greatest exposure to 1,3-butadiene at these facilities, although high concentrations were also associated with some equipment maintenance and control technician operations as well. Air concentrations associated with tank farm and transfer pumphouse operations (mean, 103 mg/m³) were at least an order of magnitude greater than those of any of the other operations. Maximum concentrations measured at this facility were as high as 1,490 mg/m³.

1,3-Butadiene has been measured in the air of petrochemical facilities (Begemann et al. 2001a; Fustinoni et al. 2004; Lovreglio et al. 2006; Tsai et al. 2001, 2005). Mean time-weighted average concentrations of 1,3-butadiene were 10.23 mg/m³ (4.55 ppm) between 1979 and 1996 and 0.56 mg/m³ (0.25 ppm) between 1997 and 2003 at the Deer Park and Norco Manufacturing complexes owned by Shell Oil Company (Tsai

6. POTENTIAL FOR HUMAN EXPOSURE

Table 6-5. Air Concentrations of 1,3-Butadiene Corresponding to Typical Operations Within a Styrene-Butadiene Rubber (SBR) Plant^a

Operation	n	Concentration (mg/m ³)			
		Mean	Median	Minimum	Maximum
SBR production					
Polymerization					
Tank farm, transfer pumphouse	231	103	33.1	0.13	1,490
Reactor, blowdown, panel board	261	9.9	2.2	0.04	146
Recovery, compressor house, high solids recovery	333	22.5	3.5	0.04	1,200
Unspecified operative	35	2.4	0.91	0.00	34.3
Coagulation, blending, solutions prep	314	2.1	0.44	0.04	42.0
Finishing					
Baler, packager, reclaim	111	0.64	0.33	0.07	4.2
Dryer, baler dryer	134	2.9	0.44	0.11	271
Unspecified operative	39	0.29	0.15	0.04	1.5
Maintenance, production, maintenance field					
Foreman, engineer	15	0.44	0.40	0.04	1.5
Instrument worker, meter person, electrician, maintenance inspector	56	4.9	0.42	0.04	108
Pipefitter, oiler, mechanic, blacksmith, boilermaker, outside machinist	250	9.7	1.8	0.04	234
Cleanup crew, laborer, work pool, utility person	74	3.1	1.1	0.11	40.0
Technical/lab					
Rubber control, technician	210	30.1	2.1	0.00	1,150
Butadiene control, hydrocarbon control, technician	41	4.9	0.15	0.00	67.4
Shipping/distribution					
Labor, utility person, service person	24	0.20	0.15	0.00	0.66
Utilities					
Copolymer effluent operative	103	1.3	0.88	0.00	17.5
Unspecified/miscellaneous operative	114	0.42	0.22	0.00	4.2

^aAir samples were collected at different times at a Canadian synthetic rubber plant between 1977 and 1991.

Source: Sathiakumar et al. 2007

6. POTENTIAL FOR HUMAN EXPOSURE

et al. 2005). Short-term exposures to this substance were as high as 987 mg/m³ (439 ppm) in 1979–1996 and 337 mg/m³ (150 ppm) in 1997–2003. The decline in 1,3-butadiene levels in air at these facilities in recent years is attributed to the implementation of new health standards in 1996 (Tsai et al. 2001, 2005). A walk-through survey of 11 monomers, 17 polymers, and 2 end-user plants found that personal exposures ranged from <0.006 ppm to 374 ppm (Fasen et al. 1990).

Two studies have reported levels of 1,3-butadiene measured in human blood, breath, and urine. Perbellini et al. (2003) measured average 1,3-butadiene concentrations of 1.0, 1.9, and 1.0 ng/L in the alveolar air, blood, and urine, respectively, of 46 forestry workers who were nonsmokers and 3.6, 11.4, and 3.9 ng/L in the alveolar air, blood, and urine, respectively, of 15 forestry workers who were smokers. The individuals had not been involved in forestry work for 2 months; therefore, occupational exposure was not considered to be a contributing factor. Fustinoni et al. (2004) measured end-shift 1,3-butadiene levels of 2.4, 3.8, and 4.3 ng/L in the exhaled air, urine, and blood, respectively, of 42 workers with a mean personal exposure of 11.5 µg/m³ and levels of 2.3, 3.1, and 5.9 ng/L in the exhaled air, urine, and blood, respectively, of 43 workers with a mean personal exposure of 0.9 µg/m³. Pre-shift levels in exhaled air and urine were 2.4 and 3.8 ng/L, respectively, for the higher exposed workers and below detection for the lower-exposed workers.

Other occupations where exposures to 1,3-butadiene may occur include petroleum refinery workers, professional bus, truck, and taxi drivers, parking garage attendants, tollbooth workers, and employees working in areas where smoking is permitted.

6.6 EXPOSURES OF CHILDREN

This section focuses on exposures from conception to maturity at 18 years in humans. Differences from adults in susceptibility to hazardous substances are discussed in Section 3.7, Children's Susceptibility.

Children are not small adults. A child's exposure may differ from an adult's exposure in many ways. Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a larger skin surface in proportion to their body volume. A child's diet often differs from that of adults. The developing human's source of nutrition changes with age: from placental nourishment to breast milk or formula to the diet of older children who eat more of certain types of foods than adults. A child's behavior and lifestyle also influence exposure. Children crawl on the floor, put things in their mouths,

6. POTENTIAL FOR HUMAN EXPOSURE

sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors. Children also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).

Children are expected to be exposed to 1,3-butadiene primarily through inhalation of low levels in air. Children who live near areas of heavy vehicle traffic or near industrial facilities where 1,3-butadiene is produced or used may be exposed to higher levels of 1,3-butadiene. The available data indicate that exposure to 1,3-butadiene through ingestion of food and drinking water is expected to be low relative to inhalation exposure. Biomonitoring data for children, including levels of 1,3-butadiene and its metabolites measured in breast milk, neonatal blood, cord blood, and meconium fluid have not been located in the available literature.

6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES

High levels of exposure to 1,3-butadiene are likely to be limited to those resulting from an occupationally related use of this compound. Inhalation is the most likely route of high exposure to 1,3-butadiene. 1,3-Butadiene is stored and transported in pressurized tanks, and it is possible that high levels of exposure by inhalation or dermal contact with the liquified gas may occur during the loading and unloading of these tanks, or by the accidental rupture of these tanks. Occupations where potentially high exposures to 1,3-butadiene may occur include those in styrene-butadiene rubber facilities, those in petroleum refineries, professional bus, truck, and taxi drivers, parking garage attendants, tollbooth workers, and employees working in areas where smoking is permitted. Individuals who live near facilities where 1,3-butadiene is produced or used have the potential for high exposure to this substance. Individuals who are frequently exposed to smoke from combustion sources, such as firefighters, may have high exposures to 1,3-butadiene (Austin et al. 2001). Individuals living very close to high traffic roads may be exposed to higher levels of butadiene.

6.8 ADEQUACY OF THE DATABASE

Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate information on the health effects of 1,3-butadiene is available. Where adequate information is not available, ATSDR, in conjunction with NTP is required to assure the initiation of a program of research designed to determine the health effects (and techniques for developing methods to determine such health effects) of 1,3-butadiene.

6. POTENTIAL FOR HUMAN EXPOSURE

The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, NTP and EPA. They are defined as substance-specific informational needs that if met would reduce the uncertainties of human health assessment. This definition should not be interpreted to mean that all data needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed.

6.8.1 Identification of Data Needs

Physical and Chemical Properties. The physical and chemical properties of 1,3-butadiene are well documented (Amoore and Hautala 1983; Hansch et al. 1995; HSDB 2009; Lewis 2007; Lide 2008; McAuliffe 1966; O'Neil et al. 2006; NIOSH 2005), and its environmental fate can be estimated from these properties (Lyman et al. 1982). No data needs are identified.

Production, Import/Export, Use, Release, and Disposal. According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required to submit substance release and off-site transfer information to the EPA. The TRI, which contains this information for 2007, became available in February of 2009. This database is updated yearly and should provide a list of industrial production facilities and emissions.

The trends in the production and use of 1,3-butadiene are well documented (Chemical Market Reporter 2006; Chemical Week 2008; Grub and Loser 2005; ICIS 2009a, 2009b; Kirshenbaum 1978; SRI 2008; Sun and Wristers 2002), and there do not appear to be any critical information gaps. 1,3-Butadiene monomer does not occur in most products used in the home, although residues of this compound in commercial packages, especially food containers (McNeal and Breder 1987), are not well described. It is clear that the majority of 1,3-butadiene is released to the atmosphere (TRI07 2009). The disposal of 1,3-butadiene appears to be a straightforward process (HSDB 2009 No data needs are identified.)

Environmental Fate. The fate of 1,3-butadiene in the atmosphere is well understood (Atkinson 1985; Atkinson and Carter 1984; Atkinson et al. 1984; Kopczynski et al. 1972). The fate of 1,3-butadiene in soil and water is not well understood, and partitioning from these media has to be determined from the physical and chemical properties of this compound (Lyman et al. 1982). A reliable method capable of detecting 1,3-butadiene in soil and water was not located in the available literature, and it is not clear whether 1,3-butadiene is absent from these media or simply not yet detected. The persistence of 1,3-butadiene in soil and water is not known, and the degree of partitioning from one environmental compartment

6. POTENTIAL FOR HUMAN EXPOSURE

to another can only be estimated. Exposure via ingestion or dermal contact to populations surrounding hazardous waste sites cannot, therefore, be accurately determined. Experimental data that address the partitioning of 1,3-butadiene in the environment, its potential to enter drinking water supplies, and its lifetime in soil and water are necessary to completely characterize the environmental fate of this compound.

Bioavailability from Environmental Media. Numerous toxicokinetic and toxicity studies in humans and animals have demonstrated the bioavailability of 1,3-butadiene from air. No data on the bioavailability of 1,3-butadiene from other sources (water or soil, for example) were located in the available literature. In conjunction with the data needs for determining 1,3-butadiene in environmental media, bioavailability studies from environmental media would be useful.

Food Chain Bioaccumulation. In theory, 1,3-butadiene is not believed to bioconcentrate significantly in fish and aquatic organisms; thus, it is not expected to biomagnify in the food chain (Hansch and Leo 1995; Lyman et al. 1982). No data addressing this point, however, were located in the available literature. Validation of these theories by valid experimental studies will aid in establishing a quantitative determination of 1,3-butadiene exposure to the general public.

Exposure Levels in Environmental Media. Reliable monitoring data for the levels of 1,3-butadiene in contaminated media at hazardous waste sites are needed so that the information obtained on levels of 1,3-butadiene in the environment can be used in combination with the known body burden of 1,3-butadiene to assess the potential risk of adverse health effects in populations living in the vicinity of hazardous waste sites.

Data on the levels of 1,3-butadiene in environmental media are limited. Extensive data on the occurrence of 1,3-butadiene in ambient air samples are available (Curren et al. 2006; Grant et al. 2007; Oguz et al. 2003; Reiss 2006; Reiss and Griffin 2004; Sax et al. 2004), but more data would be helpful. Data on the occurrence of 1,3-butadiene in water samples are very limited (Ewing et al. 1979). The presence of 1,3-butadiene in drinking water has been noted in the literature, but no concentrations or frequency of detection are available (EPA 1978; Kraybill 1980). The development of reliable analytical techniques for the analysis of 1,3-butadiene in soil and water will establish unambiguously the levels at which this compound is found in environmental media.

6. POTENTIAL FOR HUMAN EXPOSURE

Exposure Levels in Humans. Limited data on levels of occupational exposure to 1,3-butadiene were available in the literature; however, occupational exposure to this compound appears to be limited to a readily definable group of industrial classifications (NIOSH 1989; Sathiakumar et al. 2007). Exposure levels for the general population are not well defined. Studies that correlate personal exposure with daily activities are necessary to adequately establish exposure levels for 1,3-butadiene. Biological monitoring studies cannot be performed until acceptable experimental techniques are developed. Exposure levels for those living near hazardous waste sites are not available and should be established.

This information is necessary for assessing the need to conduct health studies on these populations.

Exposures of Children. No information regarding exposures of children to 1,3-butadiene are currently available. Biomonitoring data for children, including levels of 1,3-butadiene and its metabolites measured in breast milk, neonatal blood, cord blood, and meconium fluid have not been located in the available literature. Studies are needed to help determine if there are differences between childhood and adult exposure to 1,3-butadiene.

Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data Needs: Children's Susceptibility.

Exposure Registries.

No exposure registries for 1,3-butadiene were located. This substance is not currently one of the compounds for which a sub-registry has been established in the National Exposure Registry. The substance will be considered in the future when chemical selection is made for sub-registries to be established. The information that is amassed in the National Exposure Registry facilitates the epidemiological research needed to assess adverse health outcomes that may be related to exposure to this substance.

6.8.2 Ongoing Studies

Ongoing studies related to the potential for human exposure to 1,3-butadiene were not located.

6. POTENTIAL FOR HUMAN EXPOSURE

This page is intentionally blank.

7. ANALYTICAL METHODS

The purpose of this chapter is to describe the analytical methods that are available for detecting, measuring, and/or monitoring 1,3-butadiene, its metabolites, and other biomarkers of exposure and effect to 1,3-butadiene. The intent is not to provide an exhaustive list of analytical methods. Rather, the intention is to identify well-established methods that are used as the standard methods of analysis. Many of the analytical methods used for environmental samples are the methods approved by federal agencies and organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH). Other methods presented in this chapter are those that are approved by groups such as the Association of Official Analytical Chemists (AOAC) and the American Public Health Association (APHA). Additionally, analytical methods are included that modify previously used methods to obtain lower detection limits and/or to improve accuracy and precision.

7.1 BIOLOGICAL MATERIALS

No standardized method to test for the presence of 1,3-butadiene in biological materials presently exists. Only a limited number of techniques have been employed to determine this compound in biological materials.

Perbellini et al. (2003) have developed a method to measure unmetabolized 1,3-butadiene concentrations in human blood, urine, and exhaled air. Breath samples were collected by expiration into headspace vials. Urine and venous blood samples were injected into a glass tube with EDTA added to the blood samples as an anticoagulant. Samples were analyzed using gas chromatography-mass spectrometry (GC-MS). Reported detection limits for 1,3-butadiene were 0.5 ng/L in blood, 1 ng/L in urine, and 0.8 ng/L in alveolar air.

A technique for the determination of 1,3-butadiene in margarine samples was reported by Startin and Gilbert (1984). The margarine sample is placed in a vial, sealed, and heated to 70 °C where it is allowed to equilibrate for 1 hour. The amount of 1,3-butadiene in the sample is determined by withdrawing a headspace sample, and injecting it directly into a GC equipped with a MS detection system. Quantitation is obtained by comparison of the peak height to that of a standard of known concentration. The sensitivity of this method allows quantitation down to 0.001 mg/kg (1 ppb). A similar headspace technique was used to test for the presence of butadiene in olive oil, vegetable oil, and yogurt samples (McNeal and Breder 1987).

7. ANALYTICAL METHODS

7.2 ENVIRONMENTAL SAMPLES

Standardized methods for determining 1,3-butadiene in environmental samples are limited to air samples, as no methodology has been described for analyzing this compound in water or soil samples (EPA 1982, 1986). A representative list of the methods available for the determination of 1,3-butadiene in air samples can be found in Table 7-1. The determination of 1,3-butadiene in personal air can be obtained using the procedures outlined in NIOSH Method 1024 (NIOSH 1994) and OSHA Method 56 (OSHA 2009a) or EPA Methods TO-14A and TO-15 (EPA 1999a, 1999b).

For NIOSH Method 1024, the air sample is obtained by passing a known volume of air (5–25 L) through a set of tandem coconut charcoal tubes, which adsorb 1,3-butadiene and remove it from the air stream (NIOSH 1994). The collected 1,3-butadiene is then removed from the adsorption tube by extraction with methylene chloride. Injection of the methylene chloride solution into a GC equipped with a flame ionization detector (FID) separates 1,3-butadiene from any interfering compounds that may be present. The choice of chromatography column for this determination is not crucial, as long as it cleanly separates 1,3-butadiene from other compounds.

The estimated quantitation limit (LOQ) of this method is 0.02 ppm, with an applicable range of 0.04–220 µg per sample (approximately 0.04–100 ppm) for a 25 L sample. The precision of this method appears to change as a function of the concentration being measured, due to desorption efficiencies changing as a function of sample concentration. With increasing concentration, the preparation of a standard becomes more difficult. A limitation of this study is the relatively high LOQ (20 ppb), since concentrations observed in environmental settings are often <1 ppb,

In NIOSH Method 1024, quantitation of 1,3-butadiene is accomplished by comparing the area under the sample's response signal to that of a known amount of 1,3-butadiene. The preparation and injection of a gaseous 1,3-butadiene standard is a difficult procedure; it must be performed carefully or erroneous results will occur. Sample storage appears to dramatically affect the results of the measurement. Samples stored at -4 °C displayed an average recovery of 93–98% over a 21-day period, while samples stored at room temperature ranged from 61 to 95%.

OSHA Method 56 for analyzing 1,3-butadiene in air samples is similar to the NIOSH method described above. Air is drawn through sampling tubes containing charcoal absorbent coated with 4-*tert*-butylcatechol. The samples are then desorbed with carbon disulfide and analyzed using gas chromatograph-

7. ANALYTICAL METHODS

Table 7-1. Analytical Methods For Determining 1,3-Butadiene in Environmental Samples

Sample air	Preparation method	Analytical method	Sample detection limit	Percent recovery	Reference
Personal air (Method 1024)	Pass air through charcoal tube followed by desorption with methylene chloride	GC/FID	0.04–220 µg/sample (25L sample)	61–98	NIOSH 1994
Personal air (Method 56)	Pass air through charcoal tube coated with 4- <i>tert</i> -butylcatechol followed by desorption with carbon disulfide	GC/FID	200 µg/m ³ (90 ppb)	77–94	OSHA 2009a
Air (Method TO-14A)	Pressurized container sampling followed by cryogenic concentration	GC/MS/SIM or SCAN	No data	No data	EPA 1999a
Air (Method TO-15)	Pressurized container sampling followed by multisorbent concentration and thermal desorption	GC/MS/SIM or SCAN	No data	No data	EPA 1999b
Air	Collect air in Tedlar bag concentrate on Tenax cartridge, thermal desorption	GC/FID	No data	No data	Stump and Dropkin 1985
Air	Pass air through charcoal tube solvent desorption	GC/MS	No data	No data	Texas Air Control Board 1990
Air (real time)	Draw air into 12-foot sampling loop, direct injection	GS/MS	No data	No data	Texas Air Control Board 1990
Air	Pass air through sorbent tubes containing Carbopack B/Carbosieve SIII followed by thermal desorption	GC/MS	0.11–0.16 µg/m ³	>95%	Kim et al. 1999

FID = flame ionization detector; GC = gas chromatography; MS = mass spectrometry; SCAN = wide range of mass to charge ratio scanning; SIM = select ion monitoring

7. ANALYTICAL METHODS

flame ionization detector (GC-FID). The recommended air volume and sampling rate is 3 L at 0.05 L/minute. The detection limit is 200 $\mu\text{g}/\text{m}^3$ and the quantitation limit is 343 $\mu\text{g}/\text{m}^3$. As with NIOSH Method 1024, the usefulness of OSHA Method 56 for analysis of 1,3-butadiene in environmental media is limited since the reported detection and quantitation limits are much higher than levels often observed in environmental settings.

1,3-Butadiene, along with other volatile hydrocarbons, has been found in ambient air samples by a technique that uses cryogenic concentration before GC analysis. This technique is performed by collecting a large volume of air in a specially designed bag or other sampling container and concentrating the volatile components by condensation at low temperatures. The sample is separated into its components by GC and quantified with an internal standard. Numerous variations of this method were found in the literature (Curren 2006; Graham et al. 2004; Lonneman et al. 1979; Neligan 1962; Stephens and Burleson 1967, 1969; Stump and Dropkin 1985).

EPA Methods TO-14A and TO-15 describe procedures for the analysis of volatile organic compounds (VOCs) in air (EPA 1999a, 1999b). Method TO-14A calls for cryogenic concentration of the air sample as described above. Method TO-15 calls for pressurized air sampling using a stainless steel canister. The sample is then passed through a solid multisorbent concentrator and the concentrator is finally dry-purged with helium. The sample is thermally desorbed prior to analysis. For both of these methods, analysis is performed using GC followed by either a specific or nonspecific detector. However, the use of a specific detector is recommended, such as linear quadrupole mass spectrometer operating in either select ion monitoring (SIM) mode or a mode that scans a wide range of mass to charge ratios (SCAN). Precision and recovery data for 1,3-butadiene are not specified in these methods. Kim et al. (1999) developed an improved method by using a combination Carbopack B/CarbosieveSIII sorbent as a collection material. Sample collection was followed by thermal desorption and GC/MS analysis. These authors reported a precision of 2.4–13%, recoveries of >95%, and a detection limit of 0.11–0.16 $\mu\text{g}/\text{m}^3$ for this method. Therefore, this method is useful for measuring 1,3-butadiene concentrations in the low ppb ($\mu\text{g}/\text{m}^3$) range in environmental air samples.

7.3 ADEQUACY OF THE DATABASE

Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether adequate information on the health effects of 1,3-butadiene is available. Where adequate information is

7. ANALYTICAL METHODS

not available, ATSDR, in conjunction with NTP is required to assure the initiation of a program of research designed to determine the health effects (and techniques for developing methods to determine such health effects) of 1,3-butadiene.

The following categories of possible data needs have been identified by a joint team of scientists from ATSDR, NTP and EPA. They are defined as substance-specific informational needs that if met would reduce the uncertainties of human health assessment. This definition should not be interpreted to mean that all data needs discussed in this section must be filled. In the future, the identified data needs will be evaluated and prioritized, and a substance-specific research agenda will be proposed.

7.3.1 Identification of Data Needs

Methods for Determining Biomarkers of Exposure and Effect. No standardized method for the determination of biomarkers of exposure and effect for 1,3-butadiene was located.

Exposure. Biomarkers that have been proposed as indicators of exposure to 1,3-butadiene include the urinary metabolites 1,2-dihydroxybutyl mercapturic acid (DHBMA or M1) and 1- and 2-monohydroxy-3-butenyl mercapturic acid (MHBMA or M2) and the hemoglobin adducts 1- and 2-hydroxy-3-butenyl valine (MHBVal) and N-(2,3,4-trihydroxy-butyl)valine (THBVal) (Albertini et al. 2001; Boogaard et al. 2001a; Carrieri et al. 2009; McDonald et al. 2004; Sapkota et al. 2006; Schettgen et al. 2009; Shen et al. 2009). Measurement of unmetabolized 1,3-butadiene in human blood and urine may be preferable for assessing very low levels of exposure to this substance (0.4 µg/m³ median concentration in personal air) (Fustinoni et al. 2004; Perbellini et al. 2003; Schettgen et al. 2009).

Both the urinary metabolites and the hemoglobin adducts have been well correlated with exposure to 1,3-butadiene (Albertini et al. 2001; Preston 2007). Methods developed to measure these biomarkers have utilized either high-performance liquid chromatography or GC followed by tandem MS (Boogaard et al. 2001a; Carrieri et al. 2009; Sapkota et al. 2006; Schettgen et al. 2009). Shen et al. (2009) has developed a method based on liquid chromatography/electrospray ionization-mass spectrometry to measure 3-butene-1,2-diol, a 1,3-butadiene urinary metabolite intermediate.

Effect. Biomarkers of effect resulting from 1,3-butadiene exposure, such as gene mutation and chromosomal changes, have been explored; however, no clear associations have been observed (Albertini et al. 2001; Preston 2007).

7. ANALYTICAL METHODS

Methods for Determining Parent Compounds and Degradation Products in Environmental

Media. Data on the determination of 1,3-butadiene in environmental media were limited. 1,3-Butadiene in air samples has been detected by techniques routinely used for detecting volatile hydrocarbons (Kim et al. 1999; Stump and Dropkin 1985; Texas Air Control Board 1990; EPA 1999a, 1999b).

Improvements to these methods have made possible the detection of 1,3 butadiene concentrations in the low ppb ($\mu\text{g}/\text{m}^3$) range in environmental air samples (Kim et al. 1999). Procedures accepted for the determination of volatile hydrocarbons in other environmental media (soil, water, sediment, plants, etc.) may also be suitable for 1,3-butadiene. This question can be answered only by the data obtained from properly designed experiments. The information will assist in determining the prevalence of this compound in the environment and aid in a quantitative determination of human exposure to 1,3-butadiene.

7.3.2 Ongoing Studies

Ongoing studies related to the development of analytical methods for 1,3-butadiene were not located.

8. REGULATIONS, ADVISORIES, AND GUIDELINES

MRLs are substance specific estimates, which are intended to serve as screening levels, are used by ATSDR health assessors and other responders to identify contaminants and potential health effects that may be of concern at hazardous waste sites.

ATSDR has derived an acute-duration inhalation MRL of 0.1 ppm, based on a LOAEL of 40 ppm for reduced male fetal weight from exposed pregnant mice. The LOAEL of 40 ppm was adjusted for intermittent exposure (6 hours/day) resulting in a duration-adjusted LOAEL of 10 ppm. A LOAEL_{HEC} (human equivalent concentration) of 10 ppm was derived (see Appendix A), which was divided by an uncertainty factor of 90 (3 for use of a minimally adverse effect, 3 for extrapolation from animals to humans, and 10 for human variability)

EPA (IRIS 2009) has established an inhalation reference concentration (RfC) for 1,3-butadiene of 0.9 ppb based on a BMCL₁₀ of 0.88 ppm for ovarian atrophy in female B6C3F1 mice exposed to 1,3-butadiene by inhalation for 6 hours/day, 5 days/week for up to 103 weeks.

EPA has not established an oral reference dose (RfD) for 1,3-butadiene (IRIS 2009).

OSHA has required employers of workers who are occupationally exposed to 1,3-butadiene to institute engineering controls and work practices to reduce and maintain employee exposure at or below permissible exposure limits (PELs) (OSHA 2009b). The employer must use engineering and work practice controls to reduce exposures to not exceed 1 ppm for 1,3-butadiene at any time (OSHA 2009b).

EPA has designated 1,3-butadiene as a hazardous air pollutant (HAP) under the Clean Air Act (CAA) (EPA 2009b). 1,3-Butadiene is on the list of chemicals appearing in "Toxic Chemicals Subject to Section 313 of the Emergency Planning and Community Right-to-Know Act of 1986" and has been assigned a reportable quantity (RQ) limit of 100 pounds (EPA 2009d). The RQ represents the amount of a designated hazardous substance which, when released to the environment, must be reported to the appropriate authority.

The international and national regulations, advisories, and guidelines regarding 1,3-butadiene in air, water, and other media are summarized in Table 8-1.

8. REGULATIONS AND ADVISORIES

Table 8-1. Regulations, Advisories, and Guidelines Applicable to 1,3-Butadiene

Agency	Description	Information	Reference
<u>INTERNATIONAL</u>			
Guidelines:			
IARC	Carcinogenicity classification	Group 1 ^a	IARC 2009
WHO	Air quality guidelines	No guideline value is recommended at this time	WHO 2000
	Drinking water quality guidelines	No	WHO 2006
<u>NATIONAL</u>			
Regulations and Guidelines:			
a. Air			
ACGIH	TLV (8-hour TWA)	2 ppm	ACGIH 2008
AIHA	ERPG-1 ^b	10 ppm	AIHA 2008
	ERPG-2 ^b	200 ppm	
	ERPG-3 ^b	5,000 ppm	
EPA	RfC	0.9 ppb	IRIS 2009
	Inhalation unit risk	3×10^{-5} per $\mu\text{g}/\text{m}^3$	
EPA	AEGL-1 ^c		EPA 2009a
	10 minutes	670 ppm	
	30 minutes	670 ppm	
	60 minutes	670 ppm	
	4 hours	670 ppm	
	8 hours	670 ppm	
	AEGL-2 ^c		
	10 minutes	6,700 ppm	
	30 minutes	6,700 ppm	
	60 minutes	5,300 ppm	
	4 hours	3,400 ppm	
	8 hours	2,700 ppm	
	AEGL-3 ^c		
	10 minutes	27,000 ppm	
	30 minutes	27,000 ppm	
	60 minutes	22,000 ppm	
	4 hours	14,000 ppm	
	8 hours	6,800 ppm	
	Level of distinct odor awareness	3.7 ppm	
	Hazardous air pollutant	Yes	EPA 2009b 42 USC 7412

8. REGULATIONS AND ADVISORIES

Table 8-1. Regulations, Advisories, and Guidelines Applicable to 1,3-Butadiene

Agency	Description	Information	Reference
<u>NATIONAL</u> (cont.)			
	Regulated flammable substances and threshold quantities for accidental release prevention ^d	10,000 pounds	EPA 2009c 40 CFR 68.130
NIOSH	REL (10-hour TWA)	Potential occupational carcinogens	NIOSH 2005
	IDLH (10% LEL) Target organs	2,000 ppm Eyes, respiratory system, central nervous system, and reproductive system	
OSHA	PEL (8-hour TWA) for general industry STEL (15-minutes)	1 ppm 5 ppm	OSHA 2009b 29 CFR 1910.1051
b. Water			
EPA	Drinking water standards and health advisories	No	EPA 2006a
	National primary drinking water standards	No	EPA 2003b
	National recommended water quality criteria	No	EPA 2006b
c. Food			
FDA	EAFUS ^e	No	FDA 2008
d. Other			
ACGIH	Carcinogenicity classification	A2 ^f	ACGIH 2008

8. REGULATIONS AND ADVISORIES

Table 8-1. Regulations, Advisories, and Guidelines Applicable to 1,3-Butadiene

Agency	Description	Information	Reference
EPA	Carcinogenicity classification	Carcinogenic to humans	IRIS 2009
	RfD	No data	
	Superfund, emergency planning, and community right-to-know		
	Designated CERCLA hazardous substance	Yes ^g	EPA 2009d 40 CFR 302.4
	Reportable quantity	100 pounds	
EPA	Effective date of toxic chemical release reporting	01/01/1987	EPA 2009e 40 CFR 372.65
NTP	Carcinogenicity classification	Known to be a human carcinogen	NTP 2005

^aGroup 1: carcinogenic to humans

^bERPG-1 is the maximum airborne concentration below which nearly all individuals could be exposed for up to 1 hour without experiencing other than mild, transient health effects; ERPG-2 is the maximum airborne concentration below which nearly all individuals could be exposed for up to 1 hour without experiencing irreversible or other serious adverse effects; and ERPG-3 is the maximum airborne concentration below which nearly all individuals could be exposed for up to 1 hour without life-threatening health effects (AIHA 2008).

^cAEGL-1 is the airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic nonsensory effects, however, the effects are not disabling and are transient and reversible upon cessation of exposure; AEGL-2 is the airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects or an impaired ability to escape; and AEGL-3 is the airborne concentration of a substance above which it is predicted that the general population, including susceptible individuals, could experience life-threatening health effects or death (EPA 2009a).

^dBasis for listing: flammable gas

^eThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food additives or listed or affirmed as GRAS.

^fA2: suspected human carcinogen

^gDesignated CERCLA hazardous substance pursuant to Section 112 of the Clean Air Act

ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels; AIHA = American Industrial Hygiene Association; CERCLA = Comprehensive Environmental Response, Compensation, and Liability Act; CFR = Code of Federal Regulations; EAFUS = Everything Added to Food in the United States; EPA = Environmental Protection Agency; ERPG = emergency response planning guidelines; FDA = Food and Drug Administration; GRAS = Generally Recognized As Safe; IARC = International Agency for Research on Cancer; IDLH = immediately dangerous to life or health; IRIS = Integrated Risk Information System; LEL = lower explosive limit; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health Administration; PEL = permissible exposure limit; REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; STEL = short-term exposure limit; TLV = threshold limit values; TWA = time-weighted average; USC = United States Code; WHO = World Health Organization

9. REFERENCES

*Abdel-Rahman SZ, Ammenheuser MM, Omiecinski CJ, et al. 2005. Variability in human sensitivity to 1,3-butadiene: Influence of polymorphisms in the 5'-flanking region of the microsomal epoxide hydrolase gene (EPHX1). *Toxicol Sci* 85(1):624-631.

*Abdel-Rahman SZ, Ammenheuser MM, Ward JB. 2001. Human sensitivity to 1,3-butadiene: Role of microsomal epoxide hydrolase polymorphisms. *Carcinogenesis* 22(3):415-423.

Abdel-Rahman SZ, El-Zein RA, Ammenheuser MM, et al. 2002. Combined effect of Tyr113His and His139Arg polymorphisms in the mEH gene on human sensitivity to the mutagenic effects of 1,3-butadiene. *Environ Mol Mutagen* 39(Suppl 33):13.

*Abdel-Rahman SZ, El-Zein RA, Ammenheuser MM, et al. 2003. Variability in human sensitivity to 1,3-butadiene: Influence of the allelic variants of the microsomal epoxide hydrolase gene. *Environ Mol Mutagen* 41(2):140-146.

Abrantes S, Dos Santos TC, Simoes G. 2000. Headspace gas chromatographic determination of 1,3-butadiene in simulated saliva. *J AOAC Int* 83(4):929-932.

*ACGIH. 2008. 1,3-Butadiene. In: *Threshold limit values for chemical substances and physical agents and biological exposure indices*. Cincinnati, OH: American Conference of Governmental Industrial Hygienists.

Acquavella JF. 1990. Future directions in epidemiologic studies of 1,3-butadiene-exposed workers. *Environ Health Perspect* 86:129-134.

Acquavella JF. 1996. Butadiene epidemiology: A summary of results and outstanding issues. *Toxicology* 113(1-3):148-156.

*Adam T, Mitsche S, Streibel T, et al. 2006. Puff-by-puff resolved characterisation of cigarette mainstream smoke by single photon ionisation (SPI)-time-of-flight mass spectrometry (TOFMS): Comparison of the 2R4F research cigarette and pure Burley, Virginia, Oriental and Maryland tobacco cigarettes. *Anal Chim Acta* 572(2):219-229.

*Adinolfi M. 1985. The development of the human blood-CSF-brain barrier. *Dev Med Child Neurol* 27(4):532-537.

Adler ID. 2000. Spermatogenesis and mutagenicity of environmental hazards: Extrapolation of genetic risk from mouse to man. *Andrologia* 32(4-5):233-237.

Adler ID, Anderson D. 1994. Dominant lethal effects after inhalation exposure to 1,3-butadiene. *Mutat Res* 309(2):295-297.

* Cited in text

+ Cited in Supplemental Document

9. REFERENCES

Adler ID, Cao J, Filser JG, et al. 1994. Mutagenicity of 1,3-butadiene inhalation in somatic and germinal cells of mice. *Mutat Res* 309(2):307-314.

*Adler ID, Filser J, Gonda H, et al. 1998. Dose response study for 1,3-butadiene-induced dominant lethal mutations and heritable translocations in germs cells of male mice. *Mutat Res* 397(1):85-92.

*Adler ID, Filser JG, Gassner P, et al. 1995a. Heritable translocations induced by inhalation exposure of male mice to 1,3-butadiene. *Mutat Res* 347(3-4):121-127.

Adler ID, Kliesch U, Nylund L, et al. 1997. In vitro and in vivo mutagenicity of the butadiene metabolites butadiene diolepoxide, butadiene monoepoxide and diepoxybutane. *Mutagenesis* 12(5):339-345.

Adler ID, Kliesch U, Tiveron C, et al. 1995b. Clastogenicity of diepoxybutane in bone marrow cells and male germ cells of mice. *Mutagenesis* 10(6):535-541.

*Adlercreutz H. 1995. Phytoestrogens: Epidemiology and a possible role in cancer protection. *Environ Health Perspect Suppl* 103(7):103-112.

*Agency for Toxic Substances and Disease Registry. 1989. Decision guide for identifying substance-specific data needs related to toxicological profiles; Notice. Agency for Toxic Substances and Disease Registry, Division of Toxicology, Atlanta, GA. *Fed Regist* 54(174):37618-37634

Agency for Toxic Substances and Disease Registry. 1990. Biomarkers of organ damage or dysfunction for the renal, hepatobiliary, and immune systems. Subcommittee on Biomarkers of Organ Damage and Dysfunction. Atlanta, GA: Agency for Toxic Substances and Disease Registry.

*AIChE. 2000. 1,3-Butadiene. C₄H₆. In: Physical and thermodynamic properties of pure chemicals. American Institute of Chemical Engineers, Design Institute for Physical Property Data. Philadelphia, PA: Taylor and Francis.

*AIHA. 2008. Emergency Response Planning Guidelines (ERPG). Fairfax, VA: American Industrial Hygiene Association. <http://www.aiha.org/1documents/Committees/ERP-erpglevels.pdf>. May 19, 2009.

*Albertini RJ, Sram RJ, Vacek PM, et al. 2001. Biomarkers for assessing occupational exposures to 1,3-butadiene. *Chem Biol Interact* 135-136:429-453.

*Albertini RJ, Sram RJ, Vacek PM, et al. 2007. Molecular epidemiological studies in 1,3-butadiene exposed Czech workers: Female-male comparisons. *Chem Biol Interact* 166(1-3):63-77.

Albrecht OE, Filser JG, Neumann HG. 1993. Biological monitoring of 1,3-butadiene: Species differences in haemoglobin binding in rat and mouse. In: Sorsa M, Peltonen K, Vainio H, et al., eds. Butadiene and styrene: Assessment of health hazards. IARC Scientific Publications No. 127. Lyon, France: International Agency for Research on Cancer, 135-142.

*Altman PL, Dittmer DS. 1974. Biological handbooks: Biology data book. Vol. III. 2nd ed. Bethesda, MD: Federation of American Societies of Experimental Biology.

Altshuller AP, Cohen IR. 1964. Atmospheric photooxidation of the ethylene nitric oxide system. *Int J Air Water Pollut* 8:611-632.

9. REFERENCES

- Altshuller AP, Kopsczynski SL, Lonneman WA, et al. 1970. A technique for measuring photochemical reactions in atmospheric samples. *Environ Sci Technol* 4:503-506.
- *American Chemical Society. 2007. United States synthetic rubber program, 1939-1945. American Chemical Society. <http://acswebcontent.acs.org/landmarks/landmarks/rbb/index.html>. May 29, 2009.
- *Ammenheuser MM, Bechtold WE, Abdel-Rahman SZ, et al. 2001. Assessment of 1,3-butadiene exposure in polymer production workers using *HPRT* mutations in lymphocytes as a biomarker. *Environ Health Perspect* 109(12):1249-1255.
- *Amoore JE, Hautala E. 1983. Odor as an aid to chemical safety: Odor thresholds compared with threshold limit values and volatilities for 214 industrial chemicals in air and water dilution. *J Appl Toxicol* 3(6):272-290.
- *Andersen ME, Krishnan K. 1994. Relating *in vitro* to *in vivo* exposures with physiologically based tissue dosimetry and tissue response models. In: Salem H, ed. *Animal test alternatives: Refinement, reduction, and replacement*. New York, NY: Marcel Dekker, Inc., 9-25.
- *Andersen ME, Clewell HJ, Gargas ML, et al. 1987. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. *Toxicol Appl Pharmacol* 87(2):185-205.
- Anderson D. 2001. Expression of ras (p21) protein in plasma from exposed workers and from patients with lung disease. *Int J Hyg Environ Health* 204(1):55-60.
- Anderson D. 2004. Overview of male-mediated development defects. *Toxicol Appl Pharmacol* 197(3):173.
- Anderson D, Dobrzyńska MM, Jackson LI, et al. 1997a. Somatic and germ cell effects in rats and mice after treatment with 1,3-butadiene and its metabolites, 1,2-epoxybutene and 1,2,3,4-diepoxybutane. *Mutat Res* 391(3):233-242.
- Anderson D, Dobrzyńska MM, Yu TW, et al. 1997b. DNA integrity in human sperm. *Teratog Carcinog Mutagen* 17(3):97-102.
- Anderson D, Edwards AJ, Brinkworth MH. 1993. Male-mediated F1 effects in mice exposed to 1,3-butadiene. In: Sorsa M, Peltonen K, Vainio H, et al., eds. *Butadiene and styrene: Assessment of health hazards*. IARC Scientific Publications 127. Lyon, France: International Agency for Research on Cancer, 171-181.
- +*Anderson D, Edwards AJ, Brinkworth MH, et al. 1996. Male-mediated F1 effects in mice exposed to 1,3-butadiene. *Toxicology* 113(1-3):120-127.
- *+Anderson D, Hughes JA, Edwards AJ, et al. 1998. A comparison of male-mediated effects in rats and mice exposed to 1,3-butadiene. *Mutat Res* 397(1):77-84.
- *Anttinen-Klemetti T, Vaaranrinta R, Mutanen P, et al. 2006. Inhalation exposure to 1,3-butadiene and styrene in styrene-butadiene copolymer production. *Int J Hyg Environ Health* 209(2):151-158.
- Anttinen-Klemetti T, Vaaranrinta R, Peltonen K. 1999. Gas chromatographic determination of 3-butene-1,2-diol in urine samples after 1,3-butadiene exposure. *J Chromatogr B Biomed Sci Appl* 730(2):257-264.

9. REFERENCES

- *Arce GT, Vincent DR, Cunningham MJ, et al. 1989. The *in vitro* and *in vivo* genotoxicity of 1,3-butadiene and metabolites. Haskell Laboratory for Toxicology and Industrial Medicine, E.I. Du Pont de Nemours and Company, Inc.
- Arce GT, Vincent DR, Cunningham MJ, et al. 1990. *In vitro* and *in vivo* genotoxicity of 1,3-butadiene and metabolites. *Environ Health Perspect* 86:75-78.
- Atkinson R. 1985. Kinetics and mechanisms of the gas-phase reactions of hydroxyl radical with organic compounds under atmospheric conditions. *Chem Rev* 85:60-201.
- *Atkinson R. 1989. Kinetics and mechanisms of the gas-phase reactions of the hydroxyl radical with organic compounds. *J Phys Chem Ref Data* 1:110.
- Atkinson R, Aschmann SM. 1984. Rate constants for the reaction of hydroxyl radicals with a series of alkenes and dialkenes at 295 ± 1 K. *Int J Chem Kinet* 16:1175-1186.
- *Atkinson R, Carter WPL. 1984. Kinetics and mechanisms of gas-phase reactions of ozone with organic compounds under atmospheric conditions. *Chem Rev* 84:437-470.
- Atkinson R, Pitts JN. 1977. Absolute rate constants for the reaction of O^3 (P) atoms with allene, 1,3-butadiene, and vinyl methyl ether over the temperature range 297-439° K. *J Chem Phys* 67:2492-2495.
- *Atkinson R, Aschmann SM, Winer AM, et al. 1984. Kinetics of the gas-phase reactions of NO^3 radicals with a series of dialkenes, cycloalkenes, and monoterpenes at 295 ± 1 K. *Environ Sci Technol* 18:370-375.
- Atkinson R, Darnall KR, Lloyd AC, et al. 1979. Kinetics and mechanisms of the reactions of the hydroxyl radical with organic compounds in the gas phase. *Adv Photochem* 11:375-488.
- Atkinson R, Perry RA, Pitts JNJ. 1977. Absolute rate constants for the reaction of hydroxyl radicals with allene, 1,3-butadiene, and 3-methyl-1-butene over the temperature range 299-424K. *J Chem Phys* 67:3170-3174.
- *Austin CC, Wang D, Ecobichon DJ, et al. 2001. Characterization of volatile organic compounds in smoke at municipal structural fires. *J Toxicol Environ Health A* 63(6):437-458.
- Austin J. 2003. Day-of-week patterns in toxic air contaminants in Southern California. *J Air Waste Manage Assoc* 53:889-896.
- *Autio K, Renzi L, Catalan J, et al. 1994. Induction of micronuclei in peripheral blood and bone marrow erythrocytes of rats and mice exposed to 1,3-butadiene by inhalation. *Mutat Res* 309(2):315-320.
- *Baker J, Arey J, Atkinson R. 2005. Formation and reaction of hydroxycarbonyls from the reaction of OH radicals with 1,3-butadiene and isoprene. *Environ Sci Technol* 39(11):4091-4099.
- Barnes DG, Dourson M. 1988. Reference dose (RfD): Description and use in health risk assessments. *Regul Toxicol Pharmacol* 8(4):471-486.
- *Bartle KD, Bergstedt L, Novotny M, et al. 1969. Tobacco chemistry II. Analysis of the gas phase of tobacco smoke by gas chromatography-mass spectrometry. *J Chromatogr* 45(2):256-263.

9. REFERENCES

- Batterman SA, Yu Y, Jia C, et al. 2005. Non-methane hydrocarbon emissions from vehicle fuel caps. *Atmos Environ* 39(10):1855-1867.
- *Bechtold WE, Strunk MR, Chang I, et al. 1994. Species differences in urinary butadiene metabolites: Comparisons of metabolite ratios between mice, rats, and humans. *Toxicol Appl Pharmacol* 127:44-49.
- *Begemann P, Sram RJ, Neumann HG. 2001a. Hemoglobin adducts of epoxybutene in workers occupationally exposed to 1,3-butadiene. *Arch Toxicol* 74(11):680-687.
- *Begemann P, Upton PB, Ranasinghe A, et al. 2001b. Hemoglobin adducts as biomarkers of 1,3-butadiene in occupationally low exposed Italian workers and a few diesel-exposed miners. *Chem Biol Interact* 135-136:675-678.
- *Berger GS, ed. 1994. Epidemiology of endometriosis. In: *Endometriosis: Modern surgical management of endometriosis*. New York, NY: Springer-Verlag, 3-7.
- Bernardini S, Hirvonen A, Pelin K, et al. 1998. Induction of sister chromatid exchange by 1,2-epoxy-3-butene in cultured human lymphocytes: Influence of GSTT1 genotype. *Carcinogenesis* 19(2):377-380.
- *Biemer JJ. 1983. The preleukemic syndrome. *Ann Clin Lab Sci* 13(2):156-162.
- *Blomberg L, Widmark G. 1975. Separation of fresh tobacco on a packed polar gas chromatographic column prior to on-line analysis by gas chromatography-mass spectrometry using a non-polar capillary column. *J Chromatogr* 106(1):59-71.
- Bolt HM. 1993. Interspecies differences in metabolism and kinetics of 1,3-butadiene, isobutene and styrene. In: Sorsa M, Peltonen K, Vainio H, et al., eds. *Butadiene and styrene: Assessment of health hazards*. IARC Scientific Publications No. 127. Lyon, France: International Agency for Research on Cancer, 37-44.
- Bolt HM, Jelitto B. 1996. Biological formation of the 1,3-butadiene DNA adducts 7-N-(2-hydroxy-3-buten-1-yl)guanine, 7-N-(1-hydroxy-3-buten-2-yl)guanine and 7-N-(2,3,4-trihydroxy-butyl)guanine. *Toxicology* 113(1-3):328-330.
- *+Bolt HM, Filser JG, Stormer F. 1984. Inhalation pharmacokinetics based on gas uptake studies. V. Comparative pharmacokinetics of ethylene and 1,3-butadiene in rats. *Arch Toxicol* 55:213-218.
- *+Bolt HM, Schmiedel G, Filser JG, et al. 1983. Biological activation of 1,3-butadiene to vinyl oxirane by rat liver microsomes and expiration of the reactive metabolite by exposed rats. *J Cancer Res Clin Oncol* 106:112-116.
- *+Bond JA, Dahl AR, Henderson RF, et al. 1986. Species differences in the disposition of inhaled butadiene. *Toxicol Appl Pharmacol* 84(3):617-627.
- *+Bond JA, Dahl AR, Henderson RF, et al. 1987. Species differences in the distribution of inhaled butadiene in tissues. *Am Ind Hyg Assoc J* 48(10):867-872.
- Bond JA, Himmelstein MW, Seaton M, et al. 1996. Metabolism of butadiene by mice, rats, and humans: A comparison of physiologically based toxicokinetic model predictions and experimental data. *Toxicology* 113(1-3):48-54.

9. REFERENCES

- +Bond JA, Martin OS, Birnbaum LS, et al. 1988. Metabolism of 1,3-butadiene by lung and liver microsomes of rats and mice repeatedly exposed by inhalation to 1,3-butadiene. *Toxicol Lett* 44:143-151.
- Boogaard PJ, de Kloe KP, Booth ED, et al. 2004. DNA adducts in rats and mice following exposure to [4-¹⁴C]-1,2-epoxy-3-butene and to [2,3-¹⁴C]-1,3-butadiene. *Chem Biol Interact* 148(1-2):69-92.
- *Boogaard PJ, van Sittert NJ, Megens HJ. 2001a. Urinary metabolites and haemoglobin adducts as biomarkers of exposure to 1,3-butadiene: A basis for 1,3-butadiene cancer risk assessment. *Chem Biol Interact* 135-136:695-701.
- *Boogaard PJ, van Sittert NJ, Watson WP, et al. 2001b. A novel DNA adduct, originating from 1,2-epoxy-3,4-butanediol, is the major DNA adduct after exposure to [2,3-(¹⁴C)-1,3-butadiene],[4-(¹⁴C)-1,2-epoxy-3-butane. *Chem Biol Interact* 135-136:687-693.
- Booth ED, Kilgour JD, Robinson SA, et al. 2004a. Dose responses for DNA adduct formation in tissues of rats and mice exposed by inhalation to low concentrations of 1,3-[2,3-(¹⁴C)]-butadiene. *Chem Biol Interact* 147(2):195-211.
- Booth ED, Kilgour JD, Watson WP. 2004b. Dose responses for the formation of hemoglobin adducts and urinary metabolites in rats and mice exposed by inhalation to low concentrations of 1,3-[2,3-(¹⁴C)]-butadiene. *Chem Biol Interact* 147(2):213-232.
- Boysen G, Georgieva NI, Upton PB, et al. 2004. Analysis of diepoxide-specific cyclic N-terminal globin adducts in mice and rats after inhalation exposure to 1,3-butadiene. *Cancer Res* 64(23):8517-8520.
- Boysen G, Scarlett CO, Temple B, et al. 2006. Identification of covalent modifications in P450 2E1 by 1,2-epoxy-3-butene [Abstract]. *Toxicol Sci* 90(1-S):198.
- *Brinkworth MH, Anderson D, Hughes JA, et al. 1998. Genetic effects of 1,3-butadiene on the mouse testis. *Mutat Res* 397(1):67-75.
- *Brochot C, Smith TJ, Bois FY. 2007. Development of a physiologically based toxicokinetic model for butadiene and four major metabolites in humans: Global sensitivity analysis for experimental design issues. *Chem Biol Interact* 167(3):168-183.
- *Broderick BM, Marnane IS. 2002. A comparison of the C2-C9 hydrocarbon compositions of vehicle fuels and urban air in Dublin, Ireland. *Atmos Environ* 36:975-986.
- *Bronstein AC, Currance PL. 1988. Emergency care for hazardous materials exposure. St. Louis, MO: C.V. Mosby Company, 226-227.
- *Brunnemann KD, Kagan MR, Cox JE, et al. 1990. Analysis of 1,3-butadiene and other selected gas-phase components in cigarette mainstream and sidestream smoke by gas chromatography-mass selective detection. *Carcinogenesis* 11(10):1863-1868.
- Bucher JR, Melnick RL, Hildebrandt PK. 1993. Lack of carcinogenicity in mice exposed once to high concentrations of 1,3-butadiene. *J Natl Cancer Inst* 85(22):1866-1867.
- Cagen SZ, MacDonald RL, Van Gelder G. 1996. Review of risk assessments on 1,3-butadiene (1985-1991). *Toxicology* 113(1-3):215-220.

9. REFERENCES

- *Carmella SG, Chen M, Han S, et al. 2009. Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. *Chem Res Toxicol* 22(4):734-741.
- +*Carpenter CP, Shaffer CB, Weil CS, et al. 1944. Studies on the inhalation of 1,3-butadiene; with a comparison of its narcotic effect with benzol, toluol, and styrene, and a note on the elimination of styrene by the human. *J Ind Hyg Toxicol* 26:69-78.
- *Carrieri M, Bartolucci GB, Livieri M, et al. 2009. Quantitative determination of the 1,3-butadiene urinary metabolite 1,2-dihydroxybutyl mercapturic acid by high-performance liquid chromatography/tandem mass spectrometry using polynomial calibration curves. *J Chromatogr B Analyt Technol Biomed Life Sci* 877:1388-1393.
- +*Case RAM, Hosker ME. 1954. Tumour of the urinary bladder as an occupational disease in the rubber industry in England and Wales. *Br J Prev Soc Med* 8:39-50.
- +*Checkoway H, Williams TM. 1982. A hematology survey of workers at a styrene-butadiene synthetic rubber manufacturing plant. *Am Ind Hyg Assoc J* 43:164-169.
- *Chemical Market Reporter. 2006. Chemical profile: Butadiene. *Chem Market Rep* May 22-28 2006:34.
- *Chemical Week. 2008. Product focus: Butadiene. *Chem Week* March 10:31.
- *ChemID Plus Advanced. 2009. 1,3-Butadiene. ChemIDplus. Bethesda, MD: U.S. National Library of Medicine. <http://chem.sis.nlm.nih.gov/chemidplus/>. June 1, 2009.
- *Cheng H, Sathiakumar N, Graff J, et al. 2007. 1,3-Butadiene and leukemia among synthetic rubber industry workers: Exposure-response relationships. *Chem Biol Interact* 166(1-3):15-24.
- Choi HS, Shim YK, Kaye WE, et al. 2006. Potential residential exposure to toxics release inventory chemicals during pregnancy and childhood brain cancer. *Environ Health Perspect Suppl* 114(7):1113-1118.
- Christian MS. 1996. Review of reproductive and developmental toxicity of 1,3-butadiene. *Toxicology* 113(1-3):137-143.
- Christopher SL, Elfarra AA. 2004. Characterization of four mercapturic acid urinary metabolites of 3-butene-1,2-diol [Abstract]. *Toxicologist* 78(1-S):137.
- *Clewell HJ, Andersen ME. 1985. Risk assessment extrapolations and physiological modeling. *Toxicol Ind Health* 1(4):111-131.
- *Cochrane JE, Skopek TR. 1993. Mutagenicity of 1,3-butadiene and its epoxide metabolites in human TK6 cells and in splenic T cells isolated from exposed B6C3F1 mice. In: Sorsa M, Peltonen K, Vainio H, et al., eds. *Butadiene and styrene: Assessment of health hazards*. IARC Scientific Publications No. 127. Lyon, France: International Agency for Research on Cancer, 195-204.
- Colagiovanni DB, Stillman WS, Irons RD. 1993. Chemical suppression of a subpopulation of primitive hematopoietic progenitor cells: 1,3-Butadiene produces a hematopoietic defect similar to steel or white spotted mutations in mice. *Proc Natl Acad Sci USA* 90(7):2803-2806.

9. REFERENCES

- Cole P, Delzell E, Acquavella J. 1993. Exposure to butadiene and lymphatic and hematopoietic cancer. *Epidemiology* 4(2):96-103.
- Coordinating Research Council. 2004. Exploratory data analysis of benzene and 1,3-butadiene measurements for air toxics risk assessment in Houston. Alpharetta, GA: Council CR.
- *Counts ME, Hsu FS, Tewes FJ. 2006. Development of a commercial cigarette "market map" comparison methodology for evaluating new or non-conventional cigarettes. *Regul Toxicol Pharmacol* 46:225-242.
- *Cowles SR, Tsai SP, Snyder PJ, et al. 1994. Mortality, morbidity, and haematological results from a cohort of long-term workers involved in 1,3-butadiene monomer production. *Occup Environ Med* 51(5):323-329.
- +*Crouch CN, Pullinger DH, Gaunt IF. 1979. Inhalation toxicity studies with 1,3-butadiene — 2. 3 month toxicity study in rats. *Am Ind Hyg Assoc J* 40:796-802.
- *Csanady GA, Guengerich FP, Bond JA. 1992. Comparison of the biotransformation of 1,3-butadiene and its metabolite, butadiene monoepoxide, by hepatic and pulmonary tissues from humans, rats and mice. *Carcinogenesis* 13(7):1143-1153.
- Csanady GA, Kreuzer PE, Baur C, et al. 1996. A physiological toxicokinetic model for 1,3-butadiene in rodents and man: Blood concentrations of 1,3-butadiene, its metabolically formed epoxides, and of haemoglobin adducts--relevance of glutathione depletion. *Toxicology* 113(1-3):300-305.
- *Cunningham MJ, Choy WN, Arce GT, et al. 1986. *In vivo* sister chromatid exchange and micronucleus induction studies with 1,3-butadiene in B6C3F1 mice and Sprague-Dawley rats. *Mutagenesis* 1(6):449-452.
- *Currance PL, Clements B, Bronstein AC. 2007. Aliphatic hydrocarbons and related compounds. In: Honeycutt L, ed. *Emergency care for hazardous materials exposure*. 3rd ed. St. Louis, MO: MosbyJems, 240-242.
- *Curren KC, Dann TF, Wang DK. 2006. Ambient air 1,3-butadiene concentrations in Canada (1995-2003): Seasonal, day of week variations, trends, and source influences. *Atmos Environ* 40:170-181.
- Dahl AR, Henderson RF. 2000. Comparative metabolism of low concentrations of butadiene and its monoepoxide in human and monkey hepatic microsomes. *Inhal Toxicol* 12(5):439-451.
- *Dahl AR, Bechtold WE, Bond JA, et al. 1990. Species differences in the metabolism and disposition of inhaled 1,3-butadiene and isoprene. *Environ Health Perspect* 86:65-69.
- *Dahl AR, Sun JD, Birnbaum LS, et al. 1991. Toxicokinetics of inhaled 1,3-butadiene in monkeys: Comparison to toxicokinetics in rats and mice. *Toxicol Appl Pharmacol* 110(1):9-19.
- Dahl AR, Sun JD, Birnbaum LS, et al. 1992. Toxicokinetics of inhaled 1,3-butadiene in monkeys: Comparison to toxicokinetics in rats and mice. [Erratum to *Toxicol Appl Pharmacol* 110(1):9-19]. *Toxicol Appl Pharmacol* 116(1):152.

9. REFERENCES

- Darnall KR, Lloyd AC, Winer AM, et al. 1976. Reactivity scale for atmospheric hydrocarbons based on reaction with hydroxyl radicals. *Environ Sci Technol* 10(7):692-696.
- Debont JAM, Attwood MM, Primrose SB, et al. 1979. Epoxidation of short-chain alkenes in mycobacterium E20: The involvement of a specific mono-oxygenase. *FEMS Microbiol Lett* 6:183-188.
- *Delzell E, Macaluso M, Sathiakumar N, et al. 2001. Leukemia and exposure to 1,3-butadiene, styrene and dimethyldithiocarbamate among workers in the synthetic rubber industry. *Chem Biol Interact* 135-136:515-534.
- *Delzell E, Sathiakumar N, Hovinga M, et al. 1996. A follow-up study of synthetic rubber workers. *Toxicology* 113(1-3):182-189.
- *de Meester C. 1988. Genotoxic properties of 1,3-butadiene. *Mutat Res* 195(104):273-281.
- *de Meester C, Poncelet F, Roberfroid M, et al. 1978. Mutagenicity of butadiene and butadiene monoxide. *Biochem Biophys Res Commun* 80(2):298-305.
- *de Meester C, Poncelet F, Roberfroid M, et al. 1980. The mutagenicity of butadiene towards *Salmonella typhimurium*. *Toxicol Lett* 6(3):125-130.
- *+Deutschmann S, Laib RJ. 1989. Concentration-dependent depletion of non-protein sulfhydryl (NPSH) content in lung, heart and liver tissues of rats and mice after acute inhalation exposure to butadiene. *Toxicol Lett* 45:175-183.
- *Divine BJ. 1989. An update on mortality among workers at a butadiene facility—preliminary results. Report by Texaco Inc., Houston, TX.
- *Divine BJ. 1990. An update on mortality among workers at a 1,3-butadiene facility — preliminary results. *Environ Health Perspect* 86:119-128.
- *Divine BJ, Hartman CM. 1996. Mortality update of butadiene production workers. *Toxicology* 113(1-3):169-181.
- *Divine BJ, Hartman CM. 2001. A cohort mortality study among workers at a 1,3 butadiene facility. *Chem Biol Interact* 135-136:535-553.
- *Divine BJ, Wendt JK, Hartman CM. 1993. Cancer mortality among workers at a butadiene production facility. In: Sorsa M, Peltonen K, Vainio H, et al., eds. *Butadiene and styrene: Assessment of health hazards*. IARC Scientific Publications No. 127. Lyon, France: International Agency for Research on Cancer, 345-362.
- *+DOE/NTP. 1987a. Inhalation developmental toxicology studies of 1,3-butadiene in the rat. Final report. Richland, WA: U.S. Department of Energy. National Toxicology Program. PNL6414. DE88004186.
- *+DOE/NTP. 1987b. Inhalation developmental toxicology studies: Teratology study of 1,3-butadiene in mice. Final report. U.S. Department of Energy. National Toxicology Program. PNL6412. DE88004187.

9. REFERENCES

- *+DOE/NTP. 1988a. Sperm-head morphology study in B6C3F1 mice following inhalation exposure to 1,3-butadiene. Final technical report. Richland, WA: U.S. Department of Energy. National Toxicology Program. PNL6459. DE88008620.
- *+DOE/NTP. 1988b. Dominant lethal study in CD-1 mice following inhalation exposure to 1,3-butadiene: Final technical report. Richmond, WA: U.S. Department of Energy. National Toxicology Program. PNL6545. DE88010185.
- *Dolnick AA, Potash M. 1948. Butadiene. In: Kirk RE, Othmer DF, eds. Kirk-Othmer encyclopedia of chemical technology. Vol. 2. New York, NY: Interscience Encyclopedia, Inc., 669-674.
- *+Downs TD, Crane MM, Kim KW. 1987. Mortality among workers at a butadiene facility. *Am J Ind Med* 12:311-329.
- Doyle M, Sexton KG, Jeffries H, et al. 2004. Effects of 1,3-butadiene, isoprene, and their photochemical degradation products on human lung cells. *Environ Health Perspect* 112(15):1488-1495.
- *Duescher RJ, Elfarra AA. 1994. Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: Evidence for major roles by cytochromes P450 2A6 and 2E1. *Arch Biochem Biophys* 311(2):342-349.
- Durbin TD, Miller JW, Younglove T, et al. 2007. Effects of fuel ethanol content and volatility on regulated and unregulated exhaust emissions for the latest technology gasoline vehicles. *Environ Sci Technol* 41(11):4059-4064.
- Eisenreich SJ, Looney BB, Thornton JD. 1981. Airborne organic contaminants in the Great Lakes ecosystem. *Environ Sci Technol* 15(1):30-38.
- Elfarra AA, Duescher RJ, Pasch CM. 1991. Mechanisms of 1,3-butadiene oxidations to butadiene monoxide and crotonaldehyde by mouse liver microsomes and chloroperoxidase. *Arch Biochem Biophys* 286(1):244-251.
- *Elfarra AA, Krause RJ, Kemper RA. 2001. Cellular and molecular basis for species, sex and tissue differences in 1,3-butadiene metabolism. *Chem Biol Interact* 135-136:239-248.
- *Elfarra AA, Krause RJ, Selzer RR. 1996. Biochemistry of 1,3-butadiene metabolism and its relevance to 1,3-butadiene-induced carcinogenicity. *Toxicology* 113(1-3):23-30.
- *EPA. 1978. Interim primary drinking water regulations. U.S. Environmental Protection Agency. *Fed Regist* 43:29135-29150.
- *EPA. 1982. Methods for organic chemical analysis of municipal and industrial wastewater. Cincinnati, OH: U.S. Environmental Protection Agency, Environmental Monitoring and Support Laboratory. EPA6001482057.
- *EPA. 1985. Mutagenicity and carcinogenicity assessment of 1,3-butadiene. Washington, DC: U.S. Environmental Protection Agency. EPA600885004F.
- *EPA. 1986. Methods for the determination of organic compounds in finished drinking water and raw source water. Cincinnati, OH: U.S. Environmental Protection Agency, Physical and Chemical Methods Branch.

9. REFERENCES

*EPA. 1988a. Guidelines establishing test procedures for the analysis of pollutants. U.S. Environmental Protection Agency. Code of Federal Regulations. 40 CFR 1:36, 249-267.

EPA 1988b. Protection of environment. U.S. Environmental Protection Agency. Code of Federal Regulations. 40 CFR 355:182-191.

EPA. 1990. Interim methods for development of inhalation reference concentrations. Washington, DC: U.S. Environmental Protection Agency, Office of Health and Environmental Assessment, Office of Research and Development. EPA600890066A. PB90238890.

*EPA. 1994. Methods for derivation of inhalation reference concentrations and application of inhalation dosimetry. Washington, DC: U.S. Environmental Protection Agency. EPA600890066F.

*EPA. 1997. Special report on environmental endocrine disruption: An effects assessment and analysis. Washington, DC: U.S. Environmental Protection Agency, Risk Assessment Forum. EPA630R96012.

EPA. 1998a. Health risk assessment of 1,3-butadiene. Washington, DC: U.S. Environmental Protection Agency. NCEA-W-0267. <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=12179>. May 31, 2009.

EPA. 1998b. Automated Form R for Windows: User's guide (RY97). Washington, DC: U.S. Environmental Protection Agency, Office of Pollution Prevention and Toxics.

EPA. 1998c. An SAB report: Review of the health risk assessment of 1,3-butadiene. Washington, DC: U.S. Environmental Protection Agency, Science Advisory Board. EPA-SAB-EHC-99-003. [http://yosemite.epa.gov/sab/sabproduct.nsf/Web/5ED3CEEA0F3367658525718F00505E3B/\\$File/ehc9903.pdf](http://yosemite.epa.gov/sab/sabproduct.nsf/Web/5ED3CEEA0F3367658525718F00505E3B/$File/ehc9903.pdf). May 31, 2009.

*EPA. 1999a. Compendium of methods for the determination of toxic organic compounds in ambient air. Second edition. Compendium method TO-15. Determination of volatile organic compounds (VOCs) in air collected in specially-prepared canisters and analyzed by gas chromatography/mass spectrometry (GC/MS). Cincinnati, OH: U.S. Environmental Protection Agency, Office of Research and Development. EPA625R96010b.

*EPA. 1999b. Compendium of methods for determination of toxic organic compounds in ambient air. Second edition. Compendium method TO-14A. Determination of volatile organic compounds (VOCs) in ambient air using specially prepared canisters with subsequent analysis by gas chromatography. Cincinnati, OH: U.S. Environmental Protection Agency, Office of Research and Development. EPA625R96010b

*EPA. 2002. Health assessment of 1,3-butadiene. Washington, DC: U.S. Environmental Protection Agency. EPA600P98001F.

*EPA. 2003a. Estimate background concentrations for the national-scale air toxics assessment. Research Triangle Park, NC: U.S. Environmental Protection Agency, Office of Air Quality Planning and Standards.

*EPA. 2003b. National primary drinking water regulations. Washington, DC: U.S. Environmental Protection Agency. Office of Ground Water and Drinking Water, <http://www.epa.gov/safewater/contaminants/index.html>. May 19, 2009.

9. REFERENCES

- *EPA. 2005. Toxic chemical release inventory reporting forms and instructions: Revised 2004 version. Section 313 of the Emergency Planning and Community Right-to-Know Act (Title III of the Superfund Amendments and Reauthorization Act of 1986). U.S. Environmental Protection Agency, Office of Environmental Information. EPA260B05001.
- *EPA. 2006a. Drinking water standards and health advisories. Washington, DC: U.S. Environmental Protection Agency, Office of Water. EPA822R04005. <http://epa.gov/waterscience/criteria/drinking/>. May 19, 2009.
- *EPA. 2006b. National recommended water quality criteria. Washington, DC: U.S. Environmental Protection Agency. Office of Water, Office of Science and Technology, <http://www.epa.gov/waterscience/criteria/wqcriteria.html>. May 11, 2009.
- *EPA. 2008. 2005 National emissions inventory data documentation. National Emissions Inventory. U.S. Environmental Protection Agency. <http://www.epa.gov/ttn/chief/net/2005inventory.html>. May 26, 2009.
- *EPA. 2009a. Acute exposure guideline levels (AEGLs). Washington, DC: U.S. Environmental Protection Agency. <http://www.epa.gov/oppt/aegl/>. May 19, 2009.
- *EPA. 2009b. Hazardous air pollutants. Clean Air Act. U.S. Environmental Protection Agency. United States Code. 42 USC 7412. <http://www.epa.gov/ttn/atw/orig189.html>. May 19, 2009.
- *EPA. 2009c. Regulated toxic substances and threshold quantities for accidental release prevention. U.S. Environmental Protection Agency. Code of Federal Regulations. 40 CFR 68.130. <http://www.epa.gov/lawsregs/search/40cfr.html>. May 20, 2009.
- *EPA. 2009d. Superfund, emergency planning, and community right-to-know programs. Designation, reportable quantities, and notifications. U.S. Environmental Protection Agency. Code of Federal Regulations. 40 CFR 302.4. <http://www.epa.gov/lawsregs/search/40cfr.html>. May 20, 2009.
- *EPA. 2009e. Superfund, emergency planning, and community right-to-know programs. Toxic chemical release reporting. U.S. Environmental Protection Agency. Code of Federal Regulations. 40 CFR 372.65. <http://www.epa.gov/lawsregs/search/40cfr.html>. May 11, 2009.
- Fajen JM, Roberts DR, Ungers LJ, et al. 1990. Occupational exposure of workers to 1,3-butadiene. *Environ Health Perspect* 86:11-18.
- Faller TH, Bhowmik S, Midpanon S, et al. 2003. Metabolism of 1,3-butadiene during passage through livers of B6C3F1-mice [Abstract]. *Naunyn Schmiedebergs Arch Pharmacol* 367(Suppl 1):R128.
- *FDA. 2008. Everything added to food in the United States (EAFUS). Washington, DC: U.S. Food and Drug Administration. <http://vm.cfsan.fda.gov/~dms/eafus.html>. May 19, 2009.
- *FEDRIP. 2009. Federal Research in Progress Database. Springfield, VA: National Technical Information Service.
- *Filsler JG, Bolt HM. 1984. Inhalation pharmacokinetics based on gas uptake studies. VI. Comparative evaluation of ethylene oxide and butadiene monoxide as exhaled reactive metabolites of ethylene and 1,3-butadiene in rats. *Arch Toxicol* 55(4):219-223.

9. REFERENCES

- Filser JG, Althaler B, Welter HF, et al. 1992. Metabolism of 1,3-butadiene in microsomes from livers of mouse, rat, and man [Abstract]. *Naunyn-Schmiedeberg's Arch Pharmacol* 345(Suppl 1):R31.
- Filser JG, Faller TH, Bhowmik S, et al. 2001. First-pass metabolism of 1,3-butadiene in once-through perfused livers of rats and mice. *Chem Biol Interact* 135-136:249-265.
- Filser JG, Hutzler C, Meischner V, et al. 2007. Metabolism of 1,3-butadiene to toxicologically relevant metabolites in single-exposed mice and rats. *Chem Biol Interact* 166(1-3):93-103.
- Filser JG, Johanson G, Kessler W, et al. 1993. A pharmacokinetic model to describe toxicokinetic interactions between 1,3-butadiene and styrene in rats: Predictions for human exposure. In: Sorsa M, Peltonen K, Vainio H, et al., eds. *Butadiene and styrene: Assessment of health hazards*. IARC Scientific Publications No. 127. Lyon, France: International Agency for Research on Cancer, 65-78.
- *Fomon SJ. 1966. Body composition of the infant: Part I: The male reference infant. In: Falkner F, ed. *Human development*. Philadelphia, PA: WB Saunders, 239-246.
- *Fomon SJ, Haschke F, Ziegler EE, et al. 1982. Body composition of reference children from birth to age 10 years. *Am J Clin Nutr* 35(Suppl 5):1169-1175.
- +*Fox AJ, Lindars DC, Owen R. 1974. A survey of occupational cancer in the rubber and cablemaking industries: Results of five-year analysis, 1976-71. *Br J Ind Med* 31(2):140-151.
- *Fustinoni S, Perbellini L, Soleo L, et al. 2004. Biological monitoring in occupational exposure to low levels of 1,3-butadiene. *Toxicol Lett* 149(1-3):353-360.
- Fustinoni S, Soleo L, Warholm M, et al. 2002. Influence of metabolic genotypes on biomarkers of exposure to 1,3-butadiene in humans. *Cancer Epidemiol Biomarkers Prev* 11(10 Pt 1):1082-1090.
- Gaffney JS, Levine SZ. 1979. Predicting gas phase organic molecule reaction rates using linear free-energy correlations. I. O(3P) and OH addition and abstraction reactions. *Int J Chem Kinet* 11:1197-1209.
- Gay BW, Bufalini JJ. 1971. Nitric acid and the nitrogen balance of irradiated hydrocarbons in the presence of oxides of nitrogen. *Environ Sci Technol* 5:422-425.
- Genter MB, Recio L. 1994. Absence of detectable P450 2E1 in bone marrow on B6C3F1 mice: Relevance to butadiene-induced bone marrow toxicity. *Fundam Appl Toxicol* 22(3):469-473.
- Georgieva NI, Boysen G, Li Y, et al. 2004. Cyclic n-terminal hemoglobin adduct in humans, rats and mice exposed to butadiene [Abstract]. *Toxicologist* 78(1-S):177.
- *Giwerzman A, Carlsen E, Keiding N, et al. 1993. Evidence for increasing incidence of abnormalities of the human testis: A review. *Environ Health Perspect* 101(Suppl 2):65-71.
- *Goggin M, Swenberg JA, Walker VE, et al. 2009. Molecular dosimetry of 1,2,3,4-diepoxybutane-induced DNA — DNA cross-links in B6C3F1 mice and F344 rats exposed to 1,3-butadiene by inhalation. *Cancer Res* 69(6):2479-2486.
- Goldan PD, Kuster WC, Williams E, et al. 2004. Nonmethane hydrocarbon and oxy hydrocarbon measurements during the 2002 New England air quality study. *J Geophys Res* 109(D21):1-14.

9. REFERENCES

- Goodrow T, Reynolds S, Maronpot R, et al. 1990. Activation of K-ras by codon 13 mutations in C57BL/6 X C3H F1 mouse tumors induced by exposure to 1,3-butadiene. *Cancer Res* 50(15):4818-4823.
- Goodrow TL, Nichols WW, Storer RD, et al. 1994. Activation of H-ras is prevalent in 1,3-butadiene-induced and spontaneously occurring murine harderian gland tumors. *Carcinogenesis* 15(11):2665-2667.
- Gordon SM, Callahan PJ, Nishioka MG, et al. 1999. Residential environmental measurements in the national human exposure assessment survey (NHEXAS) pilot study in Arizona: Preliminary results for pesticides and VOCs. *J Expo Anal Environ Epidemiol* 9(5):456-470.
- *Graham LA, Noseworthy L, Fugler D, et al. 2004. Contribution of vehicle emissions from an attached garage to residential indoor air pollution levels. *J Air Waste Manage Assoc* 54(5):563-584.
- *Grant RL, Leopold V, McCant D, et al. 2007. Spatial and temporal trend evaluation of ambient concentrations of 1,3-butadiene and chloroprene in Texas. *Chem Biol Interact* 166(1-3):44-51.
- Grosse Y, Baan R, Straif K, et al. 2007. Carcinogenicity of 1,3-butadiene, ethylene oxide, vinyl chloride, vinyl fluoride, and vinyl bromide. *Lancet Oncol* 8(8):679-680.
- *Grub J, Loser E. 2005. Butadiene. In: Ullmann's encyclopedia of industrial chemistry, 1-17. http://mrw.interscience.wiley.com/emrw/9783527306732/ueic/article/a04_431/current/pdf. May 31, 2009.
- Guicherit R, Schulting FL. 1985. The occurrence of organic chemicals in the atmosphere of the Netherlands. *Sci Total Environ* 42:193-219.
- Gunderson EL, Fowler L. 2006. Lessons learned from fenceline monitoring at an integrated olefins facility in Jefferson County, Texas. In: AICHE Spring National Meeting, ethylene producers conference, Orlando, Florida, April 23-26, 2006. New York, NY: American Institute of Chemical Engineers.
- *Gustafson P, Barregard L, Strandberg B, et al. 2007. The impact of domestic wood burning on personal, indoor and outdoor levels of 1,3-butadiene, benzene, formaldehyde and acetaldehyde. *J Environ Monit* 9(1):23-32.
- *Guzelian PS, Henry CJ, Olin SS. 1992. Similarities and differences between children and adults: Implications for risk assessment. Washington, DC: International Life Sciences and Press Institute Press.
- *Hansch C, Leo A, Hoekman D. 1995. Exploring QSAR hydrophobic, electronic, and steric constants. Washington, DC: American Chemical Society, 8.
- Hayano S, Jang-Ho L, Furuya K, et al. 1985. Formation of hazardous substances and mutagenicity of PAH produced during the combustion process in a diesel engine. *Atmos Environ* 19:1009-1015.
- *Hayes RB, Xi L, Bechtold WE, et al. 1996. *hprt* Mutation frequency among workers exposed to 1,3-butadiene in China. *Toxicology* 113(1-3):100-105.
- *Hayes RB, Zhang L, Yin S, et al. 2000. Genotoxic markers among butadiene polymer workers in China. *Carcinogenesis* 21(1):55-62.

9. REFERENCES

- *HazDat. 2007. 1,3-Butadiene. HazDat Database: ATSDR's Hazardous Substance Release and Health Effects Database. Atlanta, GA: Agency for Toxic Substances and Disease Registry.
- *Health Canada. 2000. Canadian Environmental Protection Act, 1999. Priority substances list health assessment: 1,3-Butadiene. Health Canada. Environment Canada. Minister of Public Works and Government Services. http://www.hc-sc.gc.ca/ewh-semt/pubs/contaminants/psl2-lsp2/1_3_butadiene/index-eng.php. July 9, 2009.
- *HEI. 2000. 1,3-Butadiene: cancer, mutations, and adducts. Number 92. Cambridge, MA: Health Effects Institute.
- *HEI. 2003. Biomarkers in Czech workers exposed to 1,3-butadiene: A transitional epidemiologic study. Number 116. Boston, MA: Health Effects Institute.
- *HEI. 2006. An updated study of mortality among North American synthetic rubber industry workers. Number 132. Boston, MA: Health Effects Institute.
- Hellen H, Hakola H, Haaparanta S, et al. 2008. Influence of residential wood combustion on local air quality. *Sci Total Environ* 393(2-3):283-290.
- Henderson RF, Bechtold WE, Sabourin PJ, et al. 1993. Species differences in the metabolism of 1,3-butadiene *in vivo*. In: Sorsa M, Peltonen K, Vainio H, et al., eds. Butadiene and styrene: Assessment of health hazards. IARC Scientific Publications No. 127. Lyon, France: International Agency for Research on Cancer, 57-64.
- Henderson RF, Bechtold WE, Thornton-Manning JR, et al. 2001. Urinary butadiene diepoxide: A potential biomarker of blood diepoxide. *Toxicology* 160(1-3):81-86.
- *Henderson RF, Thornton-Manning JR, Bechtold WE, et al. 1996. Metabolism of 1,3-butadiene: Species differences. *Toxicology* 113(1-3):17-22.
- *Hendricks WD, Schultz GR. 1986. A sampling and analytical method for monitoring low ppm air concentrations of 1,3-butadiene. *Appl Ind Hyg* 1:186-189.
- Heuss JM, Glasson WA. 1968. Hydrocarbon reactivity and eye irritation. *Environ Sci Technol* 2:1109-1116.
- *Higashino H, Mita K, Yoshikado H, et al. 2007. Exposure and risk assessment of 1,3-butadiene in Japan. *Chem Biol Interact* 166(1-3):52-62.
- Himmelstein MW, Acquavella JF, Recio L, et al. 1997. Toxicology and epidemiology of 1,3-butadiene. *Crit Rev Toxicol* 27(1):1-108.
- *Himmelstein MW, Asgharian B, Bond JA. 1995. High concentrations of butadiene epoxides in livers and lungs of mice compared to rats exposed to 1,3-butadiene. *Toxicol Appl Pharmacol* 132(2):281-288.
- *Himmelstein MW, Turner MJ, Asgharian B, et al. 1994. Comparison of blood concentrations of 1,3-butadiene and butadiene epoxides in mice and rats exposed to 1,3-butadiene by inhalation. *Carcinogenesis* 15(8):1479-1486.

9. REFERENCES

*Himmelstein MW, Turner MJ, Asgharian B, et al. 1996. Metabolism of 1,3-butadiene: Inhalation pharmacokinetics and tissue dosimetry of butadiene epoxides in rats and mice. *Toxicology* 113(1-3):306-309.

Hine J, Mookerjee PK. 1975. The intrinsic hydrophilic character of organic compounds. Correlations in terms of structural contributions. *J Org Chem* 40(3):292-298.

*Hoel DG, Davis DL, Miller AB, et al. 1992. Trends in cancer mortality in 15 industrialized countries, 1969-1986. *J Natl Cancer Inst* 84(5):313-320.

*Hong HH, Devereux TR, Melnick RL, et al. 2000. Mutations of *ras* protooncogenes and *p53* tumor suppressor gene in cardiac hemangiosarcomas from B6C3F1 mice exposed to 1,3-butadiene for 2 years. *Toxicol Pathol* 28(4):529-534.

*Hou CT, Patel R, Laskin AI, et al. 1979. Microbial oxidation of gaseous hydrocarbons: Epoxidation of C2 to C4 n-alkenes by methylotrophic bacteria. *Appl Environ Microbiol* 38:127-134.

Hou CT, Patel RN, Laskin AI, et al. 1980. Microbial oxidation of gaseous hydrocarbons: Oxidation of lower n-alkenes and n-alkanes by resting cell suspensions of various methylotrophic bacteria, and the effect of methane metabolites. *FEMS Microbiol Lett* 9:267-270.

*Hou CT, Patel R, Laskin AI, et al. 1983. Epoxidation of short-chain alkenes by resting-cell suspensions of propane-grown bacteria. *Appl Environ Microbiol* 46:171-177.

*HSDB. 2009. 1,3-butadiene. Hazardous Substances Data Bank. <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB>. April 7, 2009.

*Hughes K, Meek ME, Walker M, et al. 2003. 1,3-Butadiene: Exposure estimation, hazard characterization, and exposure-response analysis. *J Toxicol Environ Health B Crit Rev* 6(1):55-83.

Hughes TW, Tierney DR, Khan ZS. 1979. Measuring fugitive emissions from petrochemical plants. *Chem Eng Prog* 75:35-39.

*Hurst HE. 2007. Toxicology of 1,3-butadiene, chloroprene, and isoprene. *Rev Environ Contam Toxicol* 189:131-179.

IARC. 1992. 1,3-Butadiene. International Agency for Research on Cancer. *IARC Monogr Eval Carcinog Risk Chem Hum* 54:237-285.

IARC. 1993. Butadiene and styrene: Assessment of health hazards. Geneva, Switzerland: International Agency for Research on Cancer; World Health Organization.

IARC. 1999. 1,3-Butadiene. International Agency for Research on Cancer. *IARC Monogr Eval Carcinog Risk Chem Hum* 71 Pt 1:109-225.

*IARC. 2009. Agents reviewed by the IARC Monographs. Volumes 1-99. Lyon, France: International Agency for Research on Cancer. <http://monographs.iarc.fr/ENG/Classification/index.php>. May 19, 2009.

*ICIS. 2009a. Butadiene uses and market data. <http://www.icis.com/v2/chemicals/9075172/butadiene/uses.html>. June 1, 2009.

9. REFERENCES

- ICIS. 2009b. Styrene butadiene rubber (SBR) prices and pricing information. <http://www.icis.com/v2/chemicals/9076466/styrene-butadiene-rubber/pricing.html>. June 1, 2009.
- *IRIS. 2009. 1,3-Butadiene. Washington, DC: Integrated Risk Information System. <http://www.epa.gov/iris/subst/index.html>. May 11, 2009.
- Irons RD. 1989. Studies on the mechanism of butadiene-induced leukemogenesis: The potential role of endogenous murine leukemia virus. Research Triangle Park, NC: Chemical Industry Institute of Toxicology.
- Irons RD. 1990. Studies on the mechanism of 1,3-butadiene-induced leukemogenesis: The potential role of endogenous murine leukemia virus. *Environ Health Perspect* 86:49-55.
- *Irons RD, Pyatt DW. 1998. Dithiocarbamates as potential confounders in butadiene epidemiology. *Carcinogenesis* 19(4):539-542.
- Irons RD, Cathro HP, Stillman WS, et al. 1989. Susceptibility to 1,3-butadiene-induced leukemogenesis correlates with endogenous ecotropic retroviral background in the mouse. *Toxicol Appl Pharmacol* 101(1):170-176.
- *Irons RD, Oshimura M, Barrett JC. 1987b. Chromosome aberrations in mouse bone marrow cells following in vivo exposure to 1,3-butadiene. *Carcinogenesis* 8(11):1711-1714.
- Irons RD, Pyatt DW, Stillman WS, et al. 2000. Comparative toxicity of known and putative metabolites of 1, 3-butadiene in human CD34(+) bone marrow cells. *Toxicology* 150(1-3):99-106.
- *+Irons RD, Smith CN, Stillman WS, et al. 1986a. Macrocytic-megaloblastic anemia in male B6C3F1 mice following chronic exposure to 1,3-butadiene. *Toxicol Appl Pharmacol* 83(1):95-100.
- *+Irons RD, Smith CN, Stillman WS, et al. 1986b. Macrocytic-megaloblastic anemia in male NIH Swiss mice following repeated exposure to 1,3-butadiene. *Toxicol Appl Pharmacol* 85(3):450-455.
- +Irons RD, Stillman WS, Cloyd MW. 1987a. Selective activation of endogenous ecotropic retrovirus in hematopoietic tissues of B6C3F1 mice during the preleukemic phase of 1,3-butadiene exposure. *Virology* 161(2):457-462.
- *Irons RD, Stillman WS, Pyatt DW, et al. 2001. Comparative toxicity of dithiocarbamates and butadiene metabolites in human lymphoid and bone marrow cells. *Chem Biol Interact* 135-136:615-625.
- *Irvine LFH. 1981. 1,3-Butadiene: Inhalation teratogenicity study in the rat. Final report. Harrogate, England: Hazleton Laboratories Europe Ltd. OTS050545.
- Jackson MA, Stack HF, Rice JM, et al. 2000a. A review of the genetic and related effects of 1,3-butadiene in rodents and humans. *Mutat Res* 463(3):181-213.
- *Jackson TE, Lilly PD, Recio L, et al. 2000b. Inhibition of cytochrome P450 2E1 decreases, but does not eliminate, genotoxicity mediated by 1,3-butadiene. *Toxicol Sci* 55(2):266-273.
- Jacobson-Kram D, Rosenthal SL. 1995. Molecular and genetic toxicology of 1,3-butadiene. *Mutat Res* 339(2):121-130.

9. REFERENCES

- *Jauhar PP, Henika PR, Macgregor JT, et al. 1988. 1,3-Butadiene: Induction of micronucleated erythrocytes in the peripheral blood of B6C3F1 mice exposed by inhalation for 13 weeks. *Mutation Research* 209(3-4):171-176.
- *Jelitto B, Vangala RR, Laib RJ. 1989. Species differences in DNA damage by butadiene: Role of diepoxybutane. *Arch Toxicol Suppl* 13:246-249.
- Johanson CE. 1980. Permeability and vascularity of the developing brain: Cerebellum vs. cerebral cortex. *Brain Res* 190(1):3-16.
- *Johanson G, Filser JG. 1993. A physiologically based pharmacokinetic model for butadiene and its metabolite butadiene monoxide in rat and mouse and its significance for risk extrapolation. *Arch Toxicol* 67(3):151-163.
- Johanson G, Filser JG. 1996. PBPK model for butadiene metabolism to epoxides: Quantitative species differences in metabolism. *Toxicology* 113(1-3):40-47.
- *Jones B, Harris RL. 1983. Calculation of time-weighted average concentrations: A computer mapping application. *Am Ind Hyg Assoc J* 44:795-801.
- Junk GA, Ford CS. 1980. A review of organic emissions from selected combustion processes. *Chemosphere* 9:187-230.
- Katzman H, Libby WF. 1975. Hydrocarbon emissions from jet engines operated at simulated high altitude supersonic flight conditions. *Atmos Environ* 9:839-842.
- *Kelsey KT, Wiencke JK, Ward J, et al. 1995. Sister-chromatid exchanges, glutathione S-transferase theta deletion and cytogenetic sensitivity to diepoxybutane in lymphocytes from butadiene monomer production workers. *Mutat Res* 335(3):267-273.
- *Kennedy CH, Catallo WJ, Wilson VL, et al. 2008. Combustion products of 1,3-butadiene inhibit catalase activity and induce expression of oxidative DNA damage repair enzymes in human bronchial epithelial cells. [Epub ahead of print] *Cell Biol Toxicol*.
- +Khalil M, Abudiab M, Ahmed AE. 2007. Clinical evaluation of 1,3-butadiene neurotoxicity in humans. *Toxicol Ind Health* 23(3):141-146.
- *Kim SR, Dominici F, Buckley TJ. 2007. Concentrations of vehicle-related air pollutants in an urban parking garage. *Environ Res* 105(3):291-299.
- *Kim Y, Hong HH, Lachat Y, et al. 2005. Genetic alterations in brain tumors following 1,3-butadiene exposure in B6C3F1 mice. *Toxicol Pathol* 33(3):307-312.
- *Kim YM, Harrad S, Harrison RM. 1999. An improved method for the determination of 1,3-butadiene in nonoccupational environments. *Environ Sci Technol* 33:4342-4345.
- *Kim YM, Harrad S, Harrison RM. 2001. Concentrations and sources of VOCs in urban domestic and public microenvironments. *Environ Sci Technol* 35(6):997-1004.
- *Kim YM, Harrad S, Harrison RM. 2002. Levels and sources of personal inhalation exposure to volatile organic compounds. *Environ Sci Technol* 36(24):5405-5410.

9. REFERENCES

- *Kirshenbaum I. 1978. Butadiene. In: Kirk-Othmer encyclopedia of chemical technology. Vol. 4. New York, NY: John Wiley & Sons, 313-337.
- *Kligerman AD, DeMarini DM, Doerr CL, et al. 1999. Comparison of cytogenetic effects of 3,4-epoxy-1-butene and 1,2:3, 4-diepoxybutane in mouse, rat and human lymphocytes following *in vitro* G0 exposures. *Mutat Res* 439(1):13-23.
- Kligerman AD, Doerr CL, Milholland VS, et al. 1996. Cytogenetic effects of butadiene metabolites in rat and mouse splenocytes following *in vitro* exposures. *Toxicology* 113(1-3):336-340.
- *Knox EG. 2005. Childhood cancers and atmospheric carcinogens. *J Epidemiol Community Health* 59:101-105.
- *Knox EG. 2006. Roads, railways, and childhood cancers. *J Epidemiol Community Health* 60(2):136-141.
- Koc H, Tretyakova NY, Walker VE, et al. 1999. Molecular dosimetry of N-7 guanine adduct formation in mice and rats exposed to 1,3-butadiene. *Chem Res Toxicol* 12(7):566-574.
- *Kohn MC, Melnick RL. 1993. Species differences in the production and clearance of 1,3-butadiene metabolites: A mechanistic model indicates predominantly physiological, not biochemical, control. *Carcinogenesis* 14(4):619-628.
- *Kohn MC, Melnick RL. 1996. Effects of the structure of a toxicokinetic model of butadiene inhalation exposure on computed production of carcinogenic intermediates. *Toxicology* 113(1-3):31-39.
- *Kohn MC, Melnick RL. 2000. The privileged access model of 1,3-butadiene disposition. *Environ Health Perspect* 108(Suppl 5):911-917.
- *Kohn MC, Melnick RL. 2001. Physiological modeling of butadiene disposition in mice and rats. *Chem Biol Interact* 135-136:285-301.
- *Koivisto P, Peltonen K. 2001. N7-guanine adducts of the epoxy metabolites of 1,3-butadiene in mice lung. *Chem Biol Interact* 135-136:363-372.
- Koivisto P, Adler ID, Pacchierotti F, et al. 1998. DNA adducts in mouse testis and lung after inhalation exposure to 1,3-butadiene. *Mutat Res* 397(1):3-10.
- Koivisto P, Adler ID, Sorsa M, et al. 1996. Inhalation exposure of rats and mice to 1,3-butadiene induces N6-adenine adducts of epoxybutene detected by 32P-postlabeling and HPLC. *Environ Health Perspect* 104 (Suppl 3):655-657.
- Koivisto P, Pacchierotti F, Adler I-D, et al. 1997. *In vivo* DNA binding of the active metabolites of 1,3-butadiene. [Abstract]. *Mutat Res* 379(Suppl 1):S163.
- Komori M, Nishio K, Kitada M, et al. 1990. Fetus-specific expression of a form of cytochrome P-450 in human livers. *Biochemistry* 29(18):4430-4433.
- Kopczynski SL, Lonneman WA, Sutterfield FD, et al. 1972. Photochemistry of atmospheric samples in Los Angeles. *Environ Sci Technol* 6:342-347.

9. REFERENCES

- *Kraybill HF. 1980. Evaluation of public health aspects of carcinogenic/mutagenic biorefractories in drinking water. *Prev Med* 9:212-218.
- *+Kreiling R, Laib RJ, Bolt HM. 1986a. Alkylation of nuclear proteins and DNA after exposure of rats and mice to carbon-14 1,3-butadiene. *Toxicol Lett* 30(2):131-136.
- *+Kreiling R, Laib RJ, Bolt HM. 1988. Depletion of hepatic non-protein sulfhydryl content during exposure of rats and mice to butadiene. *Toxicol Lett* 41(3):209-214.
- *+Kreiling R, Laib RJ, Filser JG, et al. 1986b. Species differences in butadiene metabolism between mice and rats evaluated by inhalation pharmacokinetics. *Arch Toxicol* 58(4):235-238.
- *Kreiling R, Laib RJ, Filser JG, et al. 1987. Inhalation pharmacokinetics of 1,2-epoxybutene-3 reveal species differences between rats and mice sensitive to butadiene-induced carcinogenesis. *Arch Toxicol* 61(1):7-11.
- *Krishnan K, Andersen ME. 1994. Physiologically based pharmacokinetic modeling in toxicology. In: Hayes AW, ed. *Principles and methods of toxicology*. 3rd ed. New York, NY: Raven Press, Ltd., 149-188.
- *Krishnan K, Anderson ME, Clewell HJ, et al. 1994. Physiologically based pharmacokinetic modeling of chemical mixtures. In: Yang RSH, ed. *Toxicology of chemical mixtures. Case studies, mechanisms, and novel approaches*. San Diego, CA: Academic Press, 399-437.
- *Lahdetie J, Peltonen K, Sjoblom T. 1997. Germ cell mutagenicity of three metabolites of 1,3-butadiene in the rat: Induction of spermatid micronuclei by butadiene mono-, di-, and diepoxides *in vivo*. *Environ Mol Mutagen* 29(3):230-239.
- *+Laib RJ, Filser JG, Kreiling R. 1988. Species differences in butadiene metabolism between mouse and rat. *Ann N Y Acad Sci* 534:663-670.
- *Laib RJ, Filser JG, Kreiling R, et al. 1990. Inhalation pharmacokinetics of 1,3-butadiene and 1,2-epoxybutene-3 in rats and mice. *Environ Health Perspect* 86:57-63.
- Laib RJ, Tucholski M, Filser JG, et al. 1992. Pharmacokinetic interaction between 1,3-butadiene and styrene in Sprague-Dawley rats. *Arch Toxicol* 66(5):310-314.
- Landi S, Ponzanelli I, Hirvonen A, et al. 1996. Repeated analysis of sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes: Effect of glutathione S-transferase T1 and M1 genotype. *Mutat Res* 351(1):79-85.
- Landrigan PJ. 1993. Critical assessment of epidemiological studies on the carcinogenicity of 1,3-butadiene and styrene. In: Sorsa M, Peltonen K, Vainio H, et al., eds. *Butadiene and styrene: Assessment of health hazards*. IARC Scientific Publications No. 127. Lyon, France: International Agency for Research on Cancer, 375-388.
- *Leber AP. 2001. Human exposures to monomers resulting from consumer contact with polymers. *Chem Biol Interact* 135-136:215-220.

9. REFERENCES

- *Leeder JS, Kearns GL. 1997. Pharmacogenetics in pediatrics: Implications for practice. *Pediatr Clin North Am* 44(1):55-77.
- Legator MS, Au WW. 1994. Application of integrated genetic monitoring: The optimal approach for detecting environmental carcinogens. *Environ Health Perspect* 102 (Suppl 9):125-132.
- Legator MS, Au WW, Ammenheuser M, et al. 1993. Elevated somatic cell mutant frequencies and altered DNA repair responses in nonsmoking workers exposed to 1,3-butadiene.
- *Leiderman LJ, Stillman WS, Shah RS, et al. 1986. Altered hematopoietic stem cell development in male B6C3F1 mice following exposure to 1,3-butadiene. *Exp Mol Pathol* 44(1):50-56.
- *Leikin JB, Paloucek FP. 2002. Leikin & Paloucek's poisoning & toxicology handbook. 3rd ed. Hudson, OH: Lexi-Comp, Inc., 306.
- *Leung H. 1993. Physiologically-based pharmacokinetic modelling. In: Ballantyne B, Marrs T, Turner P, eds. *General and applied toxicology*. Vol. 1. New York, NY: Stockton Press, 153-164.
- Leuratti C, Jones NJ, Marafante E, et al. 1993. Biomonitoring of exposure to 1,3-butadiene: Detection by high-performance liquid chromatography and ³²P-postlabelling of an adenine adduct formed by diepoxybutane. In: Sorsa M, Peltonen K, Vainio H, et al., eds. *Butadiene and styrene: Assessment of health hazards*. IARC Scientific Publications No. 127. Lyon, France: International Agency for Research on Cancer, 143-150.
- Lewis DFV, Bird MG, Parke DV. 1997. Molecular modelling of CYP2E1 enzymes from rat, mouse and man: An explanation for species differences in butadiene metabolism and potential carcinogenicity, and rationalization of CYP2E substrate specificity. *Toxicology* 118(2-3):93-113.
- *Lewis RJ. 2007. 1,3-Butadiene. In: Lewis RJ, ed. *Hawley's condensed chemical dictionary*. 5th ed. New York, NY: John Wiley & Sons, Inc., 190.
- *Lide DR. 2008. Physical constants of organic compounds. In: Lide DR, ed. *CRC handbook of chemistry and physics*. 88th ed. New York, NY: CRC Press, 3-72.
- *Lin YS, Smith TJ, Kelsey KT, et al. 2001. Human physiologic factors in respiratory uptake of 1,3-butadiene. *Environ Health Perspect* 109(9):921-926.
- *Lin YS, Smith TJ, Wypij D, et al. 2002. Association of the blood/air partition coefficient of 1,3-butadiene with blood lipids and albumin. *Environ Health Perspect* 110(2):165-168.
- *Liu S, Ao L, Du B, et al. 2008. *HPRT* mutations in lymphocytes from 1,3-butadiene-exposed workers in China. *Environ Health Perspect* 116:203-208.
- *Livingston AL. 1978. Forage plant estrogens. *J Toxicol Environ Health* 4(2-3):301-324.
- *Lofroth G, Burton RM, Forehand L, et al. 1989. Characterization of environmental tobacco smoke. *Environ Sci Technol* 23(5):610-614.
- *Lonneman WA, Namie GR, Bufalini JJ. 1979. Hydrocarbons in Houston air. Research Triangle Park, NC: U.S. Environmental Protection Agency. EPA600379018, 36.

9. REFERENCES

- *Loprieno N, Presciuttini S, Sbrana I, et al. 1978. Mutagenicity of industrial compounds. VII. Styrene and styrene oxide: II. Point mutations, chromosome aberrations and DNA repair induction analyses. *Scand J Work Environ Health* 4:169-178.
- Louw CW, Richards JF, Faure PK. 1977. The determination of volatile organic compounds in city air by gas chromatography combined with standard addition, selective subtraction, infrared spectrometry and mass spectrometry. *Atmos Environ* 11:703-717.
- *Lovreglio P, Bukvic N, Fustinoni S, et al. 2006. Lack of genotoxic effect in workers exposed to very low doses of 1,3-butadiene. *Arch Toxicol* 80(6):378-381.
- *Lunsford RA. 1987. Comments on sampling and analytical method for monitoring low ppm air concentrations of 1,3-butadiene. *Appl Ind Hyg* 2:93-94.
- *Lunsford RA, Gagnon YT. 1987. Use of a backflushable pre-column to maintain the performance of an aluminum oxide porous-layer open-tubular fused silica column for the determination of 1,3-butadiene in air. *J High Resolut Chromatogr* 10:102-104.
- *Lyman WJ, Reehl WF, Rosenblatt DH. 1990. In: *Handbook of chemical property estimation methods*. Washington, DC: American Chemical Society, 15-15 to 15-17.
- *Ma H, Wood TG, Ammenheuser MM, et al. 2000. Molecular analysis of *hprt* mutant lymphocytes from 1,3-butadiene-exposed workers. *Environ Mol Mutagen* 36(1):59-71.
- *Macaluso M, Larson R, Delzell E, et al. 1996. Leukemia and cumulative exposure to butadiene, styrene and benzene among workers in the synthetic rubber industry. *Toxicology* 113(1-3):190-202.
- *Macaluso M, Larson R, Lynch J, et al. 2004. Historical estimation of exposure to 1,3-butadiene, styrene, and dimethyldithiocarbamate among synthetic rubber workers. *J Occup Environ Hyg* 1(6):371-390.
- *Madhusree B, Goto S, Ohkubo T, et al. 2002. Mutagenicity testing of 1,3-butadiene, 1,4-pentadiene-3-ol, isoprene, 2,4-hexadiene, cis- and trans-piperlylene. *J Health Sci* 48(1):73-78.
- Maldotti A, Chiorboli C, Bignozzi CA, et al. 1980. Photooxidation of 1,3-butadiene containing systems rate constant determination for the reaction of acrolein with hydroxyl radicals. *Int J Chem Kinet* 12:905-913.
- *Malvoisin E, Roberfroid M. 1982. Hepatic microsomal metabolism of 1,3-butadiene. *Xenobiotica* 12(2):137-144.
- *Malvoisin E, Lhoest G, Poncelet F, et al. 1979. Identification and quantitation of 1,2-epoxybutene-3 as the primary metabolite of 1,3-butadiene. *J Chromatogr* 178(2):419-425.
- Maniglier-Poulet C, Cheng X, Ruth JA, et al. 1995. Metabolism of 1,3-butadiene to butadiene monoxide in mouse and human bone marrow cells. *Chem Biol Interact* 97(2):119-129.
- *Marshall JD, Granvold PW, Hoats AS, et al. 2006. Inhalation intake of ambient air pollution in California's south coast air basin. *Atmos Environ* 40(23):4381-4392.

9. REFERENCES

- *Matanoski GM, Schwartz L. 1987. Mortality of workers in styrene-butadiene polymer production. *J Occup Med* 29(8):675-680.
- *Matanoski GM, Santos-Burgoa C, Schwartz L. 1988. Mortality of a cohort of workers in the styrene-butadiene polymer manufacturing industry 1943-1982 (final report prepared under contract to International Institute of Synthetic Rubber Producers, Inc.). Baltimore, MD: The Johns Hopkins University, School of Hygiene and Public Health.
- *Matanoski GM, Santos-Burgoa C, Schwartz L. 1990. Mortality of a cohort of workers in the styrene-butadiene polymer manufacturing industry (1943-1982). *Environ Health Perspect* 86:107-117.
- *Matanoski GM, C. S-B, Zeger SL, et al. 1989a. Epidemiologic data related to health effects of 1,3-butadiene. In: Mohn U, ed. *Assessment of inhalation hazards: Integration and extrapolation using diverse data*. New York, NY: Springer-Verlag, 201-214.
- *Matanoski GM, Santos-Burgoa C, Zeger SL, et al. 1989b. Nested case-control study of lymphopoietic cancers in workers in the styrene-butadiene polymer manufacturing industry (final report prepared under contract to International Institute of Synthetic Rubber Producers, Inc.). Baltimore, MD: The Johns Hopkins University, School of Hygiene and Public Health.
- *+Matanoski GM, Schwartz L, Sperrazza J, et al. 1982. Mortality of workers in the styrene-butadiene rubber polymer manufacturing industry. Baltimore, MD: Johns Hopkins University School of Hygiene and Public Health.
- *Mayr U, Butsch A, Schneider S. 1992. Validation of two in vitro test systems for estrogenic activities with zearalenone, phytoestrogens and cereal extracts. *Toxicology* 74(2-3):135-149.
- *MCA. 1974. Chemical safety data sheet SD-55. Properties and essential information for safe handling and use of butadiene. Washington, DC: Manufacturing Chemicals Association.
- *McAuliffe C. 1966. Solubility in water of paraffin, cycloparaffin, olefin, acetylene, cycloolefin, and aromatic hydrocarbons. *J Phys Chem* 7(4):1267-1275.
- *McCarthy MC, Hafner HR, Montzka SA. 2006. Background concentrations of 18 air toxics for North America. *J Air Waste Manag Assoc* 56(1):3-11.
- *McDonald JD, Bechtold WE, Krone JR et al. 2004. Analysis of butadiene urinary metabolites by liquid chromatography-triple quadrupole mass spectrometry. *J Anal Toxicol* 28:168-173.
- +*McMichael AJ, Spirtas R, Gamble JF, et al. 1976. Mortality among rubber workers: Relationship to specific jobs. *J Occup Med* 18:178-185.
- +*McMichael AJ, Spirtas R, Kupper LL. 1974. An epidemiologic study of mortality within a cohort of rubber workers, 1964-1972. *J Occup Med* 16:458-464.
- +*McMichael AJ, Spirtas R, Kupper LL, et al. 1975. Solvent exposure and leukemia among rubber workers: An epidemiologic study. *J Occup Med* 17:234-239.
- *McNeal TP, Breder CV. 1987. Headspace gas chromatographic determination of residual 1,3-butadiene in rubber-modified plastics and its migration from plastic containers into selected foods. *J Assoc Off Anal Chem* 70:18-21.

9. REFERENCES

- +*Meinhardt TJ, Lemen RA, Crandall MS, et al. 1982. Environmental epidemiologic investigation of the styrene-butadiene rubber industry. *Scand J Work Environ Health* 8:250-259.
- Melnick RL, Huff JE. 1993. 1,3-Butadiene induces cancer in experimental animals at all concentrations from 6.25 to 8000 parts per million. In: Sorsa M, Peltonen K, Vainio H, et al., eds. Butadiene and styrene: Assessment of health hazards. IARC Scientific Publications No. 127. Lyon, France: International Agency for Research on Cancer, 309-322.
- *+Melnick R, Huff J, Miller R. 1989. Toxicology and carcinogenicity of 1,3-butadiene. In: Mohn U, ed. Assessment of inhalation hazards: Integration and extrapolation using diverse data. New York, NY: Springer-Verlag, 177-188.
- *Melnick RL, Huff J, Chou BJ, et al. 1990a. Carcinogenicity of 1,3-butadiene in C57BL/6 x C3H F1 mice at low exposure concentrations. *Cancer Res* 50(20):6592-6599.
- Melnick RL, Huff JE, Haseman JK, et al. 1988. Chronic toxicity results and ongoing studies of 1,3-butadiene by the National Toxicology Program. *Ann N Y Acad Sci* 534:648-662.
- *Melnick RL, Huff JE, Roycroft JH, et al. 1990b. Inhalation toxicology and carcinogenicity of 1,3-butadiene in B6C3F1 mice following 65 weeks of exposure. *Environ Health Perspect* 86:27-36.
- *Meng Q, Henderson RF, Chen T, et al. 1999. Mutagenicity of 1,3-butadiene at the *Hprt* locus of T-lymphocytes following inhalation exposures of female mice and rats. *Mutat Res* 429(1):107-125.
- *Meng Q, Singh N, Heflich RH, et al. 2000. Comparison of the mutations at *Hprt* exon 3 of T-lymphocytes from B6C3F1 mice and F344 rats exposed by inhalation to 1,3-butadiene or the racemic mixture of 1,2:3,4-diepoxybutane. *Mutat Res* 464(2):169-184.
- *Meng Q, Walker DM, McDonald JD, et al. 2007. Age-, gender-, and species-dependent mutagenicity in T cells of mice and rats exposed by inhalation to 1,3-butadiene. *Chem Biol Interact* 166(1-3):121-131.
- *Meng Q, Walker DM, Scott BR, et al. 2004. Characterization of *Hprt* mutations in cDNA and genomic DNA of T-cell mutants from control and 1,3-butadiene-exposed male B6C3F1 mice and F344 rats. *Environ Mol Mutagen* 43(2):75-92.
- *Miller LM. 1978. Investigation of selected potential environmental contaminants: Butadiene and its oligomers. Washington, DC: U.S. Environmental Protection Agency, Office of Toxic Substances. EPA560278008. PB291684.
- Moller P, Knudsen LE, Loft S, et al. 2000. The comet assay as a rapid test in biomonitoring occupational exposure to DNA-damaging agents and effect of confounding factors. *Cancer Epidemiol Biomarkers Prev* 9(10):1005-1015.
- *+Morrissey RE, Schwetz BA, Hackett PL, et al. 1990. Overview of reproductive and developmental toxicity studies of 1,3-butadiene in rodents. *Environ Health Perspect* 86:79-84.
- *Morselli PL, Franco-Morselli R, Bossi L. 1980. Clinical pharmacokinetics in newborns and infants: Age-related differences and therapeutic implications. *Clin Pharmacokinet* 5(6):485-527.

9. REFERENCES

- *NAS/NRC. 1989. Report of the oversight committee. Washington, DC: National Academy of Sciences, National Research Council, National Academy Press. Biologic markers in reproductive toxicology.
- *Nazaroff WW, Singer BC. 2004. Inhalation of hazardous air pollutants from environmental tobacco smoke in U.S. residences. *J Expo Anal Environ Epidemiol* 14(Suppl 1):S71-S77.
- *Neligan RE. 1962. Hydrocarbons in the Los Angeles atmosphere. *Arch Environ Health* 5:581-591.
- Niki H, Maker PD, Savage CM, et al. 1983. Atmospheric ozone-olefin reactions. *Environ Sci Technol* 17:312A-322A.
- NIOSH. 1987. NIOSH manual of analytical methods, 3rd ed, 2nd suppl. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control, National Institute for Occupational Safety and Health. NIOSH Publication No. 87-117.
- *NIOSH. 1989. National Occupational Exposure Survey (NOES). Cincinnati, OH: U.S. Department of Health and Human Services CfDC, National Institute for Occupational Safety and Health.
- *NIOSH. 1994. NIOSH Manual of analytical methods. 1,3-Butadiene. Method 1024. <http://www.cdc.gov/NIOSH/nmam/pdfs/1024.pdf>. June 1, 2009.
- *NIOSH. 2005. 1,3-Butadiene. In: NIOSH pocket guide to chemical hazards. Atlanta, GA: National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, <http://www.cdc.gov/niosh/npg/>. May 19, 2009.
- Nip WS, Singleton DL, Cvetanovic RJ. 1979. Temperature dependence of rate constants for reaction of oxygen atoms, O(3P) with allene and 1,3-butadiene. *Can J Chem* 57:949-952.
- NITE. 2002. Biodegradation and bioconcentration of existing chemical substances under the chemical substances control law. National Institute of Technology and Evaluation. http://www.safe.nite.go.jp/data/hazkizon/pk_e_kizon_data_result.home_data. June 1, 2009.
- Norppa H, Sorsa M. 1993. Genetic toxicity of 1,3-butadiene and styrene. In: Sorsa M, Peltonen K, Vainio H, et al., eds. Butadiene and styrene: Assessment of health hazards. IARC Scientific Publications No. 127. Lyon, France: International Agency for Research on Cancer, 185-193.
- *Norppa H, Sorsa M, Vainio H. 1980. Chromosomal aberrations in bone marrow of Chinese hamsters exposed to styrene and ethanol. *Toxicol Lett* 5:241-244.
- *NRC. 1993. Pesticides in the diets of infants and children. Washington, DC: National Research Council. National Academy Press.
- +*NTP. 1984. NTP toxicology and carcinogenesis studies of 1,3-butadiene (CAS No. 106-99-0) in B6C3F1 mice (inhalation studies). Research Triangle Park, NC: National Toxicology Program.
- +*NTP. 1993. NTP technical report on the toxicology and carcinogenesis studies of 1,3-butadiene (CAS No. 106-99-0) in B6C3F1 mice (inhalation studies). Research Triangle Park, NC: National Toxicology Program. NTP TR 434.

9. REFERENCES

- *NTP. 2005. 1,3-Butadiene. In: Report on carcinogens. 11th ed. Research Triangle Park, NC: National Toxicology Program, <http://ntp-server.niehs.nih.gov/ntp/roc/eleventh/profiles/s025buta.pdf>. May 19, 2009.
- Oe T, Kambouris SJ, Walker VE, et al. 1999. Persistence of N7-(2,3,4-trihydroxybutyl)guanine adducts in the livers of mice and rats exposed to 1,3-butadiene. *Chem Res Toxicol* 12(3):247-257.
- *Oguz O, Karman D, Tuncel G. 2003. Measurement of traffic related toxic air pollutants in an urban atmosphere. *Water Air Soil Pollut Focus*. 3:175-192.
- *O Neil MJ, Heckelman PE, Koch CB, et al. 2006. 1,3-Butadiene. In: O Neil MJ, Heckelman PE, Koch CB, et al., eds. Merck index. 14th ed. Whitehouse Station, NY: Merck & Co, Inc., 248.
- *OSHA. 2009a. 1,3-Butadiene. Occupational Safety & Health Administration. <http://www.osha.gov/dts/sltc/methods/organic/org056/org056.html>. June 2, 2009.
- *OSHA. 2009b. Toxic and Hazardous Substances. Occupational safety and health standards. Occupational Safety and Health Administration. Code of Federal Regulations. 29 CFR 1910.1051. <http://www.osha.gov/comp-links.html>. May 29, 2009.
- *Osterman-Golkar S, Peltonen K, Anttinen-Klemetti T, et al. 1996. Haemoglobin adducts as biomarkers of occupational exposure to 1,3-butadiene. *Mutagenesis* 11(2):145-149.
- Osterman-Golkar SM, Bond JA, Ward JB, Jr., et al. 1993. Use of hemoglobin adducts for biomonitoring exposure to 1,3-butadiene. In: Sorsa M, Peltonen K, Vainio H, et al., eds. Butadiene and styrene: Assessment of health hazards. IARC Scientific Publications No. 127. Lyon, France: International Agency for Research on Cancer, 127-134.
- Osterman-Golkar SM, Moss O, James A, et al. 1998. Epoxybutene-hemoglobin adducts in rats and mice: Dose response for formation and persistence during and following long-term low-level exposure to butadiene. *Toxicol Appl Pharmacol* 150(1):166-173.
- OTA. 1990. Neurotoxicity: Identifying and controlling poisons of the nervous system. Washington, DC: Office of Technology Assessment.
- *Owen GM, Brozek J. 1966. Influence of age, sex and nutrition on body composition during childhood and adolescence. In: Falkner F, ed. Human development. Philadelphia, PA: WB Saunders, 222-238.
- +*Owen PE, Glaister JR. 1990. Inhalation toxicity and carcinogenicity of 1,3-butadiene in Sprague-Dawley rats. *Environ Health Perspect* 86:19-25.
- +*Owen PE, Glaister JR, Gaunt IF, et al. 1987. Inhalation toxicity studies with 1,3-butadiene 3 two year toxicity/carcinogenicity study in rats. *Am Ind Hyg Assoc J* 48(5):407-413.
- +Pacchierotti F, Tiveron C, Ranaldi R, et al. 1998. Reproductive toxicity of 1,3-butadiene in the mouse: Cytogenetic analysis of chromosome aberrations in first-cleavage embryos and flow cytometric evaluation of spermatogonial cell killing. *Mutat Res* 397(1):55-66.
- *Pankow JF, Luo W, Tavakoli AD, et al. 2004. Delivery levels and behavior of 1,3-butadiene, acrylonitrile, benzene, and other toxic volatile organic compounds in mainstream tobacco smoke from two brands of commercial cigarettes. *Chem Res Toxicol* 17(6):805-813.

9. REFERENCES

- *Pankow JF, Watanabe KH, Toccalino PL, et al. 2007. Calculated cancer risks for conventional and "potentially reduced exposure product" cigarettes. *Cancer Epidemiol Biomarkers Prev* 16(3):584-592.
- *Patel RN, Hou CT, Laskin AI, et al. 1979. Microbial oxidation of gaseous hydrocarbons. II. Hydroxylation of alkanes and epoxidation of alkenes by cell-free particulate fractions of methane-utilizing bacteria. *J Bacteriol* 139:675-679.
- *Patel RN, Hou CT, Laskin AI. 1982a. Oxidation of gaseous hydrocarbons and related compounds by methanotrophic organisms. In: *Developments in industrial microbiology*, Vol. 23, 187-205.
- *Patel RN, Hou CT, Laskin AI, et al. 1982b. Microbial oxidation of hydrocarbons: Properties of a soluble methane monooxygenase from a facultative methane utilizing organism *Methlobacterium* sp. strain CRL-26. *Appl Environ Microbiol* 44(5):1130-1137.
- *Pellizzari ED, Michael LC, Thomas KW, et al. 1995. Identification of 1,3-butadiene, benzene, and other volatile organics from wok oil emissions. *J Expo Anal Environ Epidemiol* 5(1):77-87.
- Peltonen K, Koivisto P, Neagu I, et al. 1993. Estimating internal dose of 1,3-butadiene: Preliminary data on use of modified purine bases as markers of exposure. In: Sorsa M, Peltonen K, Vainio H, et al., eds. *Butadiene and styrene: Assessment of health hazards*. IARC Scientific Publications No. 127. Lyon, France: International Agency for Research on Cancer, 119-126.
- *Penn A, Snyder CA. 2007. 1,3-Butadiene exposure and cardiovascular disease. *Mutat Res* 621(1-2):42-49.
- *Perbellini L, Princivale A, Carpelloni M, et al. 2003. Comparison of breath, blood and urine concentrations in the biomonitoring of environmental exposure to 1,3-butadiene, 2,5-dimethylfuran, and benzene. *Int Arch Occup Environ Health* 76(6):461-466.
- *Pohlova H, Rossner P, Sram RJ. 1985. Cytogenetic analysis of human peripheral blood lymphocytes in culture exposed in vitro to styrene and styrene oxide. *J Hyg Epidemiol Microbiol Immunol* 29:269-274.
- *Preston RJ. 2007. Cancer risk assessment for 1,3-butadiene: Data integration opportunities. *Chem Biol Interact* 166(1-3):150-155.
- Przygoda RT, Bird MG, Whitman FT, et al. 1993. Induction of micronuclei in mice and hamsters by 1,3-butadiene [Abstract]. *Environ Mol Mutagen* 21(Suppl 22):56.
- Recio L, Bond JA, Pluta LJ, et al. 1993. Use of transgenic mice for assessing the mutagenicity of 1,3-butadiene *in vivo*. In: Sorsa M, Peltonen K, Vainio H, et al., eds. *Butadiene and styrene: Assessment of health hazards*. IARC Scientific Publications No. 127. Lyon, France: International Agency for Research on Cancer, 235-243.
- *Recio L, Osterman-Golkar S, Csanady GA, et al. 1992. Determination of mutagenicity in tissues of transgenic mice following exposure to 1,3-butadiene and N-ethyl-N-nitrosourea. *Toxicol Appl Pharmacol* 117(1):58-64.
- *Reiss R. 2006. Temporal trends and weekend-weekday differences for benzene and 1,3-butadiene in Houston, Texas. *Atmos Environ* 40(25):4711-4724.

9. REFERENCES

- *Reiss R, Griffin J. 2004. Exploratory data analysis of benzene and 1,3-butadiene measurements for air toxics risk assessment in Houston. Alpharetta, GA: Coordinating Research Council.
- *Reynolds P, Von Behren J, Gunier RB, et al. 2003. Childhood cancer incidence rates and hazardous air pollutants in California: An exploratory analysis. *Environ Health Perspect* 111(4):663-668.
- Richardson KA, Megens HJ, Webb JD, et al. 1996. Biological monitoring of butadiene exposure by measurement of haemoglobin adducts. *Toxicology* 113(1-3):112-118.
- Richardson KA, Peters MM, Wong BA, et al. 1999. Quantitative and qualitative differences in the metabolism of 14C-1,3-butadiene in rats and mice: Relevance to cancer susceptibility. *Toxicol Sci* 49(2):186-201.
- Rigby LJ. 1981. The collection and identification of toxic volatiles from plastics under thermal stress. *Ann Occup Hyg* 24:331-346.
- Rosenbaum AS, Axelrad DA, Woodruff TJ, et al. 1999. National estimates of outdoor air toxics concentrations. *J Air Waste Manage Assoc* 49:1138-1152.
- Rossner P, Sram RJ, Bavorova H, et al. 2001. Chromosomal aberrations in the occupationally exposed groups in the Czech Republic [Abstract]. *Mutat Res* 483(Suppl 1):S155-S156.
- Sabourin PJ, Burka LT, Dahl AR, et al. 1991. Species differences in metabolism of inhaled butadiene [Abstract]. *Toxicologist* 11(1):88.
- Salazar JJ, Ballinger SW, Postlethwait EM, et al. 2002. 1,3-butadiene and its metabolites-induced DNA damage in human and mouse cells. *Environ Mol Mutagen* 39(Suppl 33):54.
- *Sandmeyer EE. 1981. Aliphatic hydrocarbons: Butadiene. In: Clayton GD, Clayton FE, eds. *Patty's industrial hygiene and toxicology*, Vol. 2B, 3rd revised ed. New York, NY: John Wiley and Sons.
- *Santos-Burgoa C, Matanoski GM, Zeger S, et al. 1992. Lymphohematopoietic cancer in styrene-butadiene polymerization workers. *Am J Epidemiol* 136(7):843-854.
- *Sapkota A, Buckley TJ. 2003. The mobile source effect on curbside 1,3-butadiene, benzene, and particle-bound polycyclic aromatic hydrocarbons assessed at a tollbooth. *J Air Waste Manag Assoc* 53(6):740-748.
- *Sapkota A, Halden RU, Dominici F, et al. 2006. Urinary biomarkers of 1,3-butadiene in environmental settings using liquid chromatography isotope dilution tandem mass spectrometry. *Chem Biol Interact* 160(1):70-79.
- *Sasiadek M, Jarventaus H, Sorsa M. 1991. Sister-chromatid exchanges induced by 1,3-butadiene and its epoxides in CHO cells. *Mutat Res* 263(1):47-50.
- *Sathiakumar N, Delzell E. 2007. A follow-up study of women in the synthetic rubber industry: Study methods. *Chem Biol Interact* 166:25-28.
- *Sathiakumar N, Delzell E, Cheng H, et al. 2007. Validation of 1,3-butadiene exposure estimates for workers at a synthetic rubber plant. *Chem Biol Interact* 166(1-3):29-43.

9. REFERENCES

- *Sax SI, Bennett DH, Chillrud SN, et al. 2004. Differences in source emission rates of volatile organic compounds in inner-city residences of New York City and Los Angeles. *J Expo Anal Environ Epidemiol* 14(Suppl 1):S95-S109.
- *Schettgen T, Musiol A, Alt A, et al. 2009. A method for the quantification of biomarkers of exposure to acrylonitrile and 1,3-butadiene in human urine by column-switching liquid chromatography-tandem mass spectrometry. *Anal Bioanal Chem* 393(3):969-981.
- *Schmidt V, Loeser E. 1985. Species differences in the formation of butadiene monoxide from 1,3-butadiene. *Arch Toxicol* 57:222-225.
- *Schmidt V, Loeser E. 1986. Epoxidation of 1,3-butadiene in liver and lung tissue of mouse, rat, monkey and man. *Adv Exp Med Biol* 197:951-957.
- Scott D. 1993. Cytogenetic studies of workers exposed to styrene: A review. In: Sorsa M, Peltonen K, Vainio H, et al., eds. *Butadiene and styrene: Assessment of health hazards*. IARC Scientific Publications No. 127. Lyon, France: International Agency for Research on Cancer, 275-286.
- Seaton MJ, Follansbee MH, Bond JA. 1995. Oxidation of 1,2-epoxy-3-butene to 1,2:3,4-diepoxybutane by cDNA-expressed human cytochromes P450 2E1 and 3A4 and human, mouse and rat liver microsomes. *Carcinogenesis* 16(10):2287-2293.
- Seaton MJ, Plopper CG, Bond JA. 1996. 1,3-Butadiene metabolism by lung airways isolated from mice and rats. *Toxicology* 113(1-3):314-317.
- Setchell BP, Waites GMH. 1975. The blood testis barrier. In: Creep RO, Astwood EB, Geiger SR, eds. *Handbook of physiology: Endocrinology V*. Washington, DC: American Physiological Society, 143-172.
- Sexton KG, Doyle ML, Jeffries HE, et al. 2007. Development and testing of a chemical mechanism for atmospheric photochemical transformations of 1,3-butadiene. *Chem Biol Interact* 166(1-3):156-162.
- *Sharief Y, Brown AM, Backer LC, et al. 1986. Sister chromatid exchange and chromosome aberration analyses in mice after in vivo exposure to acrylonitrile, styrene, or butadiene monoxide. *Environ Mutagen* 8:439-448.
- *Shen S, Zhang F, Zeng S, et al. 2009. An approach based on liquid chromatography/electrospray ionization-mass spectrometry to detect diol metabolites as biomarkers of exposure to styrene and 1,3-butadiene. *Anal Biochem* 386(2):186-193.
- +*Shugaev BB. 1969. Concentrations of hydrocarbons in tissues as a measure of toxicity. *Arch Environ Health* 18:878-882.
- Sielken RL, Reitz RH, Hays SM. 1996. Using PBPK modeling and comprehensive realism methodology for the quantitative cancer risk assessment of butadiene. *Toxicology* 113(1-3):231-237.
- *Sigsby JEJ, Tejada S, Ray W. 1987. Volatile organic compound emissions from 46 in-use passenger cars. *Environ Sci Technol* 21:466-475.

9. REFERENCES

- *Sills RC, Hong HL, Boorman GA, et al. 2001. Point mutations of K-ras and H-ras genes in forestomach neoplasms from control B6C3F1 mice and following exposure to 1,3-butadiene, isoprene or chloroprene for up to 2-years. *Chem Biol Interact* 135-136:373-386.
- Smith CJ, Morton MJ, Brown BG, et al. 2004. Individual variations in cigarette mainstream smoke biomarkers of exposure [Abstract]. *Toxicologist* 78(1-S):256.
- *Smith TJ, Lin YS, Mezzetti M, et al. 2001. Genetic and dietary factors affecting human metabolism of 1,3-butadiene. *Chem Biol Interact* 135-136:407-428.
- Sorsa M, Autio K, Demopoulos NA, et al. 1994. Human cytogenetic biomonitoring of occupational exposure to 1,3-butadiene. *Mutat Res* 309(2):321-326.
- *Sorsa M, Osterman-Golkar S, Peltonen K, et al. 1996. Assessment of exposure to butadiene in the process industry [Abstract]. *Toxicology* 113(1-3):77-83.
- Sorsa M, Peltonen K, Vainio H, et al., eds. 1993. Butadiene and styrene: Assessment of health hazards. IARC Scientific Publications No. 127. Lyon, France: International Agency for Research on Cancer, 253-263.
- *Sram RJ, Rossner P, Peltonen K, et al. 1998. Chromosomal aberrations, sister-chromatid exchanges, cells with high frequency of SCE, micronuclei and comet assay parameters in 1, 3-butadiene-exposed workers. *Mutat Res* 419(1-3):145-154.
- Sram RJ, Rossner P, Rubes J, et al. 1999. Biomarker responses in butadiene exposed Czech workers. II. Cytogenetic analysis [Abstract]. *Environ Mol Mutagen* 33(Suppl 33):60.
- *SRI. 2008. 1,3-Butadiene. In: 2008 Directory of chemical producers. Menlo Park, CA: SRI Consulting, 457-458.
- *Startin JR, Gilbert J. 1984. Single ion monitoring of butadiene in plastics and foods by coupled mass spectrometry — automatic head-space gas chromatography. *J Chromatogr* 294:427-430.
- Stephens EA, Taylor JA, Kaplan N, et al. 1994. Ethnic variation in the CYP2E1 gene: Polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. *Pharmacogenetics*. 4(4):185-192.
- *Stephens ER, Burleson F. 1967. Analysis of the atmosphere for light hydrocarbons. *J Air Pollut Control Assoc* 17:147-153.
- *Stephens ER, Burleson FR. 1969. Distribution of light hydrocarbons in ambient air. *J Air Pollut Control Assoc* 19:929-936.
- *Stump FD, Dropkin DL. 1985. Gas chromatographic method for quantitative determination of C2 to C13 hydrocarbons in roadway vehicle emissions. *Anal Chem* 57:2629-2634.
- *Stump FD, Tejada S, Ray W, et al. 1989. The influence of ambient temperature on tailpipe emissions from 1984-1987 model year light duty gasoline motor vehicles. *Atmos Environ* 23:307-320.
- *Stutz DR, Janusz SJ. 1988. Hazardous materials injuries. A handbook for pre-hospital care 2nd ed. Beltsville, MD: Bradford Communication Corporation, 296-297.

9. REFERENCES

- *Sun HN, Wristers JP. 2002. Butadiene. In: Kirk-Othmer encyclopedia of chemical technology. New York, NY: John Wiley & Sons, 365-392.
<http://mrw.interscience.wiley.com/emrw/9780471238966/kirk/article/butasun.a01/current/pdf>. June 2, 2009.
- *Sun JD, Dahl AR, Bond JA, et al. 1989a. Metabolism of inhaled butadiene to monkeys: Comparison to rodents. *Exp Pathol* 37:133-135.
- *Sun JD, Dahl AR, Bond JA, et al. 1989b. Characterization of hemoglobin adduct formation in mice and rats after administration of [¹⁴C]butadiene or [¹⁴C]isoprene. *Toxicol Appl Pharmacol* 100:86-95.
- Swann R, Laskowski DA, McCall PJ, et al. 1983. A rapid method for the estimation of the environmental parameters octanol/water partition coefficient, soil sorption constant, water to air ratio, and water solubility. *Residue Rev* 85:17-28.
- Sweeney LM, Himmelstein MW, Gargas ML. 2001. Development of a preliminary physiologically based toxicokinetic (PBTk) model for 1,3-butadiene risk assessment. *Chem Biol Interact* 135-136:303-322.
- Sweeney LM, Himmelstein MW, Schlosser PM, et al. 1996. Physiologically based pharmacokinetic modeling of blood and tissue epoxide measurements for butadiene. *Toxicology* 113(1-3):318-321.
- *Tates AD, van Dam FJ, de Zwart FA, et al. 1996. Biological effect monitoring in industrial workers from the Czech Republic exposed to low levels of butadiene [Abstract]. *Toxicology* 113(1-3):91-99.
- *Texas Air Control Board. 1990. Written communication to Bill Henriques, Agency for Toxic Substances and Disease Registry, regarding 1,3-butadiene concentrations in air. Texas Air Control Board, Austin, TX.
- Thom NG, Agg AR. 1975. The breakdown of synthetic organic compounds in biological processes. *Proc R Soc Lond B Biol Sci* 189:347-357.
- *Thomas K, Colborn T. 1992. Organochlorine endocrine disruptors in human tissue. In: Colborn T, Clement C, eds. *Chemically induced alterations in sexual and functional development: The wildlife/human connection*. Princeton, NJ: Princeton Scientific Publishing, 365-394.
- *Thornton-Manning JR, Dahl AR, Bechtold WE, et al. 1995. Gender differences in the metabolism of 1,3-butadiene in Sprague-Dawley rats following a low level inhalation exposure. *Carcinogenesis* 16(11):2875-2878.
- *Thornton-Manning JR, Dahl AR, Bechtold WE, et al. 1997. Comparison of the disposition of butadiene epoxides in Sprague-Dawley rats and B6C3F1 mice following a single and repeated exposures to 1,3-butadiene via inhalation. *Toxicology* 123(1-2):125-134.
- +*Thurmond LM, Lauer LD, House RV, et al. 1986. Effect of short-term inhalation exposure to 1,3-butadiene on murine immune functions. *Toxicol Appl Pharmacol* 86(2):170-179.
- *Thweatt WD, Harward CN, Sr., Parrish ME. 2007. Measurement of acrolein and 1,3-butadiene in a single puff of cigarette smoke using lead-salt tunable diode laser infrared spectroscopy. *Spectrochim Acta A Mol Biomol Spectrosc* 67(1):16-24.

9. REFERENCES

- *Tice RR. 1988. The cytogenetic evaluation of in vivo genotoxic and cytotoxic activity using rodent somatic cells. *Cell Biol Toxicol* 4(4):475-486.
- *Tice RR, Boucher R, Luke CA, et al. 1987. Comparative cytogenic analysis of bone marrow damage induced in male B6C3F1 mice by multiple exposures to gaseous 1,3-butadiene. *Environ Mutagen* 9:235-250.
- *Tommasi AM, de Conti S, Dobrzynska MM, et al. 1998. Evaluation and characterization of micronuclei in early spermatids of mice exposed to 1,3-butadiene. *Mutat Res* 397(1):45-54.
- *TRI07. 2009. TRI explorer: Providing access to EPA's toxics release inventory data. Washington, DC: Office of Information Analysis and Access. Office of Environmental Information. U.S. Environmental Protection Agency. Toxics Release Inventory. <http://www.epa.gov/triexplorer/>. April 7, 2009
- *Tsai SP, Ahmed FS, Ransdell JD, et al. 2005. A hematology surveillance study of petrochemical workers exposed to 1,3 butadiene. *J Occup Environ Hyg* 2(10):508-515.
- *Tsai SP, Wendt JK, Ransdell JD. 2001. A mortality, morbidity, and hematology study of petrochemical employees potentially exposed to 1,3-butadiene monomer. *Chem Biol Interact* 135-136:555-567.
- Upton PB, Ranasinghe A, Meng Q, et al. 2001. Dose-response relationship of hemoglobin adducts in female rats and mice exposed to 1,3-butadiene. *Environ Mol Mutagen* 37(Suppl 32):76.
- *Vainiotalo S, Vaananen V, Vaaranrinta R. 2008. Measurement of 16 volatile organic compounds in restaurant air contaminated with environmental tobacco smoke. *Environ Res* 108(3):280-288.
- Van Duuren BL, Nelson N, Orris L, et al. 1963. Carcinogenicity of epoxides, lactones and peroxy compounds. *J Natl Cancer Inst* 31:41-55.
- *VanGinkel CG, Welten HGJ, Debont JAM. 1987. Oxidation of gaseous and volatile hydrocarbons by selected alkene-utilizing bacteria. *Appl Environ Microbiol* 53:2903-2907.
- *Victorin K, Stahlberg M. 1988. A method for studying the mutagenicity of some gaseous compounds in *Salmonella typhimurium*. *Environ Mol Mutagen* 11(1):65-77.
- *Vieira I, Sonnier M, Cresteil T. 1996. Developmental expression of CYP2E1 in the human liver: Hypermethylation control of gene expression during the neonatal period. *Eur J Biochem* 238(2):476-483.
- *Vodicka P, Stetina R, Smerak P, et al. 2006. Micronuclei, DNA single-strand breaks and DNA-repair activity in mice exposed to 1,3-butadiene by inhalation. *Mutat Res* 608(1):49-57.
- Vodickova L, Frantik E, Hornycyhova M, et al. 2003. Developmental toxicity of 1,2-dibromoethane and 1,3-butadiene after inhalation exposure of pregnant rats. *Toxicol Lett* 144(Suppl 1):0378-4274.
- Walker D, Henderson R, McDonald J, et al. 2003. Analysis of plasma and urine for metabolites following inhalation exposure of female and male mice and rats to 1,3-butadiene or 1,2-dihydroxy-3-butene [Abstract]. *Toxicol Sci* 72(S-1):242.

9. REFERENCES

- *Ward EM, Fajen JM, Ruder AM, et al. 1995. Mortality study of workers in 1,3-butadiene production units identified from a chemical workers cohort. *Environ Health Perspect* 103(6):598-603
- *Ward JB, Ammenheuser MM, Bechtold WE, et al. 1994. *hprt* mutant lymphocyte frequencies in workers at a 1,3-butadiene production plant. *Environ Health Perspect* 102(Suppl 9):79-85.
- *Ward JB, Ammenheuser MM, Whorton EB, et al. 1996. Biological monitoring for mutagenic effects of occupational exposure to butadiene. *Toxicology* 110:1-7.
- *Ward JB, Abdel-Rahman SZ, Henderson RF, et al. 2001. Assessment of butadiene exposure in synthetic rubber manufacturing workers in Texas using frequencies of *hprt* mutant lymphocytes as a biomarker. *Chem Biol Interact* 135-136:465-483.
- *Watabe T, Isobe M, Sawahata T, et al. 1978. Metabolism and mutagenicity of styrene. *Scand J Work Environ Health* 4(Suppl 2):142-155.
- *Watkinson RJ, Somerville HJ. 1976. The microbial utilization of butadiene. In: Sharpley JM, Kaplan AM, eds., *Proceedings of the Third International Biodegradation Symposium* London: Applied Science Publishers, 35-42.
- *West JR, Smith HW, Chasis H. 1948. Glomerular filtration rate, effective renal blood flow, and maximal tubular excretory capacity in infancy. *J Pediatr* 32:10-18.
- *Whitworth KW, Symanski E, Coker AL. 2008. Childhood lymphohematopoietic cancer incidence and hazardous air pollutants in Southeast Texas, 1995-2004. *Environ Health Perspect* 116:1576-1580.
- *WHO. 2000. Air quality guidelines. 2nd edition. Geneva, Switzerland: World Health Organization. http://www.euro.who.int/air/activities/20050223_4. May 11, 2009.
- WHO. 2001. 1,3,-Butadiene: Human health aspects. Concise international chemical assessment document 30. World Health Organization. <http://www.who.int/ipcs/publications/cicad/en/cicad30.pdf>. June 2, 2009.
- *WHO. 2006. Guidelines for drinking-water quality. 3rd edition. Geneva, Switzerland: World Health Organization. http://www.who.int/water_sanitation_health/dwq/gdwq3/en/. May 11, 2009.
- *Wickliffe JK, Ammenheuser MM, Adler PJ, et al. 2009. Evaluation of frequencies of *HPRT* mutant lymphocytes in butadiene polymer workers in a Southeast Texas facility. *Environ Mol Mutagen* 50(2):82-87.
- Wickliffe JK, Ammenheuser MM, Hastings-Smith DA, et al. 2003a. A model of sensitivity: 1,3-Butadiene induces *HPRT* mutants in mice lacking microsomal epoxide hydrolase activity [Abstract]. *Environ Mol Mutagen* 41(3):213.
- Wickliffe JK, Ammenheuser MM, Salazar JJ, et al. 2003b. A model of sensitivity: 1,3-Butadiene increases mutant frequencies and genomic damage in mice lacking a functional microsomal epoxide hydrolase gene. *Environ Mol Mutagen* 42(2):106-110.
- *Widdowson EM, Dickerson JWT. 1964. Chemical composition of the body. In: Comar CL, Bronner F, eds. *Mineral metabolism: An advance treatise. Volume II: The elements Part A.* New York, NY: Academic Press, 1-247.

9. REFERENCES

- *Wilson RH. 1944. Health hazards encountered in the manufacture of synthetic rubber. *J Am Med Assoc* 124(11):701-703.
- Xi L, Zhang L, Wang Y, et al. 1997. Induction of chromosome-specific aneuploidy and micronuclei in human lymphocytes by metabolites of 1,3-butadiene. *Carcinogenesis* 18(9):1687-1693.
- *Xiao Y, Tates AD. 1995. Clastogenic effects of 1,3-butadiene and its metabolites 1,2-epoxybutene and 1,2,3,4-diepoxybutane in splenocytes and germ cells of rats and mice *in vivo*. *Environ Mol Mutagen* 26(2):97-108.
- *Zhao C, Vodicka P, Sram RJ, et al. 2000. Human DNA adducts of 1,3-butadiene, an important environmental carcinogen. *Carcinogenesis* 21(1):107-111.
- *Zhao C, Vodicka P, Sram RJ, et al. 2001. DNA adducts of 1,3-butadiene in humans: Relationships to exposure, GST genotypes, single-strand breaks, and cytogenetic end points. *Environ Mol Mutagen* 37(3):226-230.
- *Zhou XT, Li LR, Cui MY, et al. 1986. Cytogenetic monitoring of petrochemical workers [Abstract]. *Mutat Res* 175(4):237-242.
- *Zhuang SM, Cochran C, Goodrow T, et al. 1997. Genetic alterations of p53 and ras genes in 1,3-butadiene- and 2',3'-dideoxycytidine-induced lymphomas. *Cancer Res* 57(13):2710-2714.
- Zhuang SM, Wiseman RW, Soderkvist P. 2002. Frequent mutations of the Trp53, Hras1 and beta-catenin (Catnb) genes in 1,3-butadiene-induced mammary adenocarcinomas in B6C3F1 mice. *Oncogene* 21(36):5643-5648.
- *Ziegler EE, Edwards BB, Jensen RL, et al. 1978. Absorption and retention of lead by infants. *Pediatr Res* 12(1):29-34.

10. GLOSSARY

Absorption—The taking up of liquids by solids, or of gases by solids or liquids.

Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the Toxicological Profiles.

Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the surfaces of solid bodies or liquids with which they are in contact.

Adsorption Coefficient (K_{oc})—The ratio of the amount of a chemical adsorbed per unit weight of organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.

Adsorption Ratio (K_d)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or sediment.

Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a specified magnitude of changes in a specified adverse response. For example, a BMD_{10} would be the dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 10%. The BMD is determined by modeling the dose response curve in the region of the dose response relationship where biologically observable data are feasible.

Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological or epidemiological data to calculate a BMD.

Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms at a specific time or during a discrete time period of exposure divided by the concentration in the surrounding water at the same time or during the same period.

Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have been classified as markers of exposure, markers of effect, and markers of susceptibility.

Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces significant increases in the incidence of cancer (or tumors) between the exposed population and its appropriate control.

Carcinogen—A chemical capable of inducing cancer.

Case-Control Study—A type of epidemiological study that examines the relationship between a particular outcome (disease or condition) and a variety of potential causative agents (such as toxic chemicals). In a case-controlled study, a group of people with a specified and well-defined outcome is identified and compared to a similar group of people without outcome.

Case Report—Describes a single individual with a particular disease or exposure. These may suggest some potential topics for scientific research, but are not actual research studies.

Case Series—Describes the experience of a small number of individuals with the same disease or exposure. These may suggest potential topics for scientific research, but are not actual research studies.

10. GLOSSARY

Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.

Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological Profiles.

Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are followed forward from exposure to outcome. At least one exposed group is compared to one unexposed group.

Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines the relationship between exposure and outcome to a chemical or to chemicals at one point in time.

Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human health assessment.

Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result from exposure to a chemical prior to conception (either parent), during prenatal development, or postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point in the life span of the organism.

Dose-Response Relationship—The quantitative relationship between the amount of exposure to a toxicant and the incidence of the adverse effects.

Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to a chemical; the distinguishing feature between the two terms is the stage of development during which the insult occurs. The terms, as used here, include malformations and variations, altered growth, and *in utero* death.

Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water levels for a chemical substance based on health effects information. A health advisory is not a legally enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.

Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of disease or other health-related conditions within a defined human population during a specified period.

Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific alteration of the molecular structure of the genome.

Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from the body or environmental media.

Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or irreversible health effects.

Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from exposure to environmental agents such as chemicals.

10. GLOSSARY

Immunological Effects—Functional changes in the immune response.

Incidence—The ratio of individuals in a population who develop a specified condition to the total number of individuals in that population who could have developed that condition in a specified time period.

Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the Toxicological Profiles.

In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.

In Vivo—Occurring within the living organism.

Lethal Concentration_(LO) (LC_{LO})—The lowest concentration of a chemical in air that has been reported to have caused death in humans or animals.

Lethal Concentration₍₅₀₎ (LC₅₀)—A calculated concentration of a chemical in air to which exposure for a specific length of time is expected to cause death in 50% of a defined experimental animal population.

Lethal Dose_(LO) (LD_{LO})—The lowest dose of a chemical introduced by a route other than inhalation that has been reported to have caused death in humans or animals.

Lethal Dose₍₅₀₎ (LD₅₀)—The dose of a chemical that has been calculated to cause death in 50% of a defined experimental animal population.

Lethal Time₍₅₀₎ (LT₅₀)—A calculated period of time within which a specific concentration of a chemical is expected to cause death in 50% of a defined experimental animal population.

Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, or group of studies, that produces statistically or biologically significant increases in frequency or severity of adverse effects between the exposed population and its appropriate control.

Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the lymph nodes, spleen, and thymus.

Malformations—Permanent structural changes that may adversely affect survival, development, or function.

Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is likely to be without an appreciable risk of adverse noncancer health effects over a specified route and duration of exposure.

Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty factors. The default value for a MF is 1.

Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific population.

Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified interval of time.

10. GLOSSARY

Mutagen—A substance that causes mutations. A mutation is a change in the DNA sequence of a cell's DNA. Mutations can lead to birth defects, miscarriages, or cancer.

Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of death or pathological conditions.

Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a chemical.

No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no statistically or biologically significant increases in frequency or severity of adverse effects seen between the exposed population and its appropriate control. Effects may be produced at this dose, but they are not considered to be adverse.

Octanol-Water Partition Coefficient (K_{ow})—The equilibrium ratio of the concentrations of a chemical in *n*-octanol and water, in dilute solution.

Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence among subjects exposed to a particular risk factor divided by the incidence among subjects who were not exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the exposed group compared to the unexposed group.

Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound and especially a pesticide that acts by inhibiting cholinesterase.

Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.

Pesticide—General classification of chemicals specifically developed and produced for use in the control of agricultural and public health pests.

Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate (disposition) of an exogenous substance in an organism. Utilizing computational techniques, it provides the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.

Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent chemical or metabolite in an animal system. There are two types of pharmacokinetic models: data-based and physiologically-based. A data-based model divides the animal system into a series of compartments, which, in general, do not represent real, identifiable anatomic regions of the body, whereas the physiologically-based model compartments represent real anatomic regions of the body.

Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-response model that quantitatively describes the relationship between target tissue dose and toxic end points. These models advance the importance of physiologically based models in that they clearly describe the biological effect (response) produced by the system following exposure to an exogenous substance.

Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments representing organs or tissue groups with realistic weights and blood flows. These models require a

10. GLOSSARY

variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar ventilation rates, and possibly membrane permeabilities. The models also utilize biochemical information, such as air/blood partition coefficients, and metabolic parameters. PBPK models are also called biologically based tissue dosimetry models.

Prevalence—The number of cases of a disease or condition in a population at one point in time.

Prospective Study—A type of cohort study in which the pertinent observations are made on events occurring after the start of the study. A group is followed over time.

q_1^* —The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the multistage procedure. The q_1^* can be used to calculate an estimate of carcinogenic potency, the incremental excess cancer risk per unit of exposure (usually $\mu\text{g/L}$ for water, mg/kg/day for food, and $\mu\text{g/m}^3$ for air).

Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health (NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour workweek.

Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime. The inhalation reference concentration is for continuous inhalation exposures and is appropriately expressed in units of mg/m^3 or ppm.

Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious effects during a lifetime. The RfD is operationally derived from the no-observed-adverse-effect level (NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect various types of data used to estimate RfDs and an additional modifying factor, which is based on a professional judgment of the entire database on the chemical. The RfDs are not applicable to nonthreshold effects such as cancer.

Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation either under CERCLA or under Section 311 of the Clean Water Act. Quantities are measured over a 24-hour period.

Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of this system.

Retrospective Study—A type of cohort study based on a group of persons known to have been exposed at some time in the past. Data are collected from routinely recorded events, up to the time the study is undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing records and/or examining survivors of the cohort.

Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.

10. GLOSSARY

Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or inherited characteristic that is associated with an increased occurrence of disease or other health-related event or condition.

Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed group compared to the unexposed group.

Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes continually. No more than four excursions are allowed per day, and there must be at least 60 minutes between exposure periods. The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may not be exceeded.

Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected number of deaths in a specific standard population.

Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited exposure to those assumed over a lifetime of exposure to a chemical.

Teratogen—A chemical that causes structural defects that affect the development of an organism.

Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists (ACGIH) concentration of a substance to which most workers can be exposed without adverse effect. The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit (STEL), or as a ceiling limit (CL).

Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour workday or 40-hour workweek.

Toxic Dose₍₅₀₎ (TD₅₀)—A calculated dose of a chemical, introduced by a route other than inhalation, which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.

Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.

Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or Reference Dose (RfD) or Reference Concentration (RfC) from experimental data. UFs are intended to account for (1) the variation in sensitivity among the members of the human population, (2) the uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic average of 10 and 1.

Xenobiotic—Any chemical that is foreign to the biological system.

APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS

The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99–499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological profiles for each substance included on the priority list of hazardous substances; and assure the initiation of a research program to fill identified data needs associated with the substances.

The toxicological profiles include an examination, summary, and interpretation of available toxicological information and epidemiologic evaluations of a hazardous substance. During the development of toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are used by ATSDR health assessors to identify contaminants and potential health effects that may be of concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or action levels.

MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor approach. They are below levels that might cause adverse health effects in the people most sensitive to such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and chronic (365 days and longer) durations and for the oral and inhalation routes of exposure. Currently, MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end point considered to be of relevance to humans. Serious health effects (such as irreparable damage to the liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level above the MRL does not mean that adverse health effects will occur.

MRLs are intended only to serve as a screening tool to help public health professionals decide where to look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that

APPENDIX A

are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health principle of prevention. Although human data are preferred, MRLs often must be based on animal studies because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes that humans are more sensitive to the effects of hazardous substance than animals and that certain persons may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that have been shown to be nontoxic in laboratory animals.

Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the Division of Toxicology and Environmental Medicine, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with participation from other federal agencies and comments from the public. They are subject to change as new information becomes available concomitant with updating the toxicological profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels. For additional information regarding MRLs, please contact the Division of Toxicology and Environmental Medicine, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop F-62, Atlanta, Georgia 30333.

APPENDIX A

MINIMAL RISK LEVEL (MRL) WORKSHEET

Chemical Name: 1,3-Butadiene
CAS Number: 106-99-0
Date: August 2009
Profile Status: Third Draft Pre-Public Comment
Route: Inhalation Oral
Duration: Acute Intermediate Chronic
Graph Key: 11
Species: Mice

Minimal Risk Level: 0.1 mg/m³ ppm

Reference: DOE/NTP. 1987b. Inhalation developmental toxicology studies: Teratology study of 1,3-butadiene in mice. National Toxicology Program PNL-6412.

Experimental design: Groups of 18–20 pregnant CD-1 mice were subjected to inhalation exposures of 0, 40, 200, or 1,000 ppm 1,3-butadiene for 6 hours/day on gestation days (GDs) 6–15. They were sacrificed on GD 18. Dams were weighed prior to mating and again on GDs 0, 6, 11, 16, and 18. They were observed for mortality, morbidity, clinical signs, and, at necropsy, gross reproductive tissue abnormalities. Reproductive end points included number of implants, resorptions, and live/dead fetuses. Developmental end points included fetal weights and observation of external, visceral, or skeletal abnormalities.

Effects noted in study and corresponding doses: The change in maternal body weights were comparable between controls and exposed groups during the time intervals GDs 0–6 and GDs 16–18. Between GD 11 and GD 16, decreased maternal weight changes of 5, 14, and 24% were observed in the 40, 200, and 1,000 ppm groups, respectively. No differences in body weight changes were seen at GD 0–6 or GD 16–18. In the 200 and 1,000 ppm groups, GD 20 maternal body weight and gravid uterine weights were 4–7 and 7–13% less than controls, respectively. Male fetal body weights at 40 ppm were statistically significantly less than controls (5%), while female fetal body weights were reduced (4% lower than controls), but were not statistically significant. Mean whole-litter fetal body weights at 40 ppm were reduced (4% lower than controls), but also not statistically significantly. Mean whole-litter fetal weights at ≥ 200 ppm were reduced $>15\%$ lower than controls. There was no observed treatment-related effect on number of implants, total resorptions, or live/dead fetuses/litter. Male fetal weights on GD 20 were 5, 18, and 23% lower than controls (all significant to $p \leq 0.05$) in the 40, 200, and 1,000 ppm groups, respectively, while female fetal weights were 4, 15, and 22% lower than controls (significant to $p \leq 0.05$ for ≥ 200 ppm). At ≥ 200 ppm, significantly increased incidences of extra rudimentary ribs and reduced sternebral ossification were observed.

Dose and end point used for MRL derivation: LOAEL of 40 ppm for 5% reduction in male fetal body weight, as compared to controls, a minimally adverse effect. The LOAEL of 40 ppm was adjusted for continuous, 24-hour exposure by multiplying by a factor of 6 hours/24 hours = 0.25.

NOAEL minimal LOAEL

An attempt was made to derive a benchmark dose (BMD) and its associated lower bound (BMDL) using the U.S. EPA BMD software (version 2.0). Since fetal body weight (1.38 ± 0.217 , 1.31 ± 0.087 , 1.13 ± 0.092 , or 1.06 ± 0.089 mg for mice exposed to 0, 40, 200, or 1,000 ppm 1,3-butadiene) are continuous data, the linear, polynomial, and power models were fit to the data (Too few dose groups were available

APPENDIX A

to fit the Hill model). Adequate model fit is judged by three criteria: goodness-of-fit p-value ($p > 0.1$), visual inspection of the dose-response curve, and scaled residual at the data point (except the control) closest to the predefined benchmark response (BMR), which was the one standard deviation below the control mean. Among all the models providing adequate fit to the data, the lowest lower bound on the BMC (BMCL) is selected as the point of departure when the difference between the BMDLs estimated from these models are more than 3-fold; otherwise, the BMCL from the model with the lowest AIC is chosen. Adequate fits to the models were acquired by dropping the highest dose data.

Table A-1. Model Predictions for Reduced Weight of Male Fetuses from Pregnant CD-1 Mice Exposed to 1,3-Butadiene for 6 Hours/day for 10 Days

Model	Variance p-value ^a	Means p-value ^a	AIC	BMD _{1SD} (ppm)	BMDL _{1SD} (ppm)
All dose groups					
Hill ^b	0.28	NA	-276.35	53.07	29.33
Linear ^c	0.28	<0.0001	-244.72	467.61	373.40
Polynomial (2-degree) ^c	0.28	<0.0001	-244.72	467.61	373.40
Polynomial (3-degree) ^c	0.28	<0.0001	-244.72	467.61	373.40
Power ^b	0.28	<0.0001	-244.72	467.61	373.40
Without high dose group					
Hill ^b	NA	NA	NA	NA	NA
Linear^c	0.20	0.51	-202.69	82.86	65.96
Polynomial (2-degree) ^c	0.20	0.51	-202.69	82.86	65.96
Power ^b	0.20	0.51	-202.69	82.86	65.96

^aValues <0.10 fail to meet conventional goodness-of-fit criteria

^bPower restricted to ≥ 1


^cCoefficients restricted to be negative

AIC = Akaike Information Criterion; BMD/BMC = maximum likelihood estimate of the dose/concentration associated with the selected benchmark response; BMDL = 95% lower confidence limit on the BMD; NA = Not applicable-model failed to generate; SD = standard deviation

Source: DOE/NTP 1987b

APPENDIX A

Figure A-1. Fit of Linear Model to Data on the Reduced Weight of Male Fetuses from Pregnant CD-1 Mice Exposed to 1,3-Butadiene for 6 Hours/day for 10 Days



The resulting BMDs and BMRs from each model were identical and were higher than the LOAEL. Thus, the LOAEL was used as the point of departure for deriving the MRL, rather than the BMD or BMDL.

Uncertainty Factors used in MRL derivation:

- [X] 3 for use of a LOAEL for a minimally adverse effect
- [X] 3 for extrapolation from animals to humans using a dosimetric conversion
- [X] 10 for human variability

Was a conversion used from ppm in food or water to a mg/body weight dose? No.

If an inhalation study in animals, list the conversion factors used in determining human equivalent dose:
 The LOAEL of 40 ppm was adjusted for intermittent exposure (6 hours/24 hours) resulting in a duration-adjusted LOAEL_{ADJ} of 10 ppm. The LOAEL_{ADJ} was then converted to a human equivalent concentration (HEC) according to EPA (1994) methodology for calculating a HEC for extrarespiratory effects of a category 3 gas (such as 1,3-butadiene) as follows:

$$\text{LOAEL}_{\text{HEC}} = \text{LOAEL}_{\text{ADJ}} \times ([H_{\text{b/g}}]_{\text{A}}/[H_{\text{b/g}}]_{\text{H}})$$

APPENDIX A

where:

- LOAEL_{HEC} the LOAEL dosimetrically adjusted to a human equivalent concentration
- LOAEL_{ADJ} the LOAEL adjusted from intermittent to continuous exposure
- $[H_{b/g}]_A/[H_{b/g}]_H$ the ratio of the blood:gas partition coefficient of the chemical for the laboratory animal species to the human value

If the animal blood:gas partition coefficient is greater than the human blood:gas partition coefficient, a default value of 1 is used for the ratio. According to Johanson and Filser (1993) and Brochot et al. (2007), blood:gas partition coefficients for 1,3-butadiene in mice and humans are 3.03 and 1.67, respectively. Therefore, the default value of 1 is applied, in which case, the LOAEL_[HEC] is equivalent to the LOAEL_[ADJ].

Therefore:

$$\text{LOAEL}_{\text{HEC}} = \text{LOAEL}_{\text{ADJ}} = 10 \text{ ppm}$$

The resulting LOAEL_(HEC) of 10 ppm was then divided by an uncertainty factor of 90 (3 for the use of a minimally adverse LOAEL, 3 for extrapolation from animals to humans using dosimetric conversion, and 10 for human variability) to yield the MRL value of 0.1 ppm.

Other additional studies or pertinent information that lend support to this MRL: In mice, increased fetal death (a dominant lethal effect) occurred in offspring of males exposed to 200 ppm 6 hours/day for 5 days (DOE/NTP 1988b). Ovarian atrophy occurred at 200 ppm for 6 hours/day for 40 weeks and at 6.25 ppm, 6 hours/day for 2 years (NTP 1993). Exencephalies, skull abnormalities, and late fetal death in mice exposed to 12.5 ppm, 6 hours/day for 10 weeks (Anderson et al. 1996).

Agency Contact (Chemical Manager): Annette Ashizawa

APPENDIX B. USER'S GUIDE

Chapter 1

Public Health Statement

This chapter of the profile is a health effects summary written in non-technical language. Its intended audience is the general public, especially people living in the vicinity of a hazardous waste site or chemical release. If the Public Health Statement were removed from the rest of the document, it would still communicate to the lay public essential information about the chemical.

The major headings in the Public Health Statement are useful to find specific topics of concern. The topics are written in a question and answer format. The answer to each question includes a sentence that will direct the reader to chapters in the profile that will provide more information on the given topic.

Chapter 2

Relevance to Public Health

This chapter provides a health effects summary based on evaluations of existing toxicologic, epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight-of-evidence discussions for human health end points by addressing the following questions:

1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous waste sites?

The chapter covers end points in the same order that they appear within the Discussion of Health Effects by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). *In vitro* data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in this chapter.

The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if derived) and the end points from which they were derived are indicated and discussed.

Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public health are identified in the Chapter 3 Data Needs section.

Interpretation of Minimal Risk Levels

Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not meant to support regulatory action, but to acquaint health professionals with exposure levels at which adverse health effects are not expected to occur in humans.

APPENDIX B

MRLs should help physicians and public health officials determine the safety of a community living near a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water. MRLs are based largely on toxicological studies in animals and on reports of human occupational exposure.

MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2, "Relevance to Public Health," contains basic information known about the substance. Other sections such as Chapter 3 Section 3.9, "Interactions with Other Substances," and Section 3.10, "Populations that are Unusually Susceptible" provide important supplemental information.

MRL users should also understand the MRL derivation methodology. MRLs are derived using a modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.

To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, represents the most sensitive human health effect for a given exposure route and duration. ATSDR cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available for all potential systemic, neurological, and developmental effects. If this information and reliable quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive species (when information from multiple species is available) with the highest no-observed-adverse-effect level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor (UF) of 10 must be employed. Additional uncertainty factors of 10 must be used both for human variability to protect sensitive subpopulations (people who are most susceptible to the health effects caused by the substance) and for interspecies variability (extrapolation from animals to humans). In deriving an MRL, these individual uncertainty factors are multiplied together. The product is then divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure (LSE) tables.

Chapter 3

Health Effects

Tables and Figures for Levels of Significant Exposure (LSE)

Tables and figures are used to summarize health effects and illustrate graphically levels of exposure associated with those effects. These levels cover health effects observed at increasing dose concentrations and durations, differences in response by species, MRLs to humans for noncancer end points, and EPA's estimated range associated with an upper-bound individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to locate data for a specific exposure scenario. The LSE tables and figures should always be used in conjunction with the text. All entries in these tables and figures represent studies that provide reliable, quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).

The legends presented below demonstrate the application of these tables and figures. Representative examples of LSE Table 3-1 and Figure 3-1 are shown. The numbers in the left column of the legends correspond to the numbers in the example table and figure.

APPENDIX B

LEGEND**See Sample LSE Table 3-1 (page B-6)**

- (1) Route of Exposure. One of the first considerations when reviewing the toxicity of a substance using these tables and figures should be the relevant and appropriate route of exposure. Typically when sufficient data exist, three LSE tables and two LSE figures are presented in the document. The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation (LSE Figure 3-1) and oral (LSE Figure 3-2) routes. Not all substances will have data on each route of exposure and will not, therefore, have all five of the tables and figures.
- (2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15–364 days), and chronic (365 days or more)—are presented within each relevant route of exposure. In this example, an inhalation study of intermediate exposure duration is reported. For quick reference to health effects occurring from a known length of exposure, locate the applicable exposure period within the LSE table and figure.
- (3) Health Effect. The major categories of health effects included in LSE tables and figures are death, systemic, immunological, neurological, developmental, reproductive, and cancer. NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are further defined in the "System" column of the LSE table (see key number 18).
- (4) Key to Figure. Each key number in the LSE table links study information to one or more data points using the same key number in the corresponding LSE figure. In this example, the study represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL (also see the two "18r" data points in sample Figure 3-1).
- (5) Species. The test species, whether animal or human, are identified in this column. Chapter 2, "Relevance to Public Health," covers the relevance of animal data to human toxicity and Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics. Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent human doses to derive an MRL.
- (6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure regimens are provided in this column. This permits comparison of NOAELs and LOAELs from different studies. In this case (key number 18), rats were exposed to "Chemical x" via inhalation for 6 hours/day, 5 days/week, for 13 weeks. For a more complete review of the dosing regimen, refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 1981).
- (7) System. This column further defines the systemic effects. These systems include respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. In the example of key number 18, one systemic effect (respiratory) was investigated.
- (8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system, which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see footnote "b").

APPENDIX B

- (9) LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help readers identify the levels of exposure at which adverse health effects first appear and the gradation of effects with increasing dose. A brief description of the specific end point used to quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm. MRLs are not derived from Serious LOAELs.
- (10) Reference. The complete reference citation is given in Chapter 9 of the profile.
- (11) CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in experimental or epidemiologic studies. CELs are always considered serious effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report doses not causing measurable cancer increases.
- (12) Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found in the footnotes. Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to derive an MRL of 0.005 ppm.

LEGEND**See Sample Figure 3-1 (page B-7)**

LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the reader quickly compare health effects according to exposure concentrations for particular exposure periods.

- (13) Exposure Period. The same exposure periods appear as in the LSE table. In this example, health effects observed within the acute and intermediate exposure periods are illustrated.
- (14) Health Effect. These are the categories of health effects for which reliable quantitative data exists. The same health effects appear in the LSE table.
- (15) Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log scale "y" axis. Inhalation exposure is reported in mg/m³ or ppm and oral exposure is reported in mg/kg/day.
- (16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in the rat upon which an intermediate inhalation exposure MRL is based. The key number 18 corresponds to the entry in the LSE table. The dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table).
- (17) CEL. Key number 38m is one of three studies for which CELs were derived. The diamond symbol refers to a CEL for the test species-mouse. The number 38 corresponds to the entry in the LSE table.

APPENDIX B

- (18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the cancer dose response curve at low dose levels (q_1^*).
- (19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.

SAMPLE

1 →

Table 3-1. Levels of Significant Exposure to [Chemical x] – Inhalation


	Key to figure ^a	Species	Exposure frequency/ duration	System	NOAEL (ppm)	LOAEL (effect)		Reference
						Less serious (ppm)	Serious (ppm)	
2 →	INTERMEDIATE EXPOSURE							
		5	6	7	8	9		10
3 →	Systemic	↓	↓	↓	↓	↓		↓
4 →	18	Rat	13 wk 5 d/wk 6 hr/d	Resp	3 ^b	10 (hyperplasia)		Nitschke et al. 1981
	CHRONIC EXPOSURE							
	Cancer						11	
							↓	
	38	Rat	18 mo 5 d/wk 7 hr/d			20	(CEL, multiple organs)	Wong et al. 1982
	39	Rat	89–104 wk 5 d/wk 6 hr/d			10	(CEL, lung tumors, nasal tumors)	NTP 1982
	40	Mouse	79–103 wk 5 d/wk 6 hr/d			10	(CEL, lung tumors, hemangiosarcomas)	NTP 1982

12 →

^a The number corresponds to entries in Figure 3-1.^b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5×10^{-3} ppm; dose adjusted for intermittent exposure and divided by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).

SAMPLE

Figure 3-1. Levels of Significant Exposure to [Chemical X] - Inhalation



DRAFT FOR PUBLIC COMMENT

APPENDIX B

This page is intentionally blank.

APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS

ACGIH	American Conference of Governmental Industrial Hygienists
ACOEM	American College of Occupational and Environmental Medicine
ADI	acceptable daily intake
ADME	absorption, distribution, metabolism, and excretion
AED	atomic emission detection
AFID	alkali flame ionization detector
AFOSH	Air Force Office of Safety and Health
ALT	alanine aminotransferase
AML	acute myeloid leukemia
AOAC	Association of Official Analytical Chemists
AOEC	Association of Occupational and Environmental Clinics
AP	alkaline phosphatase
APHA	American Public Health Association
AST	aspartate aminotransferase
atm	atmosphere
ATSDR	Agency for Toxic Substances and Disease Registry
AWQC	Ambient Water Quality Criteria
BAT	best available technology
BCF	bioconcentration factor
BEI	Biological Exposure Index
BMD/C	benchmark dose or benchmark concentration
BMD _x	dose that produces a X% change in response rate of an adverse effect
BMDL _x	95% lower confidence limit on the BMD _x
BMDS	Benchmark Dose Software
BMR	benchmark response
BSC	Board of Scientific Counselors
C	centigrade
CAA	Clean Air Act
CAG	Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS	Chemical Abstract Services
CDC	Centers for Disease Control and Prevention
CEL	cancer effect level
CELDS	Computer-Environmental Legislative Data System
CERCLA	Comprehensive Environmental Response, Compensation, and Liability Act
CFR	Code of Federal Regulations
Ci	curie
CI	confidence interval
CL	ceiling limit value
CLP	Contract Laboratory Program
cm	centimeter
CML	chronic myeloid leukemia
CPSC	Consumer Products Safety Commission
CWA	Clean Water Act
DHEW	Department of Health, Education, and Welfare
DHHS	Department of Health and Human Services
DNA	deoxyribonucleic acid
DOD	Department of Defense
DOE	Department of Energy
DOL	Department of Labor

APPENDIX C

DOT	Department of Transportation
DOT/UN/ NA/IMDG	Department of Transportation/United Nations/ North America/Intergovernmental Maritime Dangerous Goods Code
DWEL	drinking water exposure level
ECD	electron capture detection
ECG/EKG	electrocardiogram
EEG	electroencephalogram
EEGL	Emergency Exposure Guidance Level
EPA	Environmental Protection Agency
F	Fahrenheit
F ₁	first-filial generation
FAO	Food and Agricultural Organization of the United Nations
FDA	Food and Drug Administration
FEMA	Federal Emergency Management Agency
FIFRA	Federal Insecticide, Fungicide, and Rodenticide Act
FPD	flame photometric detection
fpm	feet per minute
FR	Federal Register
FSH	follicle stimulating hormone
g	gram
GC	gas chromatography
gd	gestational day
GLC	gas liquid chromatography
GPC	gel permeation chromatography
HPLC	high-performance liquid chromatography
HRGC	high resolution gas chromatography
HSDB	Hazardous Substance Data Bank
IARC	International Agency for Research on Cancer
IDLH	immediately dangerous to life and health
ILO	International Labor Organization
IRIS	Integrated Risk Information System
K _d	adsorption ratio
kg	kilogram
kkg	metric ton
K _{oc}	organic carbon partition coefficient
K _{ow}	octanol-water partition coefficient
L	liter
LC	liquid chromatography
LC ₅₀	lethal concentration, 50% kill
LC _{Lo}	lethal concentration, low
LD ₅₀	lethal dose, 50% kill
LD _{Lo}	lethal dose, low
LDH	lactic dehydrogenase
LH	lutinizing hormone
LOAEL	lowest-observed-adverse-effect level
LSE	Levels of Significant Exposure
LT ₅₀	lethal time, 50% kill
m	meter
MA	<i>trans,trans</i> -muconic acid
MAL	maximum allowable level
mCi	millicurie

APPENDIX C

MCL	maximum contaminant level
MCLG	maximum contaminant level goal
MF	modifying factor
MFO	mixed function oxidase
mg	milligram
mL	milliliter
mm	millimeter
mmHg	millimeters of mercury
mmol	millimole
mppcf	millions of particles per cubic foot
MRL	Minimal Risk Level
MS	mass spectrometry
NAAQS	National Ambient Air Quality Standard
NAS	National Academy of Science
NATICH	National Air Toxics Information Clearinghouse
NATO	North Atlantic Treaty Organization
NCE	normochromatic erythrocytes
NCEH	National Center for Environmental Health
NCI	National Cancer Institute
ND	not detected
NFPA	National Fire Protection Association
ng	nanogram
NHANES	National Health and Nutrition Examination Survey
NIEHS	National Institute of Environmental Health Sciences
NIOSH	National Institute for Occupational Safety and Health
NIOSH TIC	NIOSH's Computerized Information Retrieval System
NLM	National Library of Medicine
nm	nanometer
nmol	nanomole
NOAEL	no-observed-adverse-effect level
NOES	National Occupational Exposure Survey
NOHS	National Occupational Hazard Survey
NPD	nitrogen phosphorus detection
NPDES	National Pollutant Discharge Elimination System
NPL	National Priorities List
NR	not reported
NRC	National Research Council
NS	not specified
NSPS	New Source Performance Standards
NTIS	National Technical Information Service
NTP	National Toxicology Program
ODW	Office of Drinking Water, EPA
OERR	Office of Emergency and Remedial Response, EPA
OHM/TADS	Oil and Hazardous Materials/Technical Assistance Data System
OPP	Office of Pesticide Programs, EPA
OPPT	Office of Pollution Prevention and Toxics, EPA
OPPTS	Office of Prevention, Pesticides and Toxic Substances, EPA
OR	odds ratio
OSHA	Occupational Safety and Health Administration
OSW	Office of Solid Waste, EPA
OTS	Office of Toxic Substances

APPENDIX C

OW	Office of Water
OWRS	Office of Water Regulations and Standards, EPA
PAH	polycyclic aromatic hydrocarbon
PBPD	physiologically based pharmacodynamic
PBPK	physiologically based pharmacokinetic
PCE	polychromatic erythrocytes
PEL	permissible exposure limit
pg	picogram
PHS	Public Health Service
PID	photo ionization detector
pmol	picomole
PMR	proportionate mortality ratio
ppb	parts per billion
ppm	parts per million
ppt	parts per trillion
PSNS	pretreatment standards for new sources
RBC	red blood cell
REL	recommended exposure level/limit
RfC	reference concentration
RfD	reference dose
RNA	ribonucleic acid
RQ	reportable quantity
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
SCE	sister chromatid exchange
SGOT	serum glutamic oxaloacetic transaminase
SGPT	serum glutamic pyruvic transaminase
SIC	standard industrial classification
SIM	selected ion monitoring
SMCL	secondary maximum contaminant level
SMR	standardized mortality ratio
SNARL	suggested no adverse response level
SPEGL	Short-Term Public Emergency Guidance Level
STEL	short term exposure limit
STORET	Storage and Retrieval
TD ₅₀	toxic dose, 50% specific toxic effect
TLV	threshold limit value
TOC	total organic carbon
TPQ	threshold planning quantity
TRI	Toxics Release Inventory
TSCA	Toxic Substances Control Act
TWA	time-weighted average
UF	uncertainty factor
U.S.	United States
USDA	United States Department of Agriculture
USGS	United States Geological Survey
VOC	volatile organic compound
WBC	white blood cell
WHO	World Health Organization

APPENDIX C

>	greater than
≥	greater than or equal to
	equal to
<	less than
≤	less than or equal to
%	percent
α	alpha
β	beta
γ	gamma
δ	delta
μm	micrometer
μg	microgram
q ₁ *	cancer slope factor
-	negative
+	positive
(+)	weakly positive result
(-)	weakly negative result

APPENDIX C

This page is intentionally blank.

APPENDIX D. INDEX

absorbed dose.....	62
adenocarcinoma.....	37
adsorbed.....	98
adsorption.....	89, 98, 116
aerobic.....	100, 101
ambient air.....	76, 112, 118
anemia.....	8, 11, 30, 41, 70
bioaccumulation.....	89
bioavailability.....	112
bioconcentration factor.....	98
biodegradation.....	100, 101
biomarker.....	49, 62, 62, 63, 64, 65, 74, 115, 119
blood cell count.....	8, 30
body weight effects.....	32
breast milk.....	109, 110, 113
cancer.....	4, 7, 8, 9, 10, 11, 14, 15, 29, 36, 37, 38, 57, 59, 61, 68, 70, 71, 77
carcinogen.....	4, 38, 71, 124
carcinogenic.....	9, 13, 14, 38, 64, 65, 67, 71, 73, 74, 124
carcinogenicity.....	48, 64, 68, 71
carcinoma.....	37
cardiovascular.....	11, 14, 29
cardiovascular effects.....	29
cholinesterase.....	33
chromosomal aberrations.....	41, 44, 58, 66, 71
clearance.....	48, 49, 54, 55, 56, 67
death.....	4, 7, 8, 9, 10, 13, 15, 33, 34, 66, 68, 70, 124
deoxyribonucleic acid (see DNA).....	5
dermal effects.....	31
developmental effects.....	7, 8, 35, 61, 68, 73, 74, 75
DNA (see deoxyribonucleic acid).....	5, 57, 58, 59, 62, 63, 64, 74, 76, 77
elimination rate.....	49, 53
endocrine.....	59, 60
fetus.....	60
fractional absorption.....	66
gastrointestinal effects.....	29
general population.....	91, 105, 106, 113, 124
genotoxic.....	13, 39, 44, 64, 72, 77
genotoxicity.....	39, 44, 57, 58, 64, 68, 73, 77
groundwater.....	70, 97, 99
growth retardation.....	72
half-life.....	62, 89, 98, 99, 100
hematological effects.....	30
hematopoietic.....	9, 14, 30, 32, 36, 37, 41, 70, 71
hepatic effects.....	31
hydrolysis.....	43, 48, 49, 53, 54, 56, 58, 61, 66, 67
hydroxyl radical.....	89, 99, 100
immune system.....	73
immunological.....	13, 32, 33
immunological effects.....	32, 33

APPENDIX D

K _{ow}	81
leukemia	30, 32, 35, 36, 37, 38, 61
lymphatic	4, 35
lymphopoietic	9
lymphoreticular	7
micronuclei	39, 41, 42, 57, 58, 67, 72
musculoskeletal effects	31
neonatal	110, 113
neoplasm	38
neoplastic	8, 31
neurobehavioral	60, 73
neurological effects	3, 8, 9, 33, 34, 66, 73
non-Hodgkin's lymphoma	36
ocular effects	32
odds ratio	36
partition coefficients	45, 46, 53, 54, 56
pharmacodynamic	50
pharmacokinetic	49, 50, 51, 52, 60, 68, 70, 71, 72, 73
rate constant	56, 99, 100
renal effects	31
reproductive effects	11, 34, 72
respiratory effects	15, 71
sarcoma	36, 37
solubility	81
systemic effects	10, 15, 68
thyroid	9, 37, 46
toxicokinetic	13, 58, 65, 66, 71, 75, 112
tumors	9, 11, 34, 37, 58, 65, 74
vapor pressure	81, 98
volatility	98
volatilization	89, 98

